

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

=> d his

(FILE 'HOME' ENTERED AT 09:43:05 ON 24 APR 2002)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, CANCERLIT, USPATFILL' ENTERED AT 09:43:46 ON 24 APR 2002

L1 11314058 S METHOD? OR PROTOCOL?
L2 12433 S TUMOR INVASION
L3 3861 S L1 AND L2
L4 2158 S L3 NOT PY=>1999
L5 1193 DUP REM L4 (965 DUPLICATES REMOVED)
L6 6017 S RAGE OR RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS
L7 0 S L5 AND L6

=> s l5 and amphotericin
L8 0 L5 AND AMPHOTERIN

=> s l5 and agent?
L9 239 L5 AND AGENT?

=> d l9 1-239

L9 ANSWER 1 OF 239 MEDLINE
AN 199022638 PubMed ID: 9805796
DN 99022638
TI (Is laparoscopic evaluation of digestive cancers legitimate? A prospective study of 109 cases).
L'evaluation laparoscopique des cancers digestifs est-elle legitime? Etude prospective de 109 cas.

AU Barret C; Champault G; Catheline J M
CS Service de Chirurgie Generale et Digestive, Hopital Jean-Verdier, Bondy.
SO ANNALES DE CHIRURGIE, (1998) 52 (7) 602-6.
Journal code: 50E; 0140722. ISSN: 0003-3944.

CY France
DT Journal: Article; (JOURNAL ARTICLE)

LA French
FS Priority Journals

EM 199812

ED Entered STN: 19990115
Last Updated on STN: 20000303
Entered Medline: 19981202

L9 ANSWER 2 OF 239 MEDLINE
AN 1998445708 PubMed ID: 9772531
DN 98445708
TI Effects of TIMP-2 gene transfection on biological behaviors of a metastatic human lung carcinoma cell line.
L'etude de l'impact de la transfection du gene TIMP-2 sur le comportement biologique d'une lignee de cellules tumorales humaines.

AU Li H; Fang W; Shi Z
CS Department of Pathology, Beijing Medical University.
SO CHUNG-HUA I HSUEH TSA CHIH [CHINESE MEDICAL JOURNAL], (1997 Sep) 77 (9) 652-6.
Journal code: CDG; 751141. ISSN: 0376-2491.

CY China
DT Journal: Article; (JOURNAL ARTICLE)

LA Chinese
FS Priority Journals

EM 199811

ED Entered STN: 19990106
Last Updated on STN: 20000303
Entered Medline: 19981109

L9 ANSWER 3 OF 239 MEDLINE
AN 1998443373 MEDLINE

DN 98443373 PubMed ID: 9769365
TI Conservation treatment intensified with tamoxifen and CAF chemotherapy for subareolar breast cancers.

AU Ogawa Y; Nishioka A; Inomata T; Tsuboi N; Hayase N; Fukumoto M; Yoshida S; Tohchika N; Tanaka Y; Kimura M
CS Department of Radiology, Kochi Medical School, Oki-cho, Nankoku-shi, Kochi-Prefecture 783-8505, Japan.
SO ONCOLOGY REPORTS, (1998 Nov-Dec) 5 (6) 1337-41.
Journal code: CTF; 9442756. ISSN: 1021-335X.

CY Greece
DT Journal: Article; (JOURNAL ARTICLE)

LA English
FS Priority Journals

EM 199811
ED Entered STN: 19990106
Last Updated on STN: 19990106
Entered Medline: 19981125

L9 ANSWER 4 OF 239 MEDLINE
AN 1998187878 MEDLINE

DN 98187878 PubMed ID: 9529029
TI Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.

AU Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
CS Department of Urology, School of Medicine, The University of Tokushima, Kuramoto, Japan.
SO CANCER, (1998 Apr 1) 82 (7) 1359-66.
Journal code: CLZ; 0374236. ISSN: 0008-543X.

CY United States
DT Journal: Article; (JOURNAL ARTICLE)

LA English
FS Abridged Index Medicus Journals; Priority Journals

EM 199804
ED Entered STN: 19980430
Last Updated on STN: 20000303
Entered Medline: 19980423

L9 ANSWER 5 OF 239 MEDLINE
AN 1998128074 MEDLINE

DN 98128074 PubMed ID: 9467021
TI (Dura thickening adjacent to intracranial, para-dural space-occupying lesions in MRI. Histologic correlation).
Duraerkrankung am Rand intrakranieller, duranaher Raumforderungen in der MRT. Histologische Korrelation.

AU Hutzemann A; Palmie S; Freund M; Buhl R; Heller M
CS Klinik fur Radiologische Diagnostik der Christian-Albrechts-Universitat zu Kiel

SO AKTUELLE RADIOLOGIE, (1997 Nov) 7 (6) 305-8.
Journal code: A08; 9102962. ISSN: 0939-267X.

CY GERMANY: Germany, Federal Republic of
DT Journal: Article; (JOURNAL ARTICLE)

LA German
FS Priority Journals

EM 199803
ED Entered STN: 19980410
Last Updated on STN: 19980410
Entered Medline: 19980331

L9 ANSWER 6 OF 239 MEDLINE
AN 97070117 MEDLINE

DN 97070117 PubMed ID: 8913076
TI A case of embryonal carcinoma successfully treated by neoadjuvant chemotherapy: report of a case.
Shibata S; Okumichi T; Kimura A; Nishimura Y; Okamoto H; Kuraoka T; Youki

I; Kajiwara H
 Department of Surgery, Yoshijima Hospital, Hiroshima, Japan.
 CS KYOBU GERA. JAPANESE JOURNAL OF THORACIC SURGERY, (1996 Oct) 49 (11)
 SO 963-5.
 Journal code: KQJ; 0413533. ISSN: 0021-5252.
 Japan
 CY Journal; Article; (JOURNAL ARTICLE)
 DT Japanese
 FS Priority Journals
 EM 199612
 Entered STN: 19970128
 Last Updated on STN: 19970128
 Entered Medline: 19961210

L9 ANSWER 7 OF 239 MEDLINE
 AN 97045590 PubMed ID: 8890594
 DN 97045590 PubMed ID: 8890594
 TI Progress and clinical usefulness of color Doppler method in
 diagnosing abdominal diseases.
 Tomiyama T; Ueno N; Tano S; Nagamine N; Wada S; Miyata T; Aizawa T; Miyata
 T; Kunakura Y; Kimura K
 Department of Gastroenterology, Jichi Medical School.
 CS NIPPON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE, (1996 Sep) 54 (9)
 SO 2561-73. Ref: 29
 Journal code: KIM; 0420546. ISSN: 0047-1852.
 Japan
 CY Journal; Article; (JOURNAL ARTICLE)
 DT General Review; (REVIEW)
 LA Japanese
 FS Priority Journals
 EM 199612
 Entered STN: 19970128
 Last Updated on STN: 19970128
 Entered Medline: 19961206

L9 ANSWER 8 OF 239 MEDLINE
 AN 96228311 PubMed ID: 8647672
 DN 96228311 PubMed ID: 8647672
 TI Local interferon therapy for melanoma patients.
 Ilic D; Spaventi S; Padovan I; Kusic Z; Cackovic V; Ivankovic D; Dakovic
 N; Nola P
 Department of Medicine, Croatian Academy of Sciences and Arts, Zagreb,
 CS Croatia.
 SO INTERNATIONAL JOURNAL OF DERMATOLOGY, (1995 Dec) 34 (12) 872-4.
 Journal code: GRJ; 0243704. ISSN: 0011-9059.
 United States
 CY Journal; Article; (JOURNAL ARTICLE)
 DT English
 LA Priority Journals
 FS 199607
 Entered STN: 19960805
 Last Updated on STN: 20000303
 Entered Medline: 19960719

L9 ANSWER 9 OF 239 MEDLINE
 AN 96208584 PubMed ID: 8646686
 DN 96208584 PubMed ID: 8646686
 TI In vitro modulation of tumor progression-associated properties of hormone
 refractory prostate carcinoma cell lines by cytokines.
 Sokoloff M H; Tso C L; Kaboo R; Taneja S; Pang S; deGuerin J B;
 Belldegun A S
 Immunotherapy Laboratory, Prostate Cancer Program, Division of Urology,
 CS Department of Surgery, UCLA School of Medicine, Los Angeles, California

90024, USA.
 NC CA-16024 (NCI)
 SO CANCER, (1996 May 1) 77 (9) 1862-72.
 Journal code: CLZ; 0374236. ISSN: 0008-543X.
 United States
 CY Journal; Article; (JOURNAL ARTICLE)
 DT English
 LA Abridged Index Medicus Journals; Priority Journals
 FS 199607
 Entered STN: 19960805
 Last Updated on STN: 20000303
 Entered Medline: 19960722

L9 ANSWER 10 OF 239 MEDLINE
 AN 95395737 PubMed ID: 7545228
 DN 95395737 PubMed ID: 7545228
 TI Complete resection before development of drug resistance is essential for
 survival from advanced hepatoblastoma--a report from the German
 Cooperative Pediatric Liver Tumor Study HB-89.
 von Schweinitz D; Hecker H; Harms D; Bode U; Weinel P; Burger D; Ertmann
 R; Mildnerberger H
 Department of Pediatric Surgery, Medical School Hannover, Germany.
 CS JOURNAL OF PEDIATRIC SURGERY, (1995 Jun) 30 (6) 845-52.
 SO Journal code: JMJ; 0052631. ISSN: 0022-3468.
 United States
 CY Journal; Article; (JOURNAL ARTICLE)
 DT English
 LA Priority Journals
 FS 199510
 Entered STN: 19951020
 Last Updated on STN: 19960129
 Entered Medline: 19951012

L9 ANSWER 11 OF 239 MEDLINE
 AN 95122813 PubMed ID: 7822556
 DN 95122813 PubMed ID: 7822556
 TI Staging of colon carcinoma using water enema CT.
 Gazelle G S; Gaa J; Saini S; Shellito P
 Department of Radiology, Massachusetts General Hospital, Harvard Medical
 CS School, Boston 02114.
 SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, (1995 Jan-Feb) 19 (1) 87-91.
 Journal code: HVT; 7703942. ISSN: 0365-8715.
 United States
 CY Journal; Article; (JOURNAL ARTICLE)
 DT English
 LA Priority Journals
 FS 199502
 Entered STN: 19950223
 Last Updated on STN: 19950223
 Entered Medline: 19950210

L9 ANSWER 12 OF 239 MEDLINE
 AN 94237090 PubMed ID: 8181412
 DN 94237090 PubMed ID: 8181412
 TI Colon carcinoma tumors. A population-based study.
 AU Spread C; Berkel H; Jewell L; Jenkins H; Yakimets W
 Department of Surgery, University Hospital, University of Alberta,
 CS Edmonton, Canada.
 SO DISAPPS OF THE COLON AND RECTUM, (1994 May) 37 (5) 482-91.
 Journal code: EAB; 0372764. ISSN: 0012-3706.
 United States
 CY Journal; Article; (JOURNAL ARTICLE)
 DT English
 LA Priority Journals
 FS

EM 199406 Entered STN: 19940621
 ED Last Updated on STN: 19940621
 Entered Medline: 19940614

L9 ANSWER 13 OF 239 MEDLINE
 AN 94164078 MEDLINE
 DN 94164078 Pubmed ID: 8119210
 TI Assessment of response of esophageal carcinoma to induction chemotherapy.
 AU Hordijk M L; Kok T C; Wilson J H; Mulder A H
 CS Department of Internal Medicine II, University Hospital Rotterdam
 SO Dijkzigt, The Netherlands.
 CY Endoscopy, (1993 Nov) 25 (9) 592-6.
 DT Journal code: EHP: 0215166. ISSN: 0013-726X.
 LA GERMANY: Germany; Federal Republic of
 FS English
 EM Journal; Article; (JOURNAL ARTICLE)
 DT Journal; Article; (JOURNAL ARTICLE)
 FS English
 EM Priority Journals
 ED 199404
 Entered STN: 19940412
 Last Updated on STN: 19940412
 Entered Medline: 19940401

L9 ANSWER 14 OF 239 MEDLINE
 AN 94127116 MEDLINE
 DN 94127116 Pubmed ID: 8296501
 TI [The contrast enhancement of brain and spinal cord tumors using Gd-DTPA in magnetic resonance tomography with an extra-low magnetic-field intensity].
 AU Kozlovskiy V N; Pronin I N; Turkin A M; Fadeeva L M
 CS napolazhenost' in magnitnogo polia.
 SO zhurnal VOPROSY NEIROKHIRURGII IMENI N. N. BURDENKO, (1993 Oct-Dec) (4) 13-7.
 CY Journal code: Y9Z: 7809757. ISSN: 0042-8817.
 DT RUSSIA: Russian Federation
 FS Russian
 EM Journal; Article; (JOURNAL ARTICLE)
 DT Journal; Article; (JOURNAL ARTICLE)
 FS Russian
 EM Priority Journals
 ED 199403
 Entered STN: 19940314
 Last Updated on STN: 19990129
 Entered Medline: 19940303

L9 ANSWER 15 OF 239 MEDLINE
 AN 93295116 MEDLINE
 DN 93295116 Pubmed ID: 1305671
 TI Development of chemopreventive agents for bladder cancer.
 AU Kelloff G J; Boone C W; Malone W F; Steele V E; Doodly L A
 CS Chemoprevention Branch, National Cancer Institute, Bethesda, Maryland
 SO 20892.
 CY JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT, (1992) 161 1-12. Ref: 48
 DT Journal code: K8K: 8207539. ISSN: 0733-1959.
 FS United States
 EM Journal; Article; (JOURNAL ARTICLE)
 DT General Review; (REVIEW)
 FS English
 EM Priority Journals
 ED 199307
 Entered STN: 19930806
 Last Updated on STN: 19930806
 Entered Medline: 19930722

L9 ANSWER 16 OF 239 MEDLINE
 AN 93220208 MEDLINE
 DN 93220208 Pubmed ID: 8465480
 TI Intra- and perivesical tumor growth in preoperative staging of bladder cancer: the role of transrectal ultrasonography and high resolution magnetic resonance imaging.
 AU Ruecher U; Gani L; Schmidt A; Stiltz S; Bader H; Nunnensiek C; Rassweiler J; Eisenberger F; Jipp P
 CS Clinic of Internal Medicine, Department of General Internal Medicine, Institute of Pathology, Katharinenhospital, Stuttgart, FRG.
 SO UROLOGIA INTERNATIONALIS, (1993) 50 (3) 141-7.
 CY Journal code: WRI: 0417373. ISSN: 0042-1138.
 DT Switzerland
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS English
 EM Priority Journals
 ED 199305
 Entered STN: 19930521
 Last Updated on STN: 19930521
 Entered Medline: 19930504

L9 ANSWER 17 OF 239 MEDLINE
 AN 93215324 MEDLINE
 DN 93215324 Pubmed ID: 7681744
 TI Management of malignant pleural effusions.
 AU Lynch T J Jr
 CS Division of Clinical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.
 SO CHEST, (1993 Apr) 103 (4 Suppl) 385S-389S. Ref: 43
 CY Journal code: DIC: 0231335. ISSN: 0012-3692.
 DT United States
 DT Journal; Article; (JOURNAL ARTICLE)
 FS General Review; (REVIEW)
 EM (REVIEW, TUTORIAL)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 199305
 Entered STN: 19930521
 Last Updated on STN: 19960129
 Entered Medline: 19930503

L9 ANSWER 18 OF 239 MEDLINE
 AN 93001740 MEDLINE
 DN 93001740 Pubmed ID: 1389653
 TI Nonresectable adenocarcinoma of the rectum assessed by MR imaging before and after chemotherapy and irradiation.
 AU Frykholm G; Hemmingsson A; Nyman R; Pahlman L; Glimelius B
 CS Department of Oncology, Uppsala University, Sweden.
 SO ACTA RADIOLOGICA, (1992 Sep) 33 (5) 447-52.
 CY Journal code: ATA: 8706123. ISSN: 0284-1851.
 DT Denmark
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS English
 EM Priority Journals
 ED 199210
 Entered STN: 19930122
 Last Updated on STN: 19930122
 Entered Medline: 19921029

L9 ANSWER 19 OF 239 MEDLINE
 AN 90208365 MEDLINE
 DN 90208365 Pubmed ID: 2181681
 TI Magnetic resonance imaging in the evaluation of lung cancer.
 AU Gefter W B

CS Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia 19104.
SEMINARS IN RADIOLOGY. (1990 Jan) 25 (1) 73-84. Ref: 70

SO Journal code: UOJ; 0053252. ISSN: 0037-198X.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(REVIEW, TUTORIAL)

LA English
FS Priority Journals
EM 199003
ED Entered STN: 19900601
Last Updated on STN: 19900601
Entered Medline: 19900508

L9 ANSWER 20 OF 239 MEDLINE
AN 90150098 PubMed ID: 2302708
DN 90150098
TI Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma.
AU Bousquet P F; Paulsen L A; Fondy C; Lipski K M; Loucy K J; Fondy T P
CS Department of Biology, Syracuse University, New York 13244.
SO CANCER RESEARCH. (1990 Mar 1) 50 (5) 1431-9.
ED Journal code: CNF; 2984705R. ISSN: 0008-5472.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199003
ED Entered STN: 19900601
Last Updated on STN: 199070203
Entered Medline: 19900321

L9 ANSWER 21 OF 239 MEDLINE
AN 87324971 PubMed ID: 2820315
DN 87324971
TI A case of hepatocellular carcinoma with extrahepatic portal vein obstruction due to tumor invasion, responsive to oral administration of UFT.
AU Nakanishi T; Nishikawa M; Nagase T; Nakagawa C; Maeda S; Kuroda K; Tokunaga K
SO GAN TO KAGAKU RYOHO [JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY], (1987 Sep) 14 (9) 2783-6.
ED Journal code: 6r8; 7810034. ISSN: 0385-0684.

CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA Japanese
FS Priority Journals
EM 198710
ED Entered STN: 19900305
Last Updated on STN: 19900305
Entered Medline: 19871008

L9 ANSWER 22 OF 239 MEDLINE
AN 85123287 PubMed ID: 6395923
DN 85123287
TI (Hemostasis and tumor invasion. Therapeutic implications).
AU Hemostase et invasion tumorale. Deductions therapeutiques.
SO BULLETIN DU CANCER, (1984) 71 (5) 481-93. Ref: 83
CY Journal code: BDZ; 0072416. ISSN: 0007-4551.
DT (CLINICAL TRIAL)

LA Journal; Article; (JOURNAL ARTICLE)
FS General Review; (REVIEW)
EM French
ED Entered STN: 19900320
Last Updated on STN: 19980206
Entered Medline: 19850404

L9 ANSWER 23 OF 239 MEDLINE
AN 84106383 PubMed ID: 6198070
DN 84106383
TI Retroperitoneal lymphadenectomy and aggressive chemotherapy in nonbulky clinical Stage II nonseminomatous germinal testis tumors.
AU Pizzocaro G; Zanoni F; Milani A; Piva L; Salvioni R; Pasi M; Pilotti S; Monfardini S
SO CANCER, (1984 Mar 15) 53 (6) 1363-8.
ED Journal code: CLZ; 0374236. ISSN: 0008-543X.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198403
ED Entered STN: 19900319
Last Updated on STN: 19900319
Entered Medline: 19840323

L9 ANSWER 24 OF 239 MEDLINE
AN 82102255 PubMed ID: 7033659
DN 82102255
TI Histochemical localization of cathepsin B at the invasion front of the rabbit V2 carcinoma.
AU Graf M; Baici A; Strauli P
SO LABORATORY INVESTIGATION, (1981 Dec) 45 (6) 587-96.
ED Journal code: K24; 0376617. ISSN: 0023-6837.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198203
ED Entered STN: 19900317
Last Updated on STN: 19900317
Entered Medline: 19820322

L9 ANSWER 25 OF 239 CAPLUS COPYRIGHT 2002 ACS
AN 1998:438670 CAPLUS
DN 129:92270
TI Clinical study on xenon-enhanced CT and its methodological consideration
AU Hyotani, Genhachi
CS Dep. Neurol. Surg., Wakayama Med. Coll., Wakayama, 640-0000, Japan
SO Wakayama Igaku (1998), 49(2), 223-233
CODEN: WKMIQO; ISSN: 0043-0013

PB Wakayama Igakkai
DT Journal
LA Japanese

L9 ANSWER 26 OF 239 CAPLUS COPYRIGHT 2002 ACS
AN 1997:645807 CAPLUS
DN 127:314418
TI Anti-invasive activity of alkaloids and polyphenolics in vitro
AU Parmar, Virinder S.; Bracke, Marc E.; Philippe, Jan; Wengel, Jesper; Jain, Subhash C.; Olsen, Carl E.; Bishr, Kirpal S.; Sharma, Nawal K.; Courtens, Andy; Sharma, Sunil K.; Venekens, Kristl; Van Marck, Veerle; Singh,

- Sanjay K.; Kumar, Nareesh; Kumar, Ajay; Malhotra, Sanjay; Kumar, Rajesh; Rajwanshi, Vivek K.; Jain, Rajni; Mareel, Marc M. Department of Chemistry, University of Delhi, Delhi, 110 007, India
BIOORG. Med. Chem. (1997) 5(18), 1609-1619
CODEN: BMECEP; ISSN: 0968-0896
- Elsevier
DT Journal
LA English
- L9 ANSWER 27 OF 239 CAPLUS COPYRIGHT 2002 ACS
AN 1997:135978 CAPLUS
DN 126:223948
TI Implications for immunosurveillance of altered HLA class I phenotypes in human tumors
- AU Garrido, Federico; Ruiz-Cabello, Francisco; Cabrera, Teresa; Perez-Villadr, Juan J.; Lopez-Botet, Miguel; Duggan-Keen, Maggie; Stern, Peter L.
Dpto de Analisis Clinicos e Inmunologia, Univ. Granada, Granada, 18014, Spain
- CS Immunol. Today (1997), 18(2), 89-95
CODEN: IMTOB8; ISSN: 0167-4919
- SO Elsevier
PB Journal: General Review
DT English
- L9 ANSWER 28 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 1998138973 EMBASE
TI Adult T-cell leukemia with predominant skin involvement.
AU Nagatani T.; Miyazawa M.; Matsuzaki T.; Horichi Y.; Iemoto G.; Sugita Y.; Baba N.; Sugiyama A.; Nakajima H.; Kitamura H.
CS T. Nagatani, Department of Dermatology, Yokohama City Univ. Sch. of Medicine, 30-9 Fukuura, Kanazawa-Ku, Yokohama 236, Japan
SO International Journal of Dermatology, (1998) 37/4 (275-277).
Refs: 4
ISSN: 0011-9059 CODEN: IJDEBR
CY United Kingdom
DT Journal: Article
FS 005 General Pathology and Pathological Anatomy
016 Dermatology and Venereology
037 Cancer
037 Drug Literature Index
LA English
SL English
- L9 ANSWER 29 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 1998129984 EMBASE
TI Cytostatic agents in the management of malignant gliomas.
AU Mikkelsen T.
CS Dr. T. Mikkelsen, Dept. of Neurology and Neurosurgery, Henry Ford Medical Center, 2799 West Grand Blvd, Detroit, MI 48202-2689, United States
SO Cancer Control, (1998) 5/2 (150-162).
Refs: 114
ISSN: 1073-2748 CODEN: CACOFD
CY United States
DT Journal: Article
FS 008 Neurology and Neurosurgery
037 Drug Literature Index
LA English
SL English
- L9 ANSWER 30 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 95022228 EMBASE
DN 1995022228
TI Magnetic resonance imaging in obstetrics and gynecology: Progress and limitations.
- AU Worthington B.S.
CS Sub-Department of Academic Radiology, Magnetic Resonance Centre, University of Nottingham, Nottingham NG7 2RD, United Kingdom
SO Magnetic Resonance Materials in Physics, Biology, and Medicine, (1994) 2/3 (247-251).
ISSN: 1352-8661 CODEN: MRBMEQ
CY United States
DT Journal: Conference Article
FS 010 Obstetrics and Gynecology
014 Radiology
016 Cancer
027 Biophysics, Bioengineering and Medical Instrumentation
LA English
SL English
- L9 ANSWER 31 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 93109020 EMBASE
DN 1993109020
TI Development of chemopreventive agents for bladder cancer.
AU Kelloff G.J.; Boone C.W.; Malone W.F.; Steele V.E.; Dody L.A.
CS Chemoprevention Branch, National Cancer Institute, 6130 Executive Boulevard, Bethesda, MD 20892, United States
SO Journal of Cellular Biochemistry, (1992) 50/SUPPL. 16 I (1-12).
ISSN: 0730-2312 CODEN: JCEBDS
CY United States
DT Journal: Conference Article
FS 016 Cancer
028 Urology and Nephrology
030 Pharmacology
037 Drug Literature Index
LA English
SL English
- L9 ANSWER 32 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 90090236 EMBASE
DN 1990090236
TI The use of gadolinium enhancement in magnetic resonance imaging of bladder lesions.
AU Hahn D.; Schmidt H.
CS Radiologische Klinik und Poliklinik der Universitaet Muenchen, Zentrale Roentgenabteilung Pettenkoferstr. 8a, 8000 Muenchen 2, Germany
SO Problems in Urology, (1989) 3/4 (782-792).
ISSN: 0889-471X CODEN: PRUREX
CY United States
DT Journal: (Short Survey)
FS 014 Radiology
016 Cancer
028 Urology and Nephrology
037 Drug Literature Index
LA English
SL English
- L9 ANSWER 33 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 88092551 EMBASE
DN 1988092551
TI An organ culture system designed to study interaction of fetal rat calvaria with human head and neck squamous cell carcinoma.
AU Wenig B.L.; Steinberg B.M.; Sciubba J.J.; Gomes B.C.; Abramson A.L.
CS Department of Otolaryngology and Communicative Disorders, The Long Island Jewish Medical Center, New Hyde Park, NY 11042, United States
SO Otolaryngology - Head and Neck Surgery, (1988) 98/3 (235241).
ISSN: 0194-5998 CODEN: OTOLDL
CY United States
DT Journal

FS 005 General pathology and Pathological Anatomy
011 Otorhinolaryngology
LA English
SL English

L9 ANSWER 34 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B. V.
AN 78072279 EMBASE
DN 1978072279
TI Clinical uses of bone scanning.
AU Brady L.W.; Croll M.N.
CS Dept. Radiat. Ther. Nucl. Med., Hahnemann Med. Coll., Philadelphia, Pa.
SO 19102, United States
CODEN: SKRADI
CY Germany
DT Journal
FS 014 Radiology
023 Nuclear Medicine
033 Orthopedic Surgery
016 Cancer
LA English

L9 ANSWER 35 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B. V.
AN 77056726 EMBASE
DN 1977056736
TI Carcinoma of the rectum.
AU Lee Y.T.N.
CS Dept. Surg., Univ. South. California Sch. Med., Los Angeles, Calif. 90033,
SO United States
CODEN: RESUAR
DT Journal
FS 006 Internal Medicine
048 Gastroenterology
009 Surgery
016 Cancer
020 Gerontology and Geriatrics
LA English

L9 ANSWER 36 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1998:230653 BIOSIS
DN PREV199800230653
TI Immunohistochemical staining for desmogleins 1 and 2 in keratinocytic
neoplasms with squamous phenotype: Actinic keratosis, keratocanthoma and
squamous cell carcinoma of the skin.
AU Krunic, A. L.; Garrod, D. R. (1); Madani, S.; Buchanan, M. D.; Clark, R.
E.
CS (1) Epithelial Morphogenesis Res. Group, Sch. Biol. Sci., Univ. Manchester,
3, 239 Stopford Build., Oxford Road, Manchester M13 9PT UK
SO British Journal of Cancer. (April, 1998) Vol. 77, No. 8, pp. 1275-1279.
ISSN: 0007-0920.
DT Article
LA English

L9 ANSWER 37 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1998:80460 BIOSIS
DN PREV19980080460
TI Novel therapeutic strategies to selectively kill cancer cells.
AU Panchal, Rekha G. (1)
CS (1) Human Gene Therapy Res. Inst., Iowa Health Syst., 1415 Woodland Ave.,
Des Moines, IA 50309-3203 USA
SO Biochemical Pharmacology, (Feb. 1, 1998) Vol. 55, No. 3, pp. 247-252.
ISSN: 0006-2952.

DT Article
LA English

L9 ANSWER 38 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:403375 BIOSIS
DN PREV199799709578
TI Mediastinal epithelioid hemangioendothelioma in a patient with type IV
Ehlers-Danlos syndrome: A case report and review of the literature.
AU Regbie, Stephen D.; Bell, David R. (1); Neveil, David F.
CS (1) Dep. Clinical Oncol., Royal North Shore Hosp., St. Leonards, NSW 2065
Australia
SO American Journal of Clinical Oncology, (1997) Vol. 20, No. 4, pp. 412-415.
ISSN: 0277-3732.
DT (CASE REVIEW)
LA English

L9 ANSWER 39 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1995:37864 BIOSIS
DN PREV199598052164
TI Hypopituitarism and Hyponatremia in a Case with Nasopharyngeal Carcinoma.
AU Kokatsu, Toshiyuki (1); Tsukuda, Mamoru
CS (1) Dep. Otorhinolaryngol., School of Med., Yokohama City Univ., 3-9
Fukuura, Kanazawa-ku, Kanazawa-ku, Yokohama, Kanagawa 236 Japan
SO ORL (Oto-Rhino-Laryngology) (Basel), (1994) Vol. 56, No. 6, pp. 347-351.
ISSN: 0301-1569.
DT Article
LA English

L9 ANSWER 40 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1994:480113 BIOSIS
DN PREV199497493113
TI MRI manifestations of gastrointestinal wall thickening.
AU Chou, C.-K. (1); Chen, L.-T.; Sheu, R.-S.; Wang, M.-L.; Jaw, T.-S.; Liu,
G.-C.
CS (1) Dep. Radiol., Chi Mei Found. Hosp., No. 901 Chung-wha Rd., Tainan
Taiwan
SO Abdominal Imaging, (1994) Vol. 19, No. 5, pp. 389-394.
ISSN: 0942-8925.
DT Article
LA English

L9 ANSWER 41 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1994:348027 BIOSIS
DN PREV199497361027
TI Regulation of 92-kD gelatinase release in HL-60 leukemia cells: Tumor
necrosis factor-alpha as an autocrine stimulus for basal- and phorbol
ester-induced secretion.
AU Rites, Christian; Kolb, Helmut; Petrides, Petro E.
CS Moll. Oncol. Lab., Dep. Med. III, Univ. Munich Med. Sch. Grosshadern,
Marchionistr. 15, 81377 Munich Germany
SO Blood, (1994) Vol. 83, No. 12, pp. 3638-3646.
ISSN: 0006-4971.
DT Article
LA English

L9 ANSWER 42 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1993:34689 BIOSIS
DN PREV199396043689
TI Tetrrapeptide tachykinin antagonists: Synthesis and modulation of the
physicochemical and pharmacological properties of a new series of
partially cyclic analogs.
AU Kucharczyk, Nathalie; Turieau, Christophe; Paladino, Joseph; Morris,
Angela D.; Bonnet, Jacqueline; Canet, Emmanuel; Krause, James E.; Regoli,
Domenico; Coteur, Rejean; Facuchere, Jean-Luc (1)

CS (1) Inst. Recherches Servier, 11 rue Moulineaux, 92150 Suresnes France
 SO Journal of Medicinal Chemistry, (1993) Vol. 36, No. 11, pp. 1654-1661.
 ISSN: 0022-2623.

DT Article
 LA English

L9 ANSWER 43 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1982:224244 BIOSIS
 DN BAT3:84228
 TI HISTOCHEMICAL LOCALIZATION OF CATHEPSIN B AT THE INVASION FRONT OF THE RABBIT V-2 CARCINOMA.

AU GRAF M; BAICI A; STRAUL P
 CS DIVISION OF CANCER RESEARCH, INSTITUTE OF PATHOLOGY, UNIV. OF ZUERICH, BIRCHSTR. 95, CH-8050 ZUERICH, SWITZERLAND.
 SO LAB INVEST. (1981 (RECD 1982)) 45 (6), 586-596.
 CODEN: LAINMW. ISSN: 0023-6837.

FS BA, OLD
 LA English

L9 ANSWER 44 OF 239 CANCERLIT
 AN 95608359 CANCERLIT
 DN 95608359
 TI A membrane-bound metalloendoprotease expressed by C6 glioblastoma cells plays an important role in tumor invasion and cell migration in the CNS (Meeting abstract).

AU Hensel T; Amberger V; Schwab M E
 CS Brain Res. Inst., Univ. of Zurich, 8029 Zurich, Switzerland.
 SO Proc Annu Meet Am Assoc Cancer Res, (1995). Vol. 36, pp. A580.
 ISSN: 0197-016X.

DT (MEETING ABSTRACTS)
 FS ICDB
 LA English
 EM 199506

L9 ANSWER 45 OF 239 CANCERLIT
 AN 94699184 CANCERLIT
 DN 94699184
 TI Transarterial chemoembolization of icteric hepatic tumors (Meeting abstract).

AU Wu D K; Tsai T C; Chou C K; Liu G C
 CS Kachinsung Medical Coll., Kachinsung, China.
 SO Non-serial, (1993). APCVIR '93: The First Asian-Pacific Congress of Cardiovascular and Interventional Radiology. May 24-27, 1993, Seoul, Korea.

DT Journal, Article; (JOURNAL ARTICLE)
 FS ICDB
 LA English
 EM 199410

L9 ANSWER 46 OF 239 CANCERLIT
 AN 94690810 CANCERLIT
 DN 94690810
 TI A study of the proteinase, cathepsin L, in the context of tumour invasion.

AU Pike R N
 CS Univ. of Natal, South Africa.
 SO Dis Abstr Int [B], (1993). Vol. 53, No. 9, pp. 4645.
 ISSN: 0419-4217.

DT (THESIS)
 FS ICDB
 LA English
 EM 199408

L9 ANSWER 47 OF 239 CANCERLIT
 AN 90658011 CANCERLIT

DN 90658011
 TI PROTEASES AS MARKERS FOR INVASIVE AND METASTATIC CANCER.
 AU Wu C W
 CS Inst. of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
 SO Int Congr Ser, (1989). Vol. 807, pp. 259-73.

DT Journal, Article; (JOURNAL ARTICLE)
 FS ICDB
 LA English
 EM 199111

L9 ANSWER 48 OF 239 CANCERLIT
 AN 90657720 CANCERLIT
 DN 90657720
 TI OVERVIEW OF CURRENT UNDERSTANDING OF TUMOR SPREAD.

AU Goldfarb R H; Brunson K W
 CS Pittsburgh Cancer Inst., 3343 Forbes Ave., Pittsburgh, PA 15213.
 SO Cancer Growth Prog, (1989). Vol. 1, pp. 28-32.

DT Journal, Article; (JOURNAL ARTICLE)
 FS ICDB
 LA English
 EM 199001

L9 ANSWER 49 OF 239 CANCERLIT
 AN 81695438 CANCERLIT
 DN 81695438
 TI CANCER PAIN.

AU Bonica J J
 CS Dept. Anesthesiology, Univ. Washington Sch. Medicine, Seattle, WA, 98195.
 SO Monogr Ser Eur Organ Res Treat Cancer, (1981). Vol. 7, pp. 87-115.
 ISSN: 0146-0447.

DT Journal, Article; (JOURNAL ARTICLE)
 FS ICDB
 LA English
 EM 198103

L9 ANSWER 50 OF 239 CANCERLIT
 AN 81688037 CANCERLIT
 DN 81688037
 TI PLASMINOGEN ACTIVATOR, PLASMIN, AND COLLAGENASE INTERACTIONS.

AU Moscatelli D; Rifin D B; Isseroff R J; Jaffe E A
 CS Dept. Cell Biology, New York Univ. Medical Sch., New York, NY, 10016.
 SO Non-serial, (1980). Proteinases and Tumor Invasion. Strauli P, Barrett AJ, Baici A, ed. New York, Raven Press. Monograph Series of the European Organization for Research on Treatment of Cancer, Vol. 6, 215, pp., 1980.

DT Book; (MONOGRAPH)
 FS ICDB
 LA English
 EM 198101

L9 ANSWER 51 OF 239 CANCERLIT
 AN 81620284 CANCERLIT
 DN 81620284
 TI HYPERTHERMO-HYDROSTATIC PRESSURE THERAPY COMBINED WITH INTRAVESICAL INSTILLATION OF ANTICANCER DRUGS.

AU Ishituka G; Morita T; Ishida K
 CS Dept. Urology, Akita Univ. Sch. Medicine, Hondo, Akita 010, Japan.
 SO Risho Hinyokika, (1980). Vol. 34, No. 10, pp. 955-961.

DT Journal, Article; (JOURNAL ARTICLE)

FS ICDB
LA Japanese
EM 198108

L9 ANSWER 52 OF 239 USPTAFULL
AN 1998:159966 USPTAFULL
TI Phenylacetate and derivatives alone or in combination with other
IN compounds against neoplastic conditions and other disorders
PA Samd, Dvorit, Rockville, MD, United States
PI The United States of America as represented by the Department of Health
US 5852056 19981222
MO 9510271 19950420
US 1996-633833
MO 1994-US11492

AI 19960410 (8)
19941012
19960410 PCT 371 date
19960410 PCT 102(e) date

RLI Continuation of Ser. No. US 1994-207521, filed on 7 Mar 1994, now
patented, Pat. No. US 5605930 And Ser. No. US 1993-135661, filed on 12
Oct 1993, now patented, Pat. No. US 5635332, each Ser. No. US - which
is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct
1991, now abandoned

DT Utility
FS Granted
LN.CNT 5051
INCL INCLM: 514/510.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
NCLM: 514/510.000
NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000

IC [6]
ICM: A01N037-12
ICS: A01N037-44; A61K031-195; A61K031-24
EXF 514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 53 OF 239 USPTAFULL
AN 1998:150994 USPTAFULL
TI Compositions and methods for treating and preventing
IN pathologies including cancer
PA Samd, Dvorit, Rockville, MD, United States
PI The United States of America as represented by the Department of Health
US 5843994 19981201
US 1995-478264 19950607 (8)
Division of Ser. No. US 1994-207521, filed on 7 Mar 1994, now patented,
Pat. No. US 5605930 which is a continuation-in-part of Ser. No. US
1993-135661, filed on 12 Oct 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991,
now abandoned

DT Utility
FS Granted
LN.CNT 7935
INCL INCLM: 514/510.000
INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000
NCLM: 514/510.000
NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000

IC [6]
ICM: A61K031-21
ICS: A01N047-40
EXF 514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 54 OF 239 USPTAFULL
AN 1998:150674 USPTAFULL
TI Isolation of cellular material under microscopic visualization
IN Liotta, Lance A., Potomac, MD, United States
BUck, Michael E., Bethesda, MD, United States
Wells, Richard, Washington, DC, United States
Zhong, Zhongping, Bethesda, MD, United States
PA The United States of America as represented by the Department of Health
US 5843657 19981201
US 1995-543388 19951010 (8)
Continuation-in-part of Ser. No. US 1994-203780, filed on 1 Mar 1994

AI US 1995-543388 19951010 (8)
RLI Continuation-in-part of Ser. No. US 1994-203780, filed on 1 Mar 1994
DT Utility
FS Granted
LN.CNT 1033
INCL INCLM: 435/006.000
INCLS: 435/001.000; 156/057.000; 436/174.000; 436/175.000; 436/177.000;
436/063.000
NCLM: 435/006.000
NCLS: 156/057.000; 436/063.000; 436/174.000; 436/175.000; 436/177.000

IC [6]
ICM: A01N001-02
ICS: A01N001-00; A01N003-00
EXF 435/1; 435/6; 156/57; 436/63; 436/174; 436/175; 436/177
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 55 OF 239 USPTAFULL
AN 1998:150662 USPTAFULL
TI Isolation of cellular material under microscopic visualization using an
IN adhesive/extraction reagent tipped probe
Liotta, Lance A., Potomac, MD, United States
Zhong, Zhongping, Rockville, MD, United States
BUck, Michael E., Bethesda, MD, United States
Stetler-Stevenson, William G., Silver Spring, MD, United States
Lubensky, Irina A., Silver Spring, MD, United States
Roth, Mark J., Silver Spring, MD, United States
PA The United States of America as represented by the Secretary of the
Department of Health and Human Services, Washington, DC, United States
(U.S. government)

PI US 5843644 19981201
AI US 1994-203780 19940301 (8)
DT Utility
FS Granted
LN.CNT 670
INCL INCLM: 435/006.000
INCLS: 435/040.500; 435/040.520; 435/172.100; 435/808.000; 318/280.000;
382/006.000; 422/099.000; 436/805.000; 436/063.000
NCLM: 435/006.000
NCLS: 318/280.000; 382/133.000; 422/099.000; 435/040.500; 435/040.520;
435/808.000; 436/063.000; 436/805.000

IC [6]
ICM: C12Q001-68
EXF 435/172.1; 435/808; 435/6; 435/40.5; 435/40.52; 436/805; 436/63; 422/99;
318/280; 382/6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 56 OF 239 USPTAFULL
AN 1998:147284 USPTAFULL
TI DNA encoding human cysteine protease
IN Diep, Dinh, San Francisco, CA, United States
Braxton, Scott Michael, San Mateo, CA, United States
Delegeane, Angelo M., Hayward, CA, United States

PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 5840562 19981124
 AI US 1991-928613 19970912 (8)
 RLI Continuation of Ser. No. US-1993-567506, filed on 5 Dec. 1995, now abandoned
 DT Utility
 FS Granted
 IN CNT 1655
 INCL INCLM: 435/212.000
 INCLM: 435/320.100; 435/325.000; 435/254.210; 435/252.330; 536/023.200;
 NCL INCLM: 435/212.000
 NCLM: 435/212.000
 NCLM: 435/252.330; 435/254.210; 435/320.100; 435/325.000; 536/023.100;
 NCLM: 536/023.200; 536/023.500
 IC [6]
 ICM: C12N009-48
 ICS: C07H021-04
 EXF 536/23.2; 536/23.1; 536/23.5; 435/320.1; 435/212; 435/69.1; 435/325;
 435/172.3; 435/252.33; 435/254.21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 57 OF 239 USPTFUL
 AN 1998.147247 USPTFUL
 TI Nucleic acids, vectors and host cells encoding heregulin
 IN Vanden, Richard L., Hillsborough, CA, United States
 PA Holmes, William E., Pacifica, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 5840525 19981124
 AI US 1995-456241 19950531 (8)
 RLI Division of Ser. No. US 1993-126145, filed on 23 Sep 1993, now abandoned
 DT Utility
 FS Granted
 IN CNT 4160
 INCL INCLM: 435/069.100
 INCLM: 435/320.100; 435/325.000; 435/252.300; 536/023.500; 935/077.000;
 NCL INCLM: 935/078.000
 NCLM: 435/069.100
 NCLM: 435/325.300; 435/320.100; 435/325.000; 536/023.500
 IC [6]
 ICM: C12N015-00
 ICS: C12N015-63; C12N015-85; C12N001-21; C07H021-04
 EXF 435/69.1; 435/320.1; 435/242.7; 435/325; 435/252.3; 536/23.5; 530/350;
 530/399
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 58 OF 239 USPTFUL
 AN 1998.147237 USPTFUL
 TI Methode of testing cancer and anticancer drugs
 IN Livant, Donna L., Ann Arbor, MI, United States
 PA The Regents of the University of Michigan, Ann Arbor, MI, United States
 PA (U.S. corporation)
 PI US 5840514 19981124
 AI US 1996-754322 19961121 (8)
 DT Utility

FS Granted
 LN CNT 1439
 INCL INCLM: 435/029.000
 INCLM: 435/024.000; 530/300.000; 530/323.000; 530/324.000; 530/325.000;
 INCLM: 530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000;
 530/350.000; 530/382.000; 514/002.000; 514/021.000
 NCL INCLM: 435/029.000
 NCLM: 435/004.000; 514/002.000; 514/021.000; 530/300.000; 530/323.000;
 NCLM: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000;
 530/329.000; 530/330.000; 530/350.000; 530/382.000
 IC [6]
 ICM: C12O001-02
 ICS: C12O001-00
 EXF 435/29; 435/4; 530/300; 530/323; 530/324; 530/325; 530/326; 530/327;
 530/328; 530/329; 530/330; 530/350; 530/382; 514/2; 514/21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 59 OF 239 USPTFUL
 AN 1998.144102 USPTFUL
 TI Amino-alcohol substituted cyclic compounds
 IN Kumar, Anil M., Seattle, WA, United States
 IN Michnick, John, Seattle, WA, United States
 IN Underiner, Gail E., Briar, WA, United States
 IN Klein, J. Peter, Vashon Island, WA, United States
 PA Rice, Glenn C., Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5837703 19981117
 AI US 1993-152650 19931112 (8)
 RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
 now abandoned
 DT Utility
 FS Granted
 IN CNT 2596
 INCL INCLM: 514/183.000
 INCLM: 514/228.800; 514/241.000; 514/242.000; 514/249.000;
 INCLM: 514/251.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000;
 514/276.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;
 514/309.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;
 540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;
 544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000;
 546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000;
 546/340.100; 548/485.000; 548/546.000; 548/561.000
 NCL INCLM: 514/183.000
 NCLM: 514/228.800; 514/241.000; 514/242.000; 514/249.000;
 514/251.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000;
 514/276.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;
 514/309.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;
 540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;
 544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000;
 546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000;
 548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000
 IC [6]
 ICM: A61K031-55
 ICS: A61K031-515; A61K031-445; A61K031-52
 EXF 544/276; 544/272; 544/216; 544/257; 544/286; 544/301; 544/311;
 544/335; 514/263; 514/183; 514/211; 514/228.8; 514/242;
 514/249; 514/256; 514/259; 514/270; 514/274; 514/309; 514/312; 514/315;
 514/348; 514/357; 514/374; 514/400; 514/425; 514/427; 540/467;
 540/544; 546/96; 546/141; 546/142; 546/157; 546/246; 546/296; 546/334;
 548/215; 548/340.1; 548/485; 548/546; 548/561
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 60 OF 239 USPTFUL
 AN 1998.144079 USPTFUL

Agents affecting thrombosis and hemostasis
 TI Wolf, David L., Palo Alto, CA, United States
 IN Sinha, Uma, San Francisco, CA, United States
 PA COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 5837693 19981117 19950606 (8)
 AI US 1995-469301
 RLI Division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5587799 which is a continuation of Ser. No. US -808329 which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144
 DT Utility
 FS Granted
 IN CNT 2092
 INCL INCLM: 514/012.000
 INCLM: 514/008.000; 514/021.000; 514/834.000; 424/094.640; 435/069.600; 435/212.000; 530/381.000; 530/384.000; 530/395.000; 530/402.000; 530/830.000
 NCLM: 514/012.000
 NCLM: 424/094.640; 435/069.600; 435/212.000; 514/008.000; 514/021.000; 514/834.000; 530/381.000; 530/384.000; 530/395.000; 530/402.000; 530/830.000
 NCLS: 514/012.000
 IC [6]
 ICM: A61K038-36
 ICS: A61K035-14; C07K014-475; C07K001-06
 EXF 514/12; 514/21; 514/834; 514/8; 530/380; 530/381; 530/384; 530/350; 530/402; 530/829; 530/830; 530/831; 530/395; 930/100; 435/69.1; 435/69.2; 435/69.6; 435/212; 424/94.64
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 61 OF 239 USPTAFULL
 AN 1998:144076 USPTAFULL
 TI Use of scatter factor to enhance angiogenesis
 IN Goldberger, Itzhak D., Englewood, NJ, United States
 PA Rosen, Elliot M., Port Washington, NY, United States
 PI Long Island Jewish Medical Center, New Hyde Park, NY, United States (U.S. corporation)
 AI US 5857676 19981117
 RLI US 1996-746636 19961113 (8)
 DT Continuation of Ser. No. US 1993-138667, filed on 18 Oct 1993, now abandoned
 FS Utility
 IN CNT 475
 INCL INCLM: 514/008.000
 INCLM: 514/021.000; 530/399.000
 NCLM: 514/008.000
 NCLM: 514/021.000; 530/399.000
 IC [6]
 ICM: A61K038-18
 EXF 514/8; 514/21; 530/399
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 62 OF 239 USPTAFULL
 AN 1998:138936 USPTAFULL
 TI 3-(2'-halobenzyldienyl)-2-indolinone compounds for the treatment of disease
 IN Tang, Peng Cho, Moraga, CA, United States
 PA Sun, Li, Foster City, CA, United States
 PI McMahon, Gerald, Kenwood, CA, United States
 PA Sugen, Inc., Redwood City, CA, United States (U.S. corporation)
 PI US 5834504 19981110

AI US 1996-655225 19960605 (8)
 RLI Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995
 DT Utility
 FS Granted
 IN CNT 3662
 INCL INCLM: 514/418.000
 INCLM: 548/486.000
 NCLM: 514/418.000
 NCLM: 548/486.000
 IC [6]
 ICM: H61K031-40
 ICS: C07D209-34
 EXF 548/486; 514/418
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 63 OF 239 USPTAFULL
 AN 1998:138672 USPTAFULL
 TI Nucleic acids vectors and host cells encoding and expressing heregulin
 IN 2-alpha. Vandlen, Richard L., Hillsborough, CA, United States
 PA Holmes, William E., Pacifica, CA, United States
 PI Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 AI US 5834229 19981110
 RLI US 1994-330161 19941025 (8)
 DT Continuation of Ser. No. US 1993-35430, filed on 22 Mar 1993, now abandoned which is a continuation of Ser. No. US 1991-705256, filed on 24 May 1991, now abandoned
 FS Utility
 IN CNT 3467
 INCL INCLM: 435/069.100
 INCLM: 435/091.200; 435/325.000; 435/252.300; 435/320.100; 536/023.500; 536/024.310; 536/024.330; 935/077.000; 935/078.000
 NCLM: 435/069.100
 NCLM: 435/091.200; 435/252.300; 435/320.100; 435/325.000; 536/023.500; 536/024.310; 536/024.330
 IC [6]
 ICM: C12N015-00
 ICS: C12N015-85; C12N007-00; C12N015-63; C07H021-04
 EXF 435/91.2; 435/969.1; 435/320.1; 435/240.2; 435/252.3; 435/252.8; 536/23.5; 536/24.33; 536/24.31
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 64 OF 239 USPTAFULL
 AN 1998:135148 USPTAFULL
 TI Inhibitors of metalloproteinases, pharmaceutical compositions comprising same and methods of their use
 IN Campbell, David A., San Mateo, CA, United States
 PA Patel, Dinesh V., Fremont, CA, United States
 PI Xiao, Xiao-Yi, San Diego, CA, United States
 PA Affymax Technologies N.V., Greenford, England (non-U.S. corporation)
 AI US 5831004 19981103
 RLI US 1995-549345 19951027 (8)
 DT Continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned
 FS Utility
 IN CNT 2313
 INCL INCLM: 530/331.000
 INCLM: 514/018.000; 514/019.000; 564/154.000; 546/309.000; 544/159.000
 NCLM: 530/331.000
 NCLM: 544/159.000; 546/309.000; 564/154.000

IC [6]
ICM: C07K005-00
EXF 530/331; 514/18-19; 564/154; 546/309; 544/159.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 65 OF 239 USPTAFULL
AN 1998:135060 USPTAFULL
TI Phosphoric acid amides as matrix metalloproteinase inhibitors
IN Piki, Stanislaw, Mason, OH, United States
McDow-Dunham, Kelly Lynn, Loveland, OH, United States
De, Biswanath, Cincinnati, OH, United States
Taiwo, Yetunde Olabisi, West Chester, OH, United States
The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5830915 19981103
AI US 1997-918950 19970826 (8)
PRAI US 1996-24765P 19960828 (60)
DT Utility
FS Granted
LN.CNT 1864
INCL INCLM: 514/620.000
INCS: 514/357.000; 514/396.000; 514/415.000; 514/438.000; 514/451.000;
514/824.000; 514/861.000; 514/863.000; 514/864.000; 514/886.000;
514/902.000; 514/903.000; 546/021.000; 546/336.000; 546/337.000;
548/112.000; 549/006.000; 549/216.000

NCL NCIM: 514/620.000
NCS: 514/357.000; 514/396.000; 514/415.000; 514/438.000; 514/451.000;
514/824.000; 514/861.000; 514/863.000; 514/864.000; 514/886.000;
514/902.000; 514/903.000; 546/021.000; 546/336.000; 546/337.000;
548/112.000; 549/006.000; 549/216.000

IC [6]
ICM: A61K031-16
ICS: A61K031-38; A61K031-40; A61K031-44
EXF 514/357; 514/396; 514/415; 514/436; 514/451; 514/620; 514/824; 514/861;
514/863; 514/864; 514/886; 514/902; 514/903; 546/21; 546/336; 546/337;
548/112; 549/6; 549/216; 564/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 66 OF 239 USPTAFULL
AN 1998:134796 USPTAFULL
TI Determining invasiveness of prostatic adenocarcinoma
IN Patierno, Steven R., Falls Church, VA, United States
Manvak, Michael, Chevy Chase, MD, United States
George Washington University, Washington, DC, United States (U.S. corporation)
PI US 5830640 19981103
AI US 1995-486203 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-400084, filed on 7 Mar 1995
DT Utility
FS Granted
LN.CNT 2164
INCL INCLM: 435/004.000
INCS: 435/007.100; 435/040.500; 435/040.520; 530/386.000; 530/387.100;
530/387.700
NCL NCIM: 435/004.000
NCS: 435/007.100; 435/040.500; 435/040.520; 530/386.000; 530/387.100;
530/387.900

IC [6]
ICM: C120001-00
ICS: G01N033-53; C07K016-00
EXF 424/94.1; 424/184.1; 424/277.1; 536/23.1; 435/6; 435/7.1; 435/4;
435/40.5; 435/40.52; 530/387.1; 530/387.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 67 OF 239 USPTAFULL
AN 1998:134630 USPTAFULL
TI Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
IN Bini, Alessandra, New York, NY, United States
The New York Blood Center, Inc., New York, NY, United States (U.S. corporation)
PI US 5830468 19981103
AI US 1995-446887 19950517 (8)
DT Utility
FS Granted
LN.CNT 1482
INCL INCLM: 424/094.670
INCS: 424/094.630; 424/094.100; 435/219.000; 530/389.300; 206/210.000;
604/173.000
NCL NCIM: 424/094.670
NCS: 206/210.000; 424/094.100; 424/094.630; 435/219.000; 530/389.300;
604/173.000

IC [6]
ICM: A61K038-48
ICS: C12N005-50; B65D051-24; A61M005-00
EXF 424/94.67; 424/94.64; 424/94.1; 424/93.21; 206/210; 604/173; 530/389.3;
435/219
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 68 OF 239 USPTAFULL
AN 1998:128378 USPTAFULL
TI Human stromelysin-1 promoter
IN Borden, Paula Ann, Palo Alto, CA, United States
Heller, Remu Anand, Stanford, CA, United States
Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5824794 19981020
AI US 1994-362706 19941223 (8)
DT Utility
FS Granted
LN.CNT 819
INCL INCLM: 536/024.100
INCS: 435/172.300; 435/320.100; 435/325.000; 435/366.000; 435/252.300;
536/023.500

NCL NCIM: 536/024.100
NCS: 435/252.300; 435/320.100; 435/325.000; 435/366.000; 536/023.500

IC [6]
ICM: C07H021-04
ICS: C12N005-16; C12N015-12; C12N015-85
EXF 514/44; 536/23.1; 536/24.1; 536/23.5; 435/320.1; 435/240.2; 435/6;
435/252.3; 435/366; 435/172.3; 435/325; 424/93.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 69 OF 239 USPTAFULL
AN 1998:124586 USPTAFULL
TI Hydroxamic acid derivatives as inhibitors of cytokine production
IN Criminin, Michael John, Oxford, United Kingdom
Beckett, Raymond Paul, Oxford, United Kingdom
British Biotech Pharmaceuticals Limited, Oxford, England (non-U.S. corporation)
PI US 5821262 19981013
AI WO 9509841 19950413
WO 1994-GB2145 19961028 (8)
19941004 19961028 PCT 371 date
19961028 PCT 102(e) date
PRAI GB 1993-20660 19931007
DT Utility
FS Granted
LN.CNT 1077

INCL INCLM: 514/445.000
INCLM: 514/575.000; 549/062.000; 562/621.000; 562/623.000
NCLM: 514/445.000
NCLM: 514/575.000; 549/062.000; 562/621.000; 562/623.000
ICM: 514/575.000; 549/062.000; 562/621.000; 562/623.000
[6]
ICM: C07D333-34
EXF ICS: C07C323-60; C07C317-44; A61K031-16
514/575; 514/397; 514/419; 514/445; 562/621; 562/623;
548/315.1; 548/335.1; 548/335.5; 548/494; 548/495; 549/62
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 70 OF 239. USPTAFULL
AN 1998:122568 USPTAFULL
TI Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic
acids
IN Namermet, Philippe G., Maplewood, NJ, United States
Parfer, David T., Livingston, NJ, United States
Macherson, Lawrence J., Hampton, NJ, United States
Novartis Corporation, Summit, NJ, United States (U.S. corporation)
PA US 5817822 19981006
PI US 1997-787730 19970124 (8)
RLI Continuation-in-part of Ser. No. US 1995-475166, filed on 7 Jun 1995,
now patented, Pat. No. US 5646167 which is a continuation-in-part of
Ser. No. US 1994-333676, filed on 3 Nov 1994, now patented, Pat. No. US
5552419 which is a continuation-in-part of Ser. No. US 1994-265296,
filed on 24 Jun 1994, now patented, Pat. No. US 5506242
Utility
DT Utility
FS Granted
LN.CNT 1865
INCL INCLM: 546/194.000
INCLM: 546/186.000; 546/190.000; 546/192.000; 546/207.000
NCLM: 546/194.000
NCLM: 546/186.000; 546/190.000; 546/192.000; 546/207.000
ICM: 546/186.000; 546/190.000; 546/192.000; 546/207.000
[6]
EXF ICS: C07D401-02
546/186; 546/190; 546/192; 546/194; 546/207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 71 OF 239 USPTAFULL
AN 1998:122413 USPTAFULL
TI Substituted amino alkyl compounds
Klein, J. Peter, Vashon Island, WA, United States
Underiner, Gail E., Brier, WA, United States
Leigh, Alistair J., Brier, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA US 5817662 19981006
PI US 1995-468656 19950606 (8)
RLI Division of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1992-973804, filed on 9
Nov 1992, now patented, Pat. No. US 5340813
Utility
DT Utility
FS Granted
LN.CNT 1358
INCL INCLM: 514/263.000
INCLM: 424/824.000; 424/825.000; 424/885.000; 424/921.000
NCLM: 514/263.350
NCLM: 424/824.000; 424/825.000
ICM: 424/824.000; 424/825.000
[6]
EXF ICS: A61K031-52
514/397; 514/263; 424/824; 424/825; 424/885; 424/921
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 72 OF 239 USPTAFULL
AN 1998:119125 USPTAFULL

TI Compositions containing a disintegrin and methods for its use
IN in preventing metastasis and other conditions
Markland, Jr., Francis S., Manhattan Beach, CA, United States
Zhou, Qing, Alhambra, CA, United States
University of Southern California, Los Angeles, CA, United States (U.S.
corporation)
PA US 5814609 19980929
PI US 1996-745603 19961108 (8)
RLI Continuation-in-part of Ser. No. US 1996-632691, filed on 15 Apr 1996,
now patented, Pat. No. US 5731288 which is a division of Ser. No. US
1995-540423, filed on 10 Oct 1995, now abandoned which is a continuation
of Ser. No. US 1993-141321, filed on 22 Oct 1993, now abandoned
Utility
DT Utility
FS Granted
LN.CNT 1085
INCL INCLM: 514/012.000
INCLM: 530/324.000
NCLM: 514/012.000
NCLM: 530/324.000
ICM: 530/324.000
[6]
EXF ICS: A61K038-00
514/12; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 73 OF 239 USPTAFULL
AN 1998:111942 USPTAFULL
TI Therapeutic compounds containing pyrimidinyl moieties
Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA US 5807862 19980915
PI US 1995-478112 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
now abandoned
Utility
DT Utility
FS Granted
LN.CNT 2190
INCL INCLM: 514/269.000
INCLM: 544/309.000; 544/310.000; 544/311.000; 544/312.000
NCLM: 514/269.000
NCLM: 544/309.000; 544/310.000; 544/311.000; 544/312.000
ICM: 544/309.000; 544/310.000; 544/311.000; 544/312.000
[6]
EXF ICS: C07D239-54
514/269; 514/274; 544/309; 544/310; 544/311; 544/312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 74 OF 239 USPTAFULL
AN 1998:111941 USPTAFULL
TI Amine substituted xanthinyl compounds
Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
Rice, Glenn C., Seattle, WA, United States
Leung, David W., Mercer Island, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA US 5807861 19980915
PI US 1995-476911 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994,
now abandoned

DT Utility
FS Granted
LN CNT 1713
INCL INCLM: 514/263.000
NCL NCIM: 514/263.350
NCLM: 514/081.000; 514/151.000; 514/210.210; 514/263.200; 514/263.220;
514/263.230
IC [6]
ICM: A61K031-52
EXE 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 75 OF 239 USPATFULT
AN: 1998:108432 USPATFULT
TI Methods of cancer treatment using naaladase inhibitors
IN Slusher, Barbara S., Kingsville, MD, United States
Jackson, Paul F., Bel Air, MD, United States
Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
PI US 5804602 19980908
AI US 1996-665775 19960617 (8)
DT Utility
FS Granted
LN CNT 1471
INCL INCLM: 514/574.000
NCL NCIM: 562/024.000
NCLM: 514/574.000
NCLM: 562/024.000
IC [6]
ICM: A61K031-66
ICS: C07E009-28
562/24; 514/574
EXF 562/24; 514/574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 76 OF 239 USPATFULT
AN: 1998:108415 USPATFULT
TI Therapeutic compounds containing a monocyclic five- to six- membered
ring structure having one to two nitrogen atoms
IN Underiner, Gail E., Briar, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Edmonds, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5804584 19980908
AI US 1995-468659 19950606 (8)
DT Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16
Nov 1992, now patented, Pat. No. US 5473070
FS Utility
INCL INCLM: 514/269.000
NCL NCIM: 544/298.000; 544/242.000; 544/301.000; 544/302.000; 514/256.000
NCLM: 514/269.000
NCLM: 514/256.000; 544/242.000; 544/298.000; 544/301.000; 544/302.000
IC [6]
ICM: C07D239-54
ICS: A61K031-52
EXF 514/242; 514/243; 514/269; 544/298; 544/299
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 77 OF 239 USPATFULT
AN: 1998:108219 USPATFULT
TI Methods for identifying differentially expressed genes and

IN differences between genomic nucleic acid sequences
Sylkowski, Arthur J., Arlington, MA, United States
Yang, Melheng, Boston, MA, United States
PA Beth Israel Deaconess Medical Center, Inc., Boston, MA, United States
(U.S. corporation)
PI US 5804382 19980908
AI US 1996-644326 19960510 (8)
DT Utility
FS Granted
LN CNT 1251
INCL INCLM: 435/006.000
NCL NCIM: 435/091.200
NCLM: 435/006.000
NCLM: 435/091.200
IC [6]
ICM: C12P001-68
ICS: C12P019-34
435/6; 435/91.2; 935/77; 935/78
EXF 435/6; 435/91.2; 935/77; 935/78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 78 OF 239 USPATFULT
AN: 1998:104752 USPATFULT
TI Amine substituted compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Briar, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5801182 19980901
AI US 1995-485777 19950607 (8)
DT Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994,
now abandoned
FS Utility
INCL INCLM: 514/269.000
NCL NCIM: 514/274.000; 544/310.000; 544/311.000; 544/312.000
NCLM: 514/269.000
NCLM: 514/274.000; 544/310.000; 544/311.000; 544/312.000
IC [6]
ICM: A61K031-505
ICS: C07D239-02
544/312; 514/269; 514/274; 514/310; 514/311
EXF 544/312; 514/269; 514/274; 514/310; 514/311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 79 OF 239 USPATFULT
AN: 1998:104751 USPATFULT
TI Amino alcohol substituted cyclic compounds
IN Michnick, John, Seattle, WA, United States
Underiner, Gail E., Briar, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5801181 19980901
AI US 1995-474820 19950607 (8)
DT Division of Ser. No. US 1993-152650, filed on 12 Nov 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31
Mar 1993
FS Utility
INCL INCLM: 514/263.000
NCL NCIM: 514/183.000; 514/249.000; 514/259.000; 514/274.000; 514/309.000;
514/315.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ICM: 514/266.000; 514/668.000; 514/669.000

NCL: 514/263.350

NCLM: 514/183.000; 514/249.000; 514/266.300; 514/274.000; 514/309.000; 514/315.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000; 514/626.000; 514/668.000; 514/669.000

IC [6]

ICM: A01N043-00

EXF: ICS: A01N043-90; A01N043-58; A01N043-42
514/263; 514/249; 514/266; 514/274; 514/309; 514/315; 514/418;
514/425; 514/617; 514/619; 514/626; 514/668; 514/669

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 80 OF 239 USPTFULL

AN 1998:104574 USPTFULL

TI Method of detecting cancer

IN Sager, Ruth, Brookline, MA, United States

PA Zou, Zhigang, Gaithersburg, MD, United States

PA Anisowicz, Anthony, West Newton, MA, United States

PA Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)

PI US 5801001

AI US 1995-477108

RLI 19950607 (8)

FS Division of Ser. No. US 1993-121714, filed on 1 Sep 1993, now patented, Pat. No. US 5470970 which is a continuation-in-part of Ser. No. US 1992-938823, filed on 1 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-844296, filed on 28 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-662216, filed on 28 Feb 1991, now abandoned

DT Utility

FS Granted

LN CNT 1502

INCL INCLM: 435/007.230

INCLS: 435/007.210; 530/387.700; 530/387.900; 530/388.200; 530/388.800; 530/388.850; 530/389.700

NCL NCLM: 435/007.230

NCLM: 435/007.210; 530/387.700; 530/387.900; 530/388.200; 530/388.800; 530/388.850; 530/389.700

IC [6]

ICM: G01N033-536

EXF: ICS: G01N033-574; C07K016-30
435/7.1; 435/7.23; 530/387.7; 530/388.2; 530/387.9; 530/388.8;
530/388.85; 530/389.7

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 81 OF 239 USPTFULL

AN 1998:101516 USPTFULL

TI Nucleic acids encoding protocadherin

IN Suzuki, Shintaro, Torrance, CA, United States

PA Doherty Eye Institute, Los Angeles, CA, United States (U.S. corporation)

PI US 5798224

AI 19980825

RLI 19940627 (8)

FS Continuation-in-part of Ser. No. US 1992-998003, filed on 29 Dec 1992, now patented, Pat. No. US 5643781

DT Utility

FS Granted

LN CNT 3432

INCL INCLM: 435/069.100

INCLS: 536/023.500; 435/252.300; 435/254.110; 435/320.100; 435/325.000

NCL NCLM: 435/069.100

NCLM: 435/252.300; 435/254.110; 435/320.100; 435/325.000; 536/023.500

IC [6]

ICM: C12N015-09

EXF: ICS: 435/69.1; 435/240.1; 435/252.3; 435/254.11; 435/320.1; 435/240.2;
435/325; 536/23.1; 536/23.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 82 OF 239 USPTFULL

AN 1998:98901 USPTFULL

TI Inhibitors of NAD(P)ase enzyme activity

IN Jackson, Paul F., Bel Air, MD, United States

PA Slusner, Barbara S., Kingsville, MD, United States

PA Tays, Kevin L., Elkrige, MD, United States

PA McElin, Keith M., Baltimore, MD, United States

PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)

PI US 5795877

AI US 1996-775586

RLI 19980818

FS 19961231 (8)

DT Utility

FS Granted

LN CNT 2019

INCL INCLM: 514/075.000

INCLS: 562/008.000; 562/024.000

NCL NCLM: 514/075.000

NCLM: 562/008.000; 562/024.000

IC [6]

ICM: C07F009-30

EXF: ICS: C07F009-38; A61K031-66
562/8; 562/24; 514/75

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 83 OF 239 USPTFULL

AN 1998:95356 USPTFULL

TI 3-heteroaryl-2-indolinone compounds for the treatment of disease

IN Tang, Peng Cho, Moraga, CA, United States

PA Sun, Li, Foster City, CA, United States

PA McMahon, Gerald, Kenwood, CA, United States

PA Sugen, Inc., Redwood City, CA, United States (U.S. corporation)

PI US 5792783

AI 19980811

RLI 19960605 (8)

FS Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995

DT Utility

FS Granted

LN CNT 3788

INCL INCLM: 514/397.000

INCLS: 514/359.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/372.000; 514/374.000; 514/378.000; 514/381.000; 514/383.000; 514/406.000; 514/414.000; 548/125.000; 548/127.000; 548/128.000; 548/131.000; 548/134.000; 548/135.000; 548/143.000; 548/202.000; 548/214.000; 548/235.000; 548/247.000; 548/250.000; 548/255.000; 548/266.400; 548/312.100; 548/364.700; 548/468.000

NCL NCLM: 514/397.000

NCLM: 514/359.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/372.000; 514/374.000; 514/378.000; 514/381.000; 514/383.000; 514/406.000; 514/414.000; 548/125.000; 548/127.000; 548/128.000; 548/131.000; 548/134.000; 548/135.000; 548/143.000; 548/202.000; 548/214.000; 548/235.000; 548/247.000; 548/250.000; 548/255.000; 548/266.400; 548/312.100; 548/364.700; 548/468.000

IC [6]

ICM: A61K031-40

EXF: ICS: A61K031-415; C07D403-06
548/468; 548/125; 548/127; 548/128; 548/131; 548/134; 548/136; 548/143;
548/202; 548/214; 548/235; 548/247; 548/250; 548/255; 548/266.4;
548/312.1; 548/364.7; 514/414; 514/359; 514/361; 514/362; 514/363;
514/364; 514/365; 514/372; 514/374; 514/378; 514/381; 514/383; 514/397;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 84 OF 239 USPTFULL

AN 1998:91603 USPTAFULL
 Composition and method for enhancing wound healing
 TI Henkin, R. L., 6601 Broxburn Dr., Bethesda, MD, United States 20817.
 PI US 5788867 19980804
 AI US 1993-480.100 19950607 (8)
 RLI Division of Ser. No. US 1994-297083, filed on 26 Aug 1994, now abandoned
 which is a division of Ser. No. US 1993-76058, filed on 14 Jun 1993, now
 patented, Pat. No. US 5384308
 DT Utility
 FS Granted
 LN.CNT 649
 INCL INCLM: 424/172.100
 INCLTS: 424/130.100; 424/137.100; 530/387.100; 530/387.900; 530/389.100
 NCL NCLM: 424/172.100
 NCIS: 424/130.100; 424/137.100; 530/387.100; 530/387.900; 530/389.100
 IC [6]
 ICM: A61K039-395
 ICS: C07K016-00
 EXF 424/130.1; 424/137.1; 424/172.1; 530/387.9; 530/387.1; 530/389.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 85 OF 239 USPTAFULL
 AN 1998:86037 USPTAFULL
 TI Hyaluronan receptor expressed in human umbilical vein endothelial
 IN Hawkins, Phillip R., Mountain View, CA, United States
 PI US 5783659 19980721
 AI US 1996-700178 19960820 (8)
 RLI Division of Ser. No. US 1995-402217, filed on 10 Mar 1995, now patented,
 Pat. No. US 5587301
 DT Utility
 FS Granted
 LN.CNT 1140
 INCL INCLM: 530/350.000
 INCLTS: 435/069.100; 536/023.500
 NCL NCLM: 530/350.000
 NCIS: 435/069.100; 536/023.500
 IC [6]
 ICM: C07K014-705
 ICS: 530/350; 435/69.1; 536/23.5
 EXF 530/350; 435/69.1; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 86 OF 239 USPTAFULL
 AN 1998:82763 USPTAFULL
 TI Hydroxyl-containing xanthine compounds
 IN Underiner, Gail E., Briar, WA, United States
 PI US 5780476 19980714
 AI US 1995-468660 19950606 (8)
 RLI Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned
 which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16
 Nov 1992, now patented, Pat. No. US 5473070
 DT Utility
 FS Granted
 LN.CNT 1672
 INCL INCLM: 514/263.000
 INCLTS: 544/267.000
 NCL NCLM: 514/263.360

IC [6]
 ICM: A61K031-52
 ICS: C07D473-04
 EXF 514/263; 514/256; 514/257; 514/258; 514/259; 514/261; 514/269; 514/270
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 87 OF 239 USPTAFULL
 AN 1998:79342 USPTAFULL
 TI Acetal and ketal-substituted pyrimidine compounds
 IN Leigh, Alistair, Briar, WA, United States
 PI US 5777115 19980707
 AI US 1994-193331 19940207 (8)
 RLI Continuation-in-part of Ser. No. US 1993-4353, filed on 14 Jan 1993, now
 abandoned
 DT Utility
 FS Granted
 LN.CNT 1632
 INCL INCLM: 544/242.000
 INCLTS: 544/267.000; 514/269.000; 514/270.000; 514/256.000
 NCL NCLM: 544/242.000
 NCIS: 544/267.000
 IC [6]
 ICM: C07D239-26
 ICS: A61K031-505
 EXF 544/267; 544/242; 546/242; 546/243; 514/256; 514/269; 514/270
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 88 OF 239 USPTAFULL
 AN 1998:78967 USPTAFULL
 TI Reversible protease inhibitors
 IN Palmer, James T., San Ramon, CA, United States
 PI US 5776718 19980707
 AI US 1996-618704 19960320 (8)
 RLI Continuation of Ser. No. US 1995-409996, filed on 24 Mar 1995 Ser. No. US
 Ser. No. US 1995-409553, filed on 24 Mar 1995 Ser. No. US
 1995-409997, filed on 24 Mar 1995 And Ser. No. US 1995-410000, filed on
 24 Mar 1995
 DT Utility
 FS Granted
 LN.CNT 3717
 INCL INCLM: 435/023.000
 INCLTS: 435/024.000; 435/004.000; 514/208.000; 514/001.000; 514/019.000;
 514/012.000; 514/588.000; 514/600.000; 514/601.000; 424/070.240;
 530/233.000; 530/336.000; 544/106.000
 NCL NCLM: 435/023.000
 NCIS: 424/070.240; 435/004.000; 435/024.000; 514/001.000; 514/012.000;
 514/019.000; 514/208.000; 514/588.000; 514/600.000; 514/601.000;
 530/233.000; 530/336.000; 544/106.000
 IC [6]
 ICM: C12Q001-37
 ICS: C12Q001-00; A01N047-28
 EXF 435/23; 435/24; 435/4; 514/208; 514/1; 514/19; 514/12; 514/588; 514/600;
 514/601; 424/70.24; 530/233; 530/336; 544/106
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 89 OF 239 USPTAFULL
 AN 1998:75584 USPTAFULL
 TI Synthetic matrix metalloprotease inhibitors and use thereof

PI corporation) 19980602
 US 5759791 19940124 (8)
 AI US 1994-188426
 RLI Confirmation-in-part of Ser. No. US 1993-96908, filed on 26 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-917716, filed on 21 Jul 1992, now abandoned And Ser. Nos. US 1991-735522, filed on 26 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-622407, filed on 4 Dec 1990, now abandoned which is a continuation of Ser. No. US 1989-298722, filed on 17 Jan 1989, now abandoned

DT Utility
 FS Granted
 LN.CNT 2345
 INCL INCLM: 435/007.230
 INCLS: 435/007.900; 435/007.920; 435/975.000; 435/006.000; 436/518.000; 436/064.000; 530/324.000; 530/350.000; 530/388.800; 530/389.700; 536/023.100; 536/024.300

NCL NCLM: 435/007.230
 NCLS: 435/006.000; 435/007.900; 435/007.920; 435/975.000; 436/064.000; 436/518.000; 530/324.000; 530/350.000; 530/388.800; 530/389.700; 536/023.100; 536/024.300

IC [6]
 ICM: G01N033-574
 EXF 436/504; 436/518; 436/531; 436/548; 436/15; 436/63; 436/64; 436/86; 436/804; 436/813; 436/819; 435/7.1; 435/7.23; 435/7.9; 435/7.92; 435/7.95; 435/28.6; 435/960; 435/112.1; 530/324; 530/350; 530/385; 530/388.1; 530/388.8; 530/389.7; 530/828; 935/81; 536/23.1; 536/24.3
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 94 OF 239 USPATFOLL
 TI Method for enhancing functional properties of submucosal tissue graft constructs
 IN Badylak, Stephen F., W. Lafayette, IN, United States
 PA Vovlik, Sherry, Lafayette, IN, United States
 PI Purdue Research Foundation, West Lafayette, IN, United States (U.S. corporation)
 AI US 5759267 19980519
 RLI US 1993-530001 19950919 (8)
 Division of Ser. No. US 1993-38452, filed on 10 Feb 1995, now patented.
 DT Utility
 FS Granted
 LN.CNT 893
 INCL INCLM: 424/551.000
 INCLS: 424/093.100; 435/325.000; 435/366.000; 435/371.000; 435/377.000; 435/402.000; 623/015.000
 NCL NCLM: 424/551.000
 NCLS: 424/093.100; 435/325.000; 435/366.000; 435/371.000; 435/377.000; 435/402.000

IC [6]
 ICM: A61K035-38
 EXF ICS: C12N005-00; C12N005-08; A61E002-08
 435/325; 435/366; 435/371; 435/377; 435/402; 424/93.1; 424/551; 623/15
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 95 OF 239 USPATFOLL
 TI Metalloproteinase inhibitors
 IN Beckett, Raymond Paul, Cowley, United Kingdom
 PI Whitaker, Mark, Cowley, United Kingdom
 AI Miller, Andrew, Cowley, United Kingdom
 PA Martin, Fiona Mitchell, Cowley, United Kingdom
 British Biotech Pharmaceuticals Limited, Oxford, England (non-U.S.)

PI corporation) 19980505
 US 5747514 19960719 (8)
 AI US 1996-685330
 PRAI GB 1994-1034 19940120
 DT GB 1994-15618 19940802
 FS Utility
 LN.CNT 2361
 INCL INCLM: 514/352.000
 INCLS: 514/362.000; 514/363.000; 514/370.000; 514/372.000; 514/477.000; 514/626.000; 546/309.000; 548/135.000; 548/139.000; 548/192.000; 548/206.000; 549/069.000; 564/153.000; 564/155.000

NCL NCLM: 514/352.000
 NCLS: 514/362.000; 514/363.000; 514/370.000; 514/372.000; 514/477.000; 514/626.000; 546/309.000; 548/135.000; 548/139.000; 548/192.000; 548/206.000; 549/069.000; 564/153.000; 564/155.000

IC [6]
 ICM: C07D213-75
 EXF ICS: A61K031-44
 546/309; 514/352; 514/362; 514/363; 514/370; 514/372; 514/487; 514/626; 548/192; 548/206; 548/135; 548/139; 549/69; 564/153; 564/155
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 96 OF 239 USPATFOLL
 TI Method for inhibiting angiogenesis
 IN Kohn, Elise C., Olney, MD, United States
 PA Liotta, Lance A., Potomac, MD, United States
 AI Alessandro, Riccardo, Bethesda, MD, United States
 RLI United States of America, Washington, DC, United States (U.S. government)
 PI US 5744492 19980428
 AI US 1994-209651 19940310 (8)
 Continuation-in-part of Ser. No. US 1993-123614, filed on 17 Sep 1993, now abandoned
 DT Utility
 FS Granted
 LN.CNT 775
 INCL INCLM: 514/359.000
 INCLS: 514/356.000; 514/648.000; 514/650.000
 NCL NCLM: 514/359.000
 NCLS: 514/356.000; 514/648.000; 514/650.000

IC [6]
 ICM: A61K031-41
 EXF 514/359; 514/356; 514/648; 514/650
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 97 OF 239 USPATFOLL
 TI Cathepsin O protease
 IN Bromme, Dieter, San Bruno, CA, United States
 PA Okamoto, Kathleen, Mountain View, CA, United States
 AI Arris Pharmaceutical, South San Francisco, CA, United States (U.S. corporation)
 PI US 5736357 19980407
 AI US 1994-330121 19941027 (8)
 DT Utility
 FS Granted
 LN.CNT 1306
 INCL INCLM: 435/069.100
 INCLS: 435/320.100; 435/325.000; 435/252.300; 435/254.110; 536/023.500
 NCL NCLM: 435/069.100
 NCLS: 435/252.300; 435/254.110; 435/320.100; 435/325.000; 536/023.500

ICM: C12N001-21
 ICS: C12N015-15; C12N015-63; C12P021-02
 EXF 536/23.2: 435/219; 435/320.1; 435/240.2; 435/252.3; 435/325
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 98 OF 239 USPATFULTL
 AN 1998:28192 USPATFULTL
 TI Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis
 IN Chung, Ireland W. K., Houston, TX, United States
 Chan, James, Sugarland, TX, United States
 Logothetis, Christopher, Houston, TX, United States
 Hsieh, Jer-Tsong, Sugarland, TX, United States
 Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
 PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
 PI US 5728815 19980317
 AI US 1994-179569 19940107 (8)
 RLI Continuation-in-part of Ser. No. US 1992-859228, filed on 30 Mar 1992, now abandoned
 DT Utility
 FS Granted
 IN.CNT 2175
 INCL INCLM: 530/399.000; 530/412.000; 514/002.000
 NCL INCLS: 530/350.000; 530/412.000
 NCLM: 530/399.000
 NCLS: 530/350.000; 530/412.000
 IC [6]
 ICM: C07K014-475
 EXF 530/350; 530/399; 530/412; 435/240.1; 514/2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 99 OF 239 USPATFULTL
 AN 1998:25076 USPATFULTL
 TI Method to determine metastatic potential of tumor cells
 IN Mattisian, Lynn M., Nashville, TN, United States
 Vanderbilt University, Nashville, TN, United States (U.S. corporation)
 PA US 5726015 19980310
 PI US 1995-371082 19950110 (8)
 AI Continuation of Ser. No. US 1993-61827, filed on 17 May 1993, now abandoned which is a continuation of Ser. No. US 1991-700505, filed on 15 May 1991, now abandoned
 RLI Utility
 FS Granted
 IN.CNT 500
 INCL INCLM: 435/006.000
 NCL INCLS: 536/023.500
 NCLM: 435/006.000
 NCLS: 536/023.500
 IC [6]
 ICM: C12Q001-68
 EXF 435/6; 435/7.1; 435/7.2; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 100 OF 239 USPATFULTL
 AN 1998:12007 USPATFULTL
 TI Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
 IN Langley, Keith E., Newbury Park, CA, United States
 Declerck, Yves A., Los Angeles, CA, United States
 Boone, Thomas C., Newbury Park, CA, United States
 Angen Inc., Thousand Oaks, CA, United States (U.S. corporation)
 PA US 5714465 19980203
 PI US 1994-212660 19940311 (8)
 AI Continuation of Ser. No. US 1993-87021, filed on 6 Jul 1993, now

abandoned which is a continuation of Ser. No. US 1991-710728, filed on 3 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-501904, filed on 29 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-359027, filed on 19 May 1989
 DT Utility
 FS Granted
 IN.CNT 2845
 INCL INCLM: 514/012.000
 NCL INCLS: 514/002.000; 530/350.000
 NCLS: 514/012.000
 NCLS: 514/002.000; 530/350.000
 IC [6]
 ICM: A61K038-57
 EXF 530/350; 530/351; 514/12; 424/85.4; 424/85.5; 424/85.6; 424/85.7
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 101 OF 239 USPATFULTL
 AN 1998:9533 USPATFULTL
 TI Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phenylacetic acids and derivatives thereof
 IN Samid, Dvorit, Rockville, MD, United States
 The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
 PA US 5712307 19980127
 PI US 1995-465924 19950606 (8)
 AI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991
 RLI Utility
 FS Granted
 IN.CNT 4169
 INCL INCLM: 514/538.000
 NCL INCLS: 514/563.000; 514/567.000
 NCLM: 514/538.000
 NCLS: 514/563.000; 514/567.000
 IC [6]
 ICM: A01N037-12
 EXF 514/538; 514/563; 514/567
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 102 OF 239 USPATFULTL
 AN 1998:7096 USPATFULTL
 TI Compositions and methods for therapy and prevention of pathologies including cancer, AIDS, and anemia
 IN Samid, Dvorit, Rockville, VA, United States
 The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
 PA US 5710178 19980120
 PI US 1995-469691 19950606 (8)
 AI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991
 RLI Utility
 FS Granted
 IN.CNT 4261
 INCL INCLM: 514/557.000
 NCL INCLS: 514/568.000; 514/570.000
 NCLM: 514/557.000
 NCLS: 514/568.000; 514/570.000
 IC [6]
 ICM: A01N037-00
 EXF 514/557; 514/568; 514/570; 562/405; 562/493; 562/511; 562/473; 562/490
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 103 OF 239 USPATFULL
 AN 1998:4741 USPATFULL
 TI Protocaderin materials and methods
 IN Suzuki, Shinro, Torrance, CA, United States
 PA Doherty Eye Institute, Los Angeles, CA, United States (U.S. corporation)
 PI US 5708143 19980113
 AI US 1995-453695 19950530 (8)
 RLI Division of Ser. No. US 1994-268161, filed on 27 Jun 1994 which is a continuation-in-part of Ser. No. US 1992-998003, filed on 29 Dec 1992

DT Utility
 FS Granted
 LN.CNT 1738
 INCL INCLM: 530/350.000
 INCL INCLM: 435/069.100; 530/395.000
 NCL NCIM: 530/350.000
 NCL NCIS: 435/069.100; 530/395.000
 IC [6]
 ICM: C07K014-435
 ICS: C12N015-12
 EXF 530/350; 530/395; 435/69.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 104 OF 239 USPATFULL
 AN 1998:4624 USPATFULL
 TI Methods for promoting wound healing
 IN Samid, Dvorit, Rockville, MD, United States
 PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
 PI US 5708025 19980113
 AI US 1995-455835 19950606 (8)
 RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991

DT Utility
 FS Granted
 LN.CNT 4206
 INCL INCLM: 514/538.000
 INCL INCLM: 514/567.000; 514/885.000; 514/886.000; 514/928.000
 NCL NCIM: 514/538.000
 NCL NCIS: 514/567.000; 514/885.000; 514/886.000; 514/928.000
 IC [6]
 ICM: A01N037-12
 ICS: A01N037-44; A61K031-24
 EXF 514/538; 514/567; 514/885; 514/886; 514/928; 560/19
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 105 OF 239 USPATFULL
 AN 1998:1797 USPATFULL
 TI Signal transduction inhibitor compounds
 IN Kohn, Elise C., Olney, MD, United States
 PA Reid, Christian C., Bethesda, MD, United States
 PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
 PI US 5705514 19980106
 AI US 1995-455825 19950531 (8)
 RLI Division of Ser. No. US 1994-270181, filed on 1 Jul 1994, now patented, Pat. No. US 5882954 which is a division of Ser. No. US 1992-985402, filed on 4 Dec 1992, now patented, Pat. No. US 5359078 which is a continuation-in-part of Ser. No. US 1989-355744, filed on 19 May 1989, now patented, Pat. No. US 5132315 which is a continuation-in-part of Ser. No. US 1992-944009, filed on 11 Sep 1992, now abandoned which is a continuation of Ser. No. US 1991-637145, filed on 3 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1992-894891, filed

DT Utility
 FS Granted
 LN.CNT 1502
 INCL INCLM: 514/359.000
 INCL INCLM: 514/383.000; 514/396.000; 514/398.000; 514/399.000; 548/255.000; 548/265.400; 548/265.800; 548/335.500; 548/343.500
 NCL NCIM: 514/359.000
 NCL NCIS: 514/383.000; 514/396.000; 514/398.000; 514/399.000; 548/255.000; 548/265.400; 548/265.800; 548/335.500; 548/343.500
 IC [6]
 ICM: A61K031-41
 ICS: A61K031-415
 EXF 514/359; 514/383; 514/396; 514/398; 514/399; 548/255; 548/265.4; 548/265.8; 548/326.5; 548/335.5; 548/343.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 106 OF 239 USPATFULL
 AN 97:12328 USPATFULL
 TI Hydroxamic acid compounds as metalloprotease and TNF inhibitors
 IN Xue, Chu-Biao, Hockessin, DE, United States
 PA DeGrado, William F., Philadelphia, PA, United States
 PA Decicco, Carl Peter, Newark, DE, United States
 PA Jacobson, Irina Cipora, Boothwyn, PA, United States
 PA The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)
 PI US 5703092 19971230
 AI US 1996-632863 19960416 (8)
 RLI Continuation-in-part of Ser. No. US 1995-423197, filed on 18 Apr 1995, now abandoned

DT Utility
 FS Granted
 LN.CNT 2204
 INCL INCLM: 514/303.000
 INCL INCLM: 514/394.000; 514/399.000; 546/334.000; 546/118.000; 548/309.700; 548/180.000; 548/204.000; 548/217.000; 548/235.000; 548/247.000; 548/253.000; 548/338.100; 548/375.100; 562/623.000
 NCL NCIM: 514/303.000
 NCL NCIS: 514/394.000; 514/399.000; 546/118.000; 546/334.000; 548/180.000; 548/204.000; 548/217.000; 548/235.000; 548/247.000; 548/253.000; 548/309.700; 548/338.100; 548/375.100; 562/623.000
 IC [6]
 ICM: A61K031-435
 ICS: A61K031-415; C07D471-04; C07D235-16
 EXF 546/118; 546/334; 548/180; 548/204; 548/217; 548/235; 548/247; 548/253; 548/309.7; 548/333.1; 548/375.1; 514/303; 514/394; 514/399
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 107 OF 239 USPATFULL
 AN 97:123185 USPATFULL
 TI Protection against liver damage by HGF
 IN Roos, Filip, Brisbane, CA, United States
 PA Schwall, Ralph, Pacifica, CA, United States
 PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)
 PI US 5703048 19971230
 AI US 1995-452485 19950526 (8)
 RLI Continuation of Ser. No. US 1994-310361, filed on 21 Sep 1994, now abandoned which is a continuation of Ser. No. US 1992-968711, filed on 30 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-946663, filed on 16 Sep 1992, now abandoned

DT Utility
 FS Granted
 LN.CNT 2062
 INCL INCLM: 514/012.000

INCL: 514/002.000; 514/893.000; 514/894.000; 514/838.000; 530/350.000;
 530/399.000; 435/360.000; 935/013.000
 NCL: 514/012.000
 NCIM: 514/012.000
 NCL: 435/360.000; 514/002.000; 514/838.000; 514/893.000; 514/894.000;
 530/350.000; 530/399.000
 IC [6]
 ICM: A61K038-18
 ICS: C07K014-475; C12N015-12; C07H021-04
 514/12; 514/893; 514/894; 514/838; 514/2; 424/130.1; 530/350; 530/399;
 435/360; 935/13
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 108 OF 239 USPTAFULL
 AN 97:120654 USPTAFULL
 TI Hydroxamic acid derivatives as metalloproteinase inhibitors
 IN Dickens, Jonathan Philip, Cambridge, United Kingdom
 Crimmin, Michael John, Cowley, United Kingdom
 Beckett, Raymond Paul, Cowley, United Kingdom
 British Biotech Pharmaceuticals Limited, Oxford, United Kingdom
 PA (non-U.S. corporation)
 PI US 5700838 19971223
 WO 9402447 19940203
 US 1995-374602 19950123 (8)
 WO 1993-GB1557 19930723
 PCT 371 date
 19950123 PCT 102(e) date
 19920723

PRAI GB 1992-15665
 DT Utility
 FS Granted
 LN.CNT 1624
 INCL INCLM: 514/575.000
 INCL: 562/623.000
 NCIM: 514/575.000
 NCL: 562/623.000
 IC [6]
 ICM: A61K031-19
 ICS: 562/623; 514/575
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 109 OF 239 USPTAFULL
 AN 97:120498 USPTAFULL
 TI Selection of cells having increased cell adhesion properties
 IN Pierschbacher, Michael D., San Diego, CA, United States
 Ruoslahti, Erkki I., San Diego, CA, United States
 Dechbar, Shoukat, North Vancouver, Canada
 PA La Jolla Cancer Research Foundation, La Jolla, CA, United States (U.S. corporation)
 PI US 5700681 19971223
 US 1994-359956 19941220 (8)
 Continuation of Ser. No. US 1991-683482, filed on 9 Apr. 1991, now abandoned which is a continuation of Ser. No. US 1987-102021, filed on 28 Sep. 1987, now abandoned
 DT Utility
 FS Granted
 LN.CNT 921
 INCL INCLM: 435/240.210
 INCL: 435/240.200; 435/240.230; 530/350.000; 530/356.000
 NCIM: 435/377.000
 NCL: 435/378.000; 530/350.000; 530/356.000
 IC [6]
 ICM: C12N005-06
 ICS: C07K014-00
 435/240.2; 435/240.21; 435/240.23; 435/948; 435/70.3; 435/375; 435/377;
 530/350; 530/356

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 110 OF 239 USPTAFULL
 AN 97:117898 USPTAFULL
 TI Method of predicting fetal membrane rupture based on
 pro-matrix metalloproteinase-9 (pro-mmp-9)
 IN Strauss, III, Jerome Frank, Wyndmoor, PA, United States
 Vadillo-Oreaga, Felipe, La Magdalena, Mexico
 University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
 PA US 5698404 19971216
 US 1996-727883 19961009 (8)
 Continuation of Ser. No. US 1994-246814, filed on 20 May 1994, now patented, Pat. No. US 5641636
 DT Utility
 FS Granted
 LN.CNT 681
 INCL INCLM: 435/074.000
 INCL: 435/018.000; 435/023.000; 435/024.000; 436/518.000; 436/530.000;
 436/531.000
 NCIM: 435/007.400
 NCL: 435/018.000; 435/023.000; 435/024.000; 436/518.000; 436/530.000;
 436/531.000
 IC [6]
 ICM: G01N033-53
 ICS: 435/7.1; 435/7.4; 435/18; 435/23; 435/24; 436/518; 436/528; 436/529;
 436/530; 436/531
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 111 OF 239 USPTAFULL
 AN 97:115252 USPTAFULL
 TI Methods and compositions for inhibiting metastasis of
 epithelial cell-derived cancers
 IN Paterno, Steven R., Falls Church, VA, United States
 Manyak, Michael, Chevy Chase, MD, United States
 George Washington University, Washington, DC, United States (U.S. corporation)
 PA US 5696092 19971209
 US 1995-400084 19950307 (8)
 DT Utility
 FS Granted
 LN.CNT 1239
 INCL INCLM: 514/021.000
 INCL: 514/012.000
 NCIM: 514/021.000
 NCL: 514/012.000
 IC [6]
 ICM: A61K038-17
 ICS: 530/350; 530/352; 530/359; 530/386; 530/395; 530/850; 530/851; 530/853;
 514/7; 514/8; 514/12; 514/21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 112 OF 239 USPTAFULL
 AN 97:115246 USPTAFULL
 TI Methods and kits using macrophage stimulating protein
 IN Avraham, Hava Karsenty, Brookline, MA, United States
 Godowski, Paul J., Burlingame, CA, United States
 Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 PA Beth Israel Deaconess Medical Center, Inc., Boston, MA, United States (U.S. corporation)
 PI US 5696086 19971209
 US 1994-334177 19941103 (8)
 DT Utility

FS Granted
LN.CNT 1417
INCL INCLM: 514/012.000
INCLS: 530/351.000; 536/380.000
NCLM: 514/012.000
NCLS: 530/351.000; 536/380.000
IC [6]
ICM: A61K038-16
ICS: A61K038-19; C07K014-00; C07K014-52
EXF 530/351; 530/380; 530/12; 514/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 113 OF 239 USPATFULL
97:115162 USPATFULL
TI Submucosa as a growth substrate for islet cells
IN Badylak, Stephen F., W. Lafayette, IN, United States
Boder, George, Martinsville, IN, United States
Voytk, Sherry, Lafayette, IN, United States
Demeter, Robert J., Mooresville, IN, United States
Crittser, John, Carmel, IN, United States
Liu, Chi, Indianapolis, IN, United States
Purdue Research Foundation, West Lafayette, IN, United States (U.S. corporation)
PA Methodist Hospital of Indiana, Inc., Indianapolis, IN, United States (U.S. corporation)
PI US 5695998 19971209
AI US 1995-386452 19950210 (8)
DT Utility
FS Granted
LN.CNT 847
INCL INCLM: 435/391.000
NCLM: 435/391.000
IC [6]
ICM: C12N005-00
EXF 435/240.2; 435/240.23; 435/240.243; 435/240.3; 435/391
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 114 OF 239 USPATFULL
97:109937 USPATFULL
TI Hydroxamic and carbocyclic acids as metalloprotease inhibitors
IN Jacobson, Irina Cipora, Boothwyn, PA, United States
Decicco, Carl Peter, Newark, DE, United States
Cherney, Robert Joseph, Newark, DE, United States
The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States
PA (U.S. corporation)
PI US 5691381 19971125
AI US 1996-632973 19960416 (8)
RLI Continuation-in-part of Ser. No. US 1995-423192, filed on 18 Apr 1995, now abandoned
DT Utility
FS Granted
LN.CNT 1970
INCL INCLM: 514/562.000
INCLS: 514/563.000; 514/575.000; 546/348.000; 548/100.000; 548/338.100; 562/405.000; 562/430.000; 562/440.000; 562/444.000; 562/452.000; 562/455.000; 562/512.000; 562/801.000
NCLM: 514/562.000
NCLS: 514/563.000; 514/575.000; 546/348.000; 548/100.000; 548/338.100; 562/405.000; 562/430.000; 562/440.000; 562/444.000; 562/452.000; 562/455.000; 562/512.000; 562/801.000
IC [6]
ICM: A61K031-195
ICS: A61K031-19; C07D211-72
EXF 562/801; 562/405; 562/512; 562/430; 562/440; 562/444; 562/452; 562/455;

514/575; 514/562; 514/563; 548/100; 548/338.1; 546/348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 115 OF 239 USPATFULL
97:106931 USPATFULL
TI Cancer diagnosis using nucleic acid hybridization
IN Sager, Ruth, Brookline, MA, United States
Zou, Zhiqiang, Gaithersburg, MD, United States
Lee, Sam Whan, Newton, MA, United States
Tomasetto, Catherine Laure, Strasbourg, France
Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)
PA
PI US 5688641 19971118
AI US 1994-322742 19941013 (8)
RLI Continuation of Ser. No. US 1992-938823, filed on 1 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-844296, filed on 28 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-662216, filed on 28 Feb 1991, now abandoned
DT Utility
FS Granted
LN.CNT 1283
INCL INCLM: 435/006.000
INCLS: 435/040.500; 436/503.000; 436/811.000
NCLM: 435/006.000
NCLS: 435/040.500; 436/503.000; 436/811.000
IC [6]
ICM: C12Q001-68
EXF 436/501; 436/503; 436/811; 435/6; 435/40.5; 530/350; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 116 OF 239 USPATFULL
97:104449 USPATFULL
TI Basic, alpha.-aminoalkylphosphonate derivatives
IN Powers, James C., Atlanta, GA, United States
Boduszek, Bogdan, Wroclaw, Poland
Oleksyszyn, Jozef, Arlington, MA, United States
Georgia Tech Research Corp., Atlanta, GA, United States (U.S. corporation)
PA
PI US 5686419 19971111
AI US 1994-184286 19940121 (8)
DT Utility
FS Granted
LN.CNT 1660
INCL INCLM: 514/018.000
INCLS: 514/019.000; 514/007.000; 562/445.000; 530/331.000; 530/345.000
NCLM: 514/018.000
NCLS: 514/007.000; 514/019.000; 530/331.000; 530/345.000; 562/445.000
IC [6]
ICM: A61K038-06
EXF 514/18; 514/19; 562/445; 530/331; 530/345
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 117 OF 239 USPATFULL
97:104323 USPATFULL
TI Hepatocyte growth factor receptor antagonist antibodies and uses thereof
IN Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly Helen, Hillsborough, CA, United States
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PA
PI US 5686292 19971111
AI US 1995-460368 19950602 (8)
DT Utility
FS Granted
LN.CNT 1406

INCL INCLM: 435/240.270
INCL: 424/133.100; 424/143.100; 530/387.300; 530/387.700; 530/388.100;
530/388.200; 530/388.220; 530/388.800; 530/388.850; 530/389.100;
530/389.700
NCLM: 424/143.100
NCL: 424/133.100; 435/334.000; 530/387.300; 530/387.700; 530/388.100;
530/388.200; 530/388.220; 530/388.800; 530/388.850; 530/389.100;
530/389.700
IC [6]
ICM: C12N005-12
ICS: A6IK039-395; C07K06-28
EXF 530/387.7; 530/388.1; 530/388.2; 530/388.8; 530/388.85; 530/389.1;
530/389.7; 530/387.3; 424/133.1; 424/143.1; 435/240.27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 118 OF 239 USPTAFULL
AN 97.101902 USPTAFULL
TI Preparation of carbonylalkyl derivatives as inhibitors of matrix
metalloproteinases
IN Pompidom, Miree M., Branchburg, NJ, United States
Hagmann, William K., Westfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5684152 19971104
AI US 1996-716042 19960919 (8)
PRAI US 1995-5272P 19950928 (60)
DT Utility
FS Granted
LN.CNT 1337
INCL INCLM: 544/242.000
INCL: 544/264.000; 544/336.000; 544/358.000; 546/152.000; 546/193.000;
546/221.000; 548/152.000; 548/206.000; 548/213.000; 548/215.000;
548/221.000; 548/335.100; 548/343.500; 548/440.000;
548/469.000; 548/470.000; 548/489.000; 548/491.000; 548/530.000;
549/006.000; 549/023.000; 549/030.000; 549/049.000;
549/229.000; 549/266.000; 549/273.000; 549/307.000; 549/313.000;
549/735.000
NCLM: 544/242.000
NCL: 544/264.000; 544/336.000; 544/358.000; 546/152.000; 546/193.000;
546/229.000; 548/152.000; 548/206.000; 548/213.000; 548/215.000;
548/221.000; 548/335.100; 548/343.500; 548/440.000;
548/469.000; 548/470.000; 548/489.000; 548/491.000; 548/530.000;
549/006.000; 549/023.000; 549/030.000; 549/049.000;
549/229.000; 549/266.000; 549/273.000; 549/307.000;
549/313.000
IC [6]
ICM: C07C039-225
ICS: C07D009-02; C07D007-00; C07D63-04; C07D277-04; C07D307-00;
C07D413-08; C07D279-00
EXF 544/242; 544/336; 544/358; 544/264; 546/152; 546/193; 546/249; 548/152;
548/206; 548/213; 548/335.1; 548/343.5; 548/250; 548/215; 548/221;
548/440; 548/469; 548/470; 548/489; 548/491; 548/530; 549/6; 549/23;
549/30; 549/33; 549/49; 549/229; 549/313; 549/266; 549/273; 549/307;
549/735
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 119 OF 239 USPTAFULL
AN 97.99272 USPTAFULL
TI Fluorescent 1-peptidylaminoalkane phosphonate derivatives
IN Powers, James C., Atlanta, GA, United States
Abuelyaman, Ahmed S., St. Paul, MN, United States
PA Georgia Tech Research Corp., Atlanta, GA, United States (U.S.
corporation)
PI US 5681821 19971028
AI US 1994-324809 19941018 (8)
DT Utility
FS Granted

LN.CNT 927
INCL INCLM: 514/019.000
INCL: 514/018.000; 514/007.000; 530/331.000; 435/004.000
NCLM: 514/019.000
NCL: 435/004.000; 514/007.000; 514/018.000; 530/331.000
IC [6]
ICM: A6IK038-05
EXF 514/18; 514/19; 514/7; 530/331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 120 OF 239 USPTAFULL
AN 97.96892 USPTAFULL
TI Substituted phosphinic acid-containing peptidyl derivatives as
antidegenerative agents
IN Caldwell, Charles G., Scotch Plains, NJ, United States
Durette, Philippe L., New Providence, NJ, United States
Goulet, Jounq L., Westfield, NJ, United States
Hagmann, William K., Westfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5679700 19971021
AI US 1995-555535 19951109 (8)
RLI Continuation of Ser. No. US 1994-256217, filed on 5 Jul 1994, now
abandoned which is a continuation-in-part of Ser. No. US 1992-821113,
filed on 15 Jan 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1997
INCL INCLM: 514/416.000
INCL: 514/417.000; 514/422.000; 514/429.000; 514/399.000; 514/418.000;
514/419.000; 548/413.000; 548/414.000; 548/415.000; 548/481.000;
548/472.000; 548/491.000; 548/112.000; 549/058.000; 549/005.000;
549/220.000; 549/048.000; 549/221.000; 546/145.000; 546/117.000;
544/243.000; 544/337.000; 568/015.000; 568/170.000
NCLM: 514/416.000
NCL: 514/399.000; 514/417.000; 514/418.000; 514/419.000; 514/422.000;
514/428.000; 546/117.000; 546/145.000; 548/112.000; 548/413.000;
548/414.000; 548/415.000; 548/472.000; 548/481.000; 548/491.000;
549/005.000; 549/058.000; 549/218.000; 549/220.000; 549/221.000
IC [6]
ICM: A6IK031-40
ICS: C07F009-50
EXF 514/399; 514/416; 514/419; 514/417; 514/422; 514/428; 548/481; 548/472;
548/491; 548/112; 548/414; 548/415; 548/413; 549/58; 549/5; 549/220;
549/218; 549/221; 546/145; 546/117; 544/243; 544/337; 568/15; 568/170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 121 OF 239 USPTAFULL
AN 97.96832 USPTAFULL
TI Bone and prostate-derived protein factors affecting prostate cancer
growth, differentiation, and metastasis
IN Chung, Leland W. K., Houston, TX, United States
Chan, James C., Sugarland, TX, United States
PA Logothetis, Christopher J., Houston, TX, United States
Board of Regents, The University of Texas, Austin, TX, United States
PI US 5679636 19971021
AI US 1994-341297 19941115 (8)
RLI Continuation of Ser. No. US 1992-859228, filed on 30 Mar 1992, now
abandoned
DT Utility
FS Granted
LN.CNT 1620
INCL INCLM: 514/002.000

INCLS: 530/399.000; 530/350.000; 530/412.000; 530/413.000
 NCLM: 514/002.000
 NCLS: 530/350.000; 530/399.000; 530/412.000; 530/413.000
 IC 161 A61K038-18
 ICM: A61K038-18
 ICS: C07K014-475; A23J001-00
 EXF 514/2; 530/350; 530/399; 530/412; 530/413
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 122 OF 239 USPTAFULL
 AN 97:86559 USPTAFULL
 TI Method of delivery of a medicament to a cancer cell using a
 pathway of plasmidogen activator material
 Janjani, Jerzy, Sylvania, OH, United States
 Hart, Richard, Greenwich, CT, United States
 PA The University of Toledo, Toledo, OH, United States (U.S. corporation)
 PI US 5679380 19971021
 RLI US 1996-646561 19960508 (8)
 Continuation of Ser. No. US 1994-294950, filed on 24 Aug 1994, now
 abandoned which is a continuation-in-part of Ser. No. US 1993-59813,
 filed on 10 May 1993, now abandoned which is a continuation-in-part of
 Ser. No. US 1992-889783, filed on 28 May 1992, now abandoned

DT Utility
 FS Granted
 LN.CNT 1079
 INCL INCLM: 424/193.100
 INCLS: 424/197.110; 424/542.000; 435/326.000; 435/346.000
 NCLM: 424/193.100
 NCLS: 424/197.110; 424/542.000; 435/326.000; 435/346.000
 IC 161
 ICM: A61K039-385
 EXF 424/193.11; 424/197.11; 424/196.11; 424/542; 435/240.26; 435/240.27;
 435/326; 435/346
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 123 OF 239 USPTAFULL
 AN 97:86548 USPTAFULL
 TI Method of using IL-11 for treating spondyloarthropathies
 Keith, James, 28 Vine St., Andover, MA, United States 01810
 IN Schendel, Paul, 39 Jeffrey Rd., Wayland, MA, United States 01778
 PI US 5679339 19971021
 AI US 1995-495724 19950627 (8)
 DT Utility
 FS Granted
 LN.CNT 711
 INCL INCLM: 424/085.200
 INCLS: 530/351.000
 NCLM: 424/085.200
 NCLS: 530/351.000
 IC 161
 ICM: A61K045-05
 ICS: C07K017-00
 EXF 530/350T; 530/351; 424/85.1; 424/85.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 124 OF 239 USPTAFULL
 AN 97:94079 USPTAFULL
 TI Recombinant DNA encoding CCK 2, a receptor tyrosine kinase
 Ullrich, Axel, Adalbertstr. 108, Munchen, Germany, Federal Republic of
 Alves, Frauke Hildegard Elisabeth, Rohmsweg 2, Gollingen, Germany,
 Federal Republic of
 PI US 5677144 19971014
 AI US 1994-336343 19941108 (8)
 RLI Continuation-in-part of Ser. No. US 1993-153397, filed on 16 Nov 1993

DT Utility
 FS Granted
 LN.CNT 2400
 INCL INCLM: 435/069.100
 INCLS: 435/069.700; 435/257.300; 435/320.100; 530/350.000; 536/023.400;
 536/023.500
 NCLM: 435/069.100
 NCLS: 435/069.700; 435/252.300; 435/320.100; 530/350.000; 536/023.400;
 536/023.500
 IC 161
 ICM: C07K014-705
 ICS: C12N015-62; C12N015-12
 EXF 435/69.1; 435/69.7; 435/252.3; 435/320.1; 530/350; 536/23.4; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 125 OF 239 USPTAFULL
 AN 97:88995 USPTAFULL
 TI Arylsulfonamido-substituted hydrokamic acids
 MacPherson, Lawrence J., Hampton, NJ, United States
 Parter, David Thomas, Livingston, NJ, United States
 PA Novartis Corporation, Summit, NJ, United States (U.S. corporation)
 PI US 5672615 19970930
 AI US 1996-613303 19960311 (8)
 RLI Division of Ser. No. US 1994-333676, filed on 3 Nov 1994, now patented,
 Pat. No. US 5552419 which is a continuation-in-part of Ser. No. US
 1994-265296, filed on 24 Jun 1994, now patented, Pat. No. US 5506242
 which is a continuation-in-part of Ser. No. US 1993-1136, filed on 6 Jan
 1993, now patented, Pat. No. US 5455258, issued on 3 Nov 1995

DT Utility
 FS Granted
 LN.CNT 3487
 INCL INCLM: 514/357.000
 INCLS: 514/237.800; 514/311.000; 514/331.000; 514/332.000; 514/341.000;
 514/365.000; 514/396.000; 514/406.000; 514/432.000; 514/445.000;
 514/451.000; 514/602.000; 514/604.000; 540/524.000; 540/531.000;
 544/058.100; 544/168.000; 544/130.000; 544/131.000; 544/133.000;
 546/175.000; 546/194.000; 546/209.000; 546/247.000; 546/265.000;
 546/283.400; 546/282.100; 546/333.000; 546/337.000; 546/280.400;
 546/284.400; 546/281.700; 546/275.100; 546/275.100; 548/335.100;
 548/338.100; 549/013.000; 549/065.000; 549/126.000; 549/126.000;
 564/090.000; 564/092.000; 564/094.000
 NCLM: 514/357.000
 NCLS: 514/237.800; 514/311.000; 514/331.000; 514/332.000; 514/341.000;
 514/365.000; 514/396.000; 514/406.000; 514/432.000; 514/445.000;
 514/451.000; 514/602.000; 514/604.000; 540/524.000; 540/531.000;
 544/058.100; 544/130.000; 544/131.000; 544/133.000; 546/168.000;
 546/175.000; 546/194.000; 546/209.000; 546/247.000; 546/265.000;
 546/275.100; 546/280.400; 546/281.700; 546/282.100; 546/283.400;
 546/284.400; 546/333.000; 546/337.000; 548/335.100; 548/338.100;
 549/013.000; 549/065.000; 549/126.000; 549/126.000; 564/094.000;
 564/090.000; 564/092.000; 564/094.000
 IC 161
 ICM: C07D213-42
 ICS: A61K031-44
 EXF 514/237.81; 514/357; 514/311; 514/331; 514/332; 514/341; 514/365;
 514/396; 514/406; 514/432; 514/445; 514/451; 514/602; 514/604; 540/524;
 540/531; 544/168; 544/130; 544/131; 546/175; 546/194; 546/209;
 546/247; 546/265; 546/283.4; 546/282.1; 546/333; 546/337; 546/280.4;
 546/284.4; 546/281.7; 546/275.1; 548/205; 548/335.1; 548/338.1; 549/13;
 549/65; 549/426; 564/84; 564/90; 564/92; 564/94
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 126 OF 239 USPTAFULL
 AN 97:88979 USPTAFULL

TI Lactam-containing hydroxamic acids
 IN De, Bismarck, Cincinnati, OH, United States
 Wahle, Christopher Thomas, Hamilton, OH, United States
 Natchus, Michael George, Cincinnati, OH, United States
 Geng, Henry, West Chester, OH, United States
 PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
 PI US 5672598 19970930
 AI US 1996-407839 19950321 (8)
 DT Utility
 FS Granted
 LN.CNT 1837
 INCL INCLM: 514/212.000
 NCL INCLM: 540/528.000; 546/243.000; 548/550.000; 514/327.000; 514/424.000
 NCIM: 514/212.030
 NCLM: 514/327.000; 514/424.000; 540/528.000; 546/243.000; 548/550.000
 IC [6]
 ICM: C07D223-10
 ICS: A61K031-35
 EXF 540/528; 546/243; 548/550; 514/212; 514/327; 514/424
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 127 OF 239 USPTFULL
 AN 97-88973 USPTFULL
 TI Certain phosphonometethyl-pentanedioic acid derivatives thereof
 IN Jackson, Paul F., Bel Air, MD, United States
 Slusher, Barbara S., Kingsville, MD, United States
 PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
 PI US 5672592 19970930
 AI US 1996-665776 19960617 (8)
 DT Utility
 FS Granted
 LN.CNT 1347
 INCL INCLM: 514/075.000
 NCL INCLM: 562/008.000; 562/012.000; 546/021.000; 546/022.000; 548/412.000; 548/413.000; 549/005.000; 549/006.000; 549/007.000; 549/008.000; 549/216.000; 549/218.000; 562/008.000; 562/012.000
 NCIM: 514/075.000
 NCLM: 546/021.000; 546/022.000; 548/412.000; 548/413.000; 549/005.000; 549/006.000; 549/007.000; 549/008.000; 549/216.000; 549/218.000; 562/008.000; 562/012.000
 IC [6]
 ICM: A61K031-66
 ICS: C07F009-38; C07F009-58; C07F009-572
 EXF 562/8; 562/12; 514/75
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 128 OF 239 USPTFULL
 AN 97-88965 USPTFULL
 TI Carboxy-peptidyl derivatives as antidegenerative active agents
 IN Chapman, Kevin, Scotch Plains, NJ, United States
 Hagmann, William, Westfield, NJ, United States
 Burette, Philippe, New Providence, NJ, United States
 Baser, Craig, Belford, NJ, United States
 Kopka, Ihor, Millburn, NJ, United States
 Caldwell, Charles, Scotch Plains, NJ, United States
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 5672583 19970930
 AI US 1995-436347 19950517 (8)
 WO 1993-US11207 19931118
 RLI 19950517 PCT 311 date
 19950517 PCT 102(e) date
 Continuation-in-part of Ser. No. US 1992-981970, filed on 25 Nov 1992, now abandoned

DT Utility
 FS Granted
 LN.CNT 3440
 INCL INCLM: 514/019.000
 INCLM: 514/020.000; 514/330.000; 514/375.000; 514/367.000; 514/394.000; 514/416.000; 562/450.000; 562/574.000; 548/152.000; 548/217.000; 548/304.400; 548/486.000; 548/400.000; 548/116.000; 548/206.000; 548/252.000; 548/254.000; 548/336.000; 548/357.000; 548/213.000; 548/252.000; 548/254.000; 546/152.000; 549/491.000; 549/498.000; 549/029.000; 549/065.000; 549/069.000; 549/462.000; 549/049.000; 544/295.000; 544/296.000; 544/264.000; 544/336.000; 544/357.000
 NCL NCIM: 514/019.000
 INCLM: 514/020.000; 514/330.000; 514/367.000; 514/375.000; 514/394.000; 514/416.000; 548/152.000; 548/206.000; 548/217.000; 548/304.400; 548/486.000; 562/450.000; 562/574.000
 IC [6]
 ICM: A61K037-02
 ICS: C07C259-06; C07C237-52; C07D271-62
 EXF 514/19; 514/20; 514/416; 514/394; 514/367; 514/375; 514/330; 562/567; 562/574; 562/450; 548/486; 548/304.4; 548/152; 548/217; 548/400; 548/146; 548/206; 548/252; 548/254; 548/336; 548/357; 548/213; 548/240; 546/245
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 129 OF 239 USPTFULL
 AN 97-81418 USPTFULL
 TI Cancer related antigen
 IN Kuhnada, Francis P., Lutherville, MD, United States
 Pasternack, Gary R., Baltimore, MD, United States
 PA John Hopkins University, Baltimore, MD, United States (U.S. corporation)
 PI US 565874 19970909
 AI US 1995-469005 19950605 (8)
 RLI Division of Ser. No. US 1994-188426, filed on 24 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-96908, filed on 26 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-917716, filed on 24 Jul 1992, now abandoned and a continuation-in-part of Ser. No. US 1991-735522, filed on 26 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-622407, filed on 4 Dec 1990, now abandoned which is a continuation of Ser. No. US 1989-297722, filed on 17 Jan 1989, now abandoned
 DT Utility
 FS Granted
 LN.CNT 2924
 INCL INCLM: 536/024.300
 INCLM: 536/022.100; 536/023.100; 536/024.310; 536/024.320; 536/024.330; 435/006.000; 435/912.000; 435/320.100; 435/325.000
 NCL NCIM: 536/024.300
 NCLM: 435/006.000; 435/091.200; 435/320.100; 435/325.000; 536/022.100; 536/023.100; 536/024.310; 536/024.320; 536/024.330
 IC [6]
 ICM: C07H021-02
 ICS: C07H021-04; C12P019-34; C12O001-68
 EXF 536/22.1; 536/23.1; 536/24.3; 536/24.32; 536/24.33; 435/240.2; 435/91.2; 435/520.1; 435/6
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 130 OF 239 USPTFULL
 AN 97-81301 USPTFULL
 TI Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
 IN Frazee, James Simpson, Sewell, NJ, United States
 Gleason, John Gerald, Dornotown, PA, United States
 Metcalf, Brian Walter, Radnor, PA, United States
 PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

PI US 5665753 19970909
 WO 9523790 19950908
 AI US 1996-702528 19960903 (8)
 WO 1995-US2606 19960903
 PRAI GB 1994-4046 19940303 PCT 371 date
 FS Utility 19960903 PCT 102 (e)
 LN CNT 1021
 INCL INCLM: 514/394.000
 INCL: 514/396.000; 548/302.700; 548/304.400; 548/335.100; 548/338.100;
 NCL NCLM: 514/394.000
 NCL: 514/396.000; 548/302.700; 548/304.400; 548/335.100; 548/338.100;
 IC [6]
 ICM: A01N043-52
 ICS: A61K031-415; C07D233-64; C07D235-04
 EXF 514/394; 514/396; 548/302.7; 548/304.4; 548/335.1; 548/338.1; 548/343.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 131 OF 239 USPTFULL
 AN 97:78669 USPTFULL
 TI Sphingosine-1-phosphate essentially free of L-threo isomer
 IN Igarashi, Yasuyuki, Seattle, WA, United States
 Ruan, Fugiang, Seattle, WA, United States
 Sadahira, Yoshito, Seattle, WA, United States
 Kawa, Shigeyuki, Seattle, WA, United States
 Hakomori, Sen-itiroh, Seattle, WA, United States
 Onomomachi, Seattle, WA, United States (U.S. corporation)
 PA US 5664404 19970902
 PI US 1995-371866 19950112 (8)
 RLI Division of Ser. No. US 1993-104504, filed on 9 Aug 1993, now patented,
 Pat. No. US 5391800 which is a division of Ser. No. US 1992-863179,
 filed on 3 Apr 1992, now patented, Pat. No. US 5260288
 DT Utility
 FS Granted
 LN CNT 983
 INCL INCLM: 558/169.000
 NCL NCLM: 558/169.000
 IC [6]
 ICM: C07F009-09
 EXF 558/169
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 132 OF 239 USPTFULL
 AN 97:78569 USPTFULL
 TI Prolocadherin-42
 IN Suzuki, Shintaro, Torrance, CA, United States
 PA Dohany Eye Institute, Los Angeles, CA, United States (U.S. corporation)
 PI US 5663300 19970902 (8)
 RLI Division of Ser. No. US 1992-998003, filed on 29 Dec 1992
 DT Utility
 FS Granted
 LN CNT 1474
 INCL INCLM: 530/350.000
 INCL: 530/350.000
 NCL NCLM: 530/350.000
 NCL: 530/350.000
 IC [6]
 ICM: C07K014-705
 EXF 530/350; 530/395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 133 OF 239 USPTFULL
 AN 97:76161 USPTFULL
 TI Methods for treating neoplastic conditions using phenylacetic
 acid and derivatives thereof
 IN Samd, Dvorit, Rockville, MD, United States
 PA The United States of America as represented by the Department of Health
 and Human Services, Washington, DC, United States (U.S. Government)
 PI US 5661179 19970826
 RLI US 1995-469466 19950606 (8)
 Continuation of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a
 continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991,
 now abandoned
 DT Utility
 FS Granted
 LN CNT 4056
 INCL INCLM: 514/538.000
 INCL: 514/563.000; 514/567.000; 560/019.000
 NCL NCLM: 514/538.000
 NCL: 514/563.000; 514/567.000; 560/019.000
 IC [6]
 ICM: A01N037-12
 ICS: A01N037-44
 EXF 514/538; 514/563; 514/567; 560/19
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 134 OF 239 USPTFULL
 AN 97:73765 USPTFULL
 TI Tumor procease activated prodrugs of phosphoramidate mustard analogs with
 toxification and detoxification functionalities
 IN Glazier, Arnold, Newton, MA, United States
 PA Drug Innovation & Design, Inc., Newton, MA, United States (U.S.
 corporation)
 PI US 5659061 19970819
 RLI US 1995-425477 19950420 (8)
 DT Utility
 FS Granted
 LN CNT 758
 INCL INCLM: 558/166.000
 INCL: 558/169.000; 558/170.000; 558/171.000; 514/114.000; 514/118.000;
 514/137.000; 514/553.000; 514/603.000; 562/067.000; 564/085.000;
 564/094.000
 NCL NCLM: 558/166.000
 NCL: 558/169.000; 558/170.000; 558/171.000; 562/067.000; 564/085.000;
 564/094.000
 IC [6]
 ICM: C07F009-02
 ICS: A61K031-66
 EXF 558/166; 558/169; 558/170; 558/171; 558/172; 514/118; 514/553; 514/603;
 514/114; 514/137; 562/67; 564/85; 564/94
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 135 OF 239 USPTFULL
 AN 97:68570 USPTFULL
 TI Protection against liver damage by HGF
 IN Roos, Filip, Brisbane, CA, United States
 PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)
 PI US 5654404 19970805
 RLI US 1995-419654 19950410 (8)
 Division of Ser. No. US 1994-310361, filed on 21 Sep 1994 which is a
 continuation of Ser. No. US 1992-968711, filed on 30 Oct 1992, now
 abandoned which is a continuation-in-part of Ser. No. US 1992-946263.

filed on 16 Sep 1992, now abandoned

DT Utility

FS Granted

LN.CNT 2330

INCL INCLM: 530/387.300

NCL INCLM: 530/350.000; 424/134.100; 424/136.100; 424/178.100

NCLM: 530/387.300

NCLS: 424/134.100; 424/136.100; 424/178.100; 530/350.000

IC [6]

ICM: C07K014-435

ICS: C12P021-08; A61K039-00; A61K038-16

EXF 530/389.1; 530/387.3; 530/399; 530/350; 424/138.1; 424/124.1; 424/145.1; 514/12; 514/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 136 OF 239 USPATFULT

AN 97.68500 USPATFULT

TI Methods for prevention of cancer using phenylacetic acids and derivatives thereof

IN Samd, Dvorit, Rockville, MD, United States

PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

PI US 5654333 19970805

AI US 1995-465941 19950606 (8)

RLT Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991

DT Utility

FS Granted

LN.CNT 4088

INCL INCLM: 514/538.000

NCL INCLM: 514/563.000; 514/567.000

NCLM: 514/538.000

NCLS: 514/563.000; 514/567.000

IC [6]

ICM: A01N037-12

ICS: A01N037-44; A61K031-24

EXF 514/538; 514/563; 514/567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 137 OF 239 USPATFULT

AN 97.59225 USPATFULT

TI Arylsulfonamido-substituted hydroxamix acids

IN Macpherson, Lawrence J., Hampton, NJ, United States

PA Parker, David T., Livingston, NJ, United States

PI Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)

AI US 3646167 19970708

RLT US 1995-475166 19950607 (8)

Continuation-in-part of Ser. No. US 1994-333676, filed on 3 Nov 1994, now patented, Pat. No. US 5552419 which is a continuation-in-part of Ser. No. US 1994-265296, filed on 24 Jun 1994, now patented, Pat. No. US 5506242 which is a continuation-in-part of Ser. No. US 1993-1136, filed on 6 Jan 1993, now patented, Pat. No. US 5455258

DT Utility

FS Granted

LN.CNT 3483

INCL INCLM: 514/357.000

NCL INCLM: 546/336.000; 546/337.000

NCLM: 514/357.000

NCLS: 546/336.000; 546/337.000

IC [6]

ICM: A61K031-44

ICS: C07D213-42

EXF 546/175; 546/247; 546/265; 546/276.4; 546/336; 546/337; 548/205; 548/335.1; 548/338.1; 544/168; 549/13; 549/65; 549/426; 564/84; 564/92;

564/94; 564/90; 514/237.8; 514/311; 514/331; 514/332; 514/341; 514/357; 514/365; 514/396; 514/445; 514/602; 514/604; 514/406; 514/432; 514/451

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 138 OF 239 USPATFULT

AN 97.59098 USPATFULT

TI Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies

IN Schwall, Ralph H., Pacifica, CA, United States

PA Tabor, Kelly Helen, Hillsborough, CA, United States

PI denentech, Inc., South San Francisco, CA, United States (U.S. corporation)

AI US 5646036 19970708

RLT US 1995-459388 19950602 (8)

DT Utility

FS Granted

LN.CNT 1402

INCL INCLM: 435/252.300

NCL INCLM: 435/240.200; 435/320.100; 536/023.530; 530/387.700; 530/388.220; 530/388.800; 530/388.800; 530/388.850; 530/389.100; 530/389.700

NCLM: 435/252.300

NCLS: 435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/388.800; 530/388.850; 530/389.100; 530/389.700; 536/023.530

IC [6]

ICM: C12N015-13

ICS: C12N015-85; C12N001-21; C07K016-28

EXF 536/23.53; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/388.85; 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 139 OF 239 USPATFULT

AN 97.56730 USPATFULT

TI Natural amino acid derivatives as metalloproteinase inhibitors

IN Dickens, Jonathan Philip, Cambridge, England

PA Criminin, Michael John, Cowley, England

PI Beckett, Raymond Paul, Cowley, England

AI British Biotech Pharmaceuticals Limited, Cowley, United Kingdom (non-U.S. corporation)

PI US 5643964 19970701

RLT WO 9402446 19940203 #STR1#

US 1995-374601 19950123 (8)

WO 1993-GB1556 19950123 PCT 371 date 19950123 PCT 102(e) date 19920723

PRAI GB 1992-15665 19920723

DT Utility

FS Granted

LN.CNT 772

INCL INCLM: 514/575.000

NCL INCLM: 562/623.000

NCLM: 514/575.000

NCLS: 562/623.000

IC [6]

ICM: A01N037-28

ICS: 562/623; 514/575

EXF 562/623; 514/575

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 140 OF 239 USPATFULT

AN 97.56656 USPATFULT

TI Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases

IN Iversen, Patrick L., Ralston, NE, United States

PA Mata, John E., Omaha, NE, United States

The Board of Regents of the University of Nebraska, Lincoln, NE, United

States (U.S. corporation)
 PI US 5643890 19970701
 US 1995-381097 19950131 (8)
 Utility
 FS Granted
 LN.CNT 1011
 INCL INCLM: 514/044.000
 INCLM: 424/093.210; 435/375.000; 536/023.100
 NCL INCLM: 514/044.000
 NCLM: 514/044.000
 DT NCLM: 424/093.210; 435/375.000; 536/023.100
 FS [6]
 IC ICM: A61K048-00
 ICS: C12N005-10; C07H021-04
 EXF 435/240.2; 514/44; 536/24.5; 424/93.21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 141 OF 239 USPTFUL
 AN 97:56553 USPTFUL
 TI Adenocarcinoma cell basement membrane composition
 IN Adenocarcinoma cell, Los Angeles, CA, United States
 PA Stenlicht, Mark, Los Angeles, CA, United States
 PI The Regents of the University of California, Oakland, CA, United States
 (U.S. corporation)
 AI US 5643787 19970701
 US 1995-381384 19950131 (8)
 Continuation-in-part of Ser. No. US 1994-184720, filed on 21 Jan 1994,
 now patented, Pat. No. US 5508188, issued on 16 Apr 1996
 DT Utility
 FS Granted
 LN.CNT 1397
 INCL INCLM: 435/371.000
 INCLM: 435/378.000; 435/373.000; 435/395.000; 435/383.000; 435/391.000;
 NCL INCLM: 435/371.000
 NCLM: 435/378.000; 435/373.000; 435/395.000; 435/383.000; 435/391.000;
 DT NCLM: 435/371.000
 DT NCLM: 435/378.000; 435/373.000; 435/395.000; 435/383.000; 435/391.000;
 IC [6]
 ICM: C12N005-02
 ICS: C12N005-02
 EXF 435/172.3; 435/240.1; 435/371; 435/240.2; 435/373; 435/240.21;
 435/240.25; 435/391; 424/93.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 142 OF 239 USPTFUL
 AN 97:56547 USPTFUL
 TI DNA encoding protocadherin-42
 IN Suzuki, Shintaro, Torrance, CA, United States
 PA Doheny Eye Institute, Los Angeles, CA, United States (U.S. corporation)
 PI US 5643781 19970701
 US 1992-998003 19921229 (7)
 DT Utility
 FS Granted
 LN.CNT 1496
 INCL INCLM: 435/325.000
 INCLM: 435/325.330; 435/328.100; 536/023.400
 NCL INCLM: 435/325.000
 NCLM: 435/325.330; 435/320.100; 536/023.400
 DT [6]
 IC ICM: C12N001-21
 ICS: C12N005-10; C12N015-70; C12N015-85
 EXF 435/69.1; 435/172.3; 435/320.1; 435/252.3; 536/23.4
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 143 OF 239 USPTFUL

97:56527 USPTFUL
 TI Method for generating a subtracted cDNA library and uses of
 the generated library
 IN Fisher, Paul B., Scarsdale, NY, United States
 PA Jiang, Hongping, New York, NY, United States
 PI The Trustees of Columbia University in the City of New York, New York,
 NY, United States (U.S. corporation)
 AI US 5643761 19970701
 US 1993-143576 19931027 (8)
 DT Utility
 FS Granted
 LN.CNT 5927
 INCL INCLM: 435/091.100
 INCLM: 435/006.000; 435/091.200; 435/069.100; 435/172.300; 435/810.000;
 NCL INCLM: 435/006.000; 435/023.100; 536/024.100; 536/024.300; 536/024.310;
 436/501.000; 536/023.100; 536/024.100; 536/024.300; 536/024.310;
 536/024.320; 536/024.330; 935/009.000; 935/077.000; 935/078.000
 DT NCLM: 435/091.100
 DT NCLM: 435/006.000; 435/069.100; 435/091.200; 435/488.000; 435/489.000;
 435/810.000; 436/501.000; 536/023.100; 536/024.100; 536/024.300;
 536/024.310; 536/024.320; 536/024.330
 IC [6]
 ICM: C12P019-34
 EXF 435/6; 435/91.1; 435/91.2; 435/69.1; 435/810; 435/172.3; 436/501;
 536/22.1; 536/23.5; 536/24.5; 536/24.3-24.33; 935/9; 935/77; 935/78
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 144 OF 239 USPTFUL
 AN 97:54319 USPTFUL
 TI Method for purifying heregulin
 IN Vandlen, Richard L., Hillsborough, CA, United States
 PA Holmes, William E., Pacifica, CA, United States
 Genentech, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 AI US 5641869 19970624
 US 1995-456201 19950531 (8)
 Continuation of Ser. No. US 1993-126145, filed on 23 Sep 1993, now
 abandoned which is a continuation of Ser. No. US 1992-880917, filed on
 11 May 1992, now abandoned which is a continuation-in-part of Ser. No.
 US 1992-847743, filed on 6 Mar 1992, now patented, Pat. No. US 5367060,
 issued on 22 Nov 1994 which is a continuation-in-part of Ser. No. US
 1991-790801, filed on 8 Nov 1991, now abandoned which is a
 continuation-in-part of Ser. No. US 1991-765212, filed on 25 Sep 1991,
 now abandoned which is a continuation-in-part of Ser. No. US
 1991-705256, filed on 24 May 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 3894
 INCL INCLM: 530/413.000
 INCLM: 530/412.000; 530/415.000; 530/416.000; 530/417.000; 530/418.000
 NCL INCLM: 530/413.000
 NCLM: 530/412.000; 530/415.000; 530/416.000; 530/417.000; 530/418.000
 DT [6]
 IC ICM: C07K001-14
 ICS: C07K001-18; C07K001-20; C07K001-22
 EXF 530/415; 530/412; 530/413; 530/416; 530/417; 530/418
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 145 OF 239 USPTFUL
 AN 97:54088 USPTFUL
 TI Method of predicting fetal membrane rupture based on matrix
 metalloproteinase-9 activity
 IN Strauss, Ili, Jerome Frank, Wyndmoor, PA, United States
 PA Vadillo-Ortega, Felipe, La Magdalena, Mexico
 University of Pennsylvania, Philadelphia, PA, United States (U.S.

PI corporation) 19970624
 US 5641636
 AI US 1994-246814 19940520 (8)
 DT Utility
 FS Granted
 LN.CNT 692
 INCL INCLM: 435/007.400
 INCL: 435/018.000; 435/023.000; 436/065.000
 NCLM: 435/007.400
 NCL: 435/018.000; 435/023.000; 436/065.000
 IC [6]
 ICM: G01N033-573
 ICS: C120001-34; C120001-37
 EXF 435/7.4; 435/18; 435/24; 435/23; 435/4; 436/518; 436/530; 436/65
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 146 OF 239 USPTFULL
 AN 97:51993 USPTFULL
 TI Hydroxamic acid-containing inhibitors of matrix metalloproteinases
 IN Yelm, Kenneth Edward, Fairfield, OH, United States
 PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
 PI US 5639746 19970617
 AI US 1994-366062 19941229 (8)
 DT Utility
 FS Granted
 LN.CNT 1062
 INCL INCLM: 514/210.000
 INCL: 514/212.000; 514/277.000; 514/359.000; 514/507.000; 546/341.000;
 NCLM: 548/535.000; 560/041.000; 560/049.000; 562/623.000
 NCL: 514/018.000
 NCLM: 514/019.000; 514/210.020; 514/210.170; 514/212.030; 514/217.110;
 ICS: 514/277.000; 514/359.000; 514/507.000; 530/331.000; 546/341.000;
 548/535.000; 560/041.000; 560/049.000; 562/623.000
 IC [6]
 ICM: A61K031-215
 ICS: C07D007-00; C07C229-00
 EXF 562/623; 560/41; 560/169; 514/507; 514/210; 514/212; 514/277; 514/359;
 548/535; 546/341
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 147 OF 239 USPTFULL
 AN 97:49530 USPTFULL
 TI Method of modulating DNA binding activity of recombinant
 IN alpha-1 antichymotrypsin and other serine protease inhibitors
 IN Rubin, Harvey, Philadelphia, PA, United States
 PA Cooperman, Barry, Penn Valley, PA, United States
 The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
 PI US 5637479 19970610
 AI US 1995-435480 19950505 (8)
 DT Utility
 FS Granted
 LN.CNT 2642
 INCL INCLM: 530/388.200
 INCL: 530/388.700; 530/389.600; 435/070.210; 435/172.200; 424/139.100;
 NCLM: 424/139.100; 424/158.100; 424/172.100
 NCL: 530/388.200
 NCLM: 424/139.100; 424/144.100; 424/144.100; 424/158.100; 424/172.100;
 ICS: 530/388.700; 530/389.600
 IC [6]
 ICM: A61K039-395
 ICS: C07K016-28; C12P021-08; C12N015-06
 EXF 424/139.1; 424/143.1; 424/158.1; 424/172.1; 435/69.6;
 435/172.2; 435/172.2; 435/240.27; 530/387.9; 530/388.2; 530/388.22;
 530/388.7; 530/389.2; 530/389.6
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LN.CNT 702
 INCL INCLM: 435/069.200
 INCL: 435/172.300; 530/350.000; 530/395.000; 536/023.500
 NCLM: 435/069.200
 NCL: 530/350.000; 530/395.000; 536/023.500
 IC [6]
 ICM: C07K014-435
 ICS: C07K014-81; C12N015-15
 EXF 435/69.2; 435/172.3; 530/350; 530/395; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 148 OF 239 USPTFULL
 AN 97:49514 USPTFULL
 TI Cathespin C homolog
 IN Coleman, Roger, Mountain View, CA, United States
 PA Braxton, Scott M., San Mateo, CA, United States
 Seilheimer, Jeffrey J., Los Altos Hills, CA, United States
 Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 5637462 19970610
 AI US 1995-426428 19950419 (8)
 DT Utility
 FS Granted
 LN.CNT 1076
 INCL INCLM: 435/006.000
 INCL: 536/022.100; 536/023.100; 536/024.300; 536/024.310
 NCLM: 435/006.000
 NCL: 435/091.200; 536/022.100; 536/023.100; 536/024.300; 536/024.310
 IC [6]
 ICM: C120001-68
 ICS: C12P019-34; C07H021-02; C07H021-04
 EXF 536/22.1; 536/23.1; 536/24.3; 536/24.31; 435/6; 435/91.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 149 OF 239 USPTFULL
 AN 97:47505 USPTFULL
 TI Beta-8 integrin subunit antibodies
 IN Moyle, Matthew, Walnut Creek, CA, United States
 PA McLean, John W., San Francisco, CA, United States
 Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 5635601 19970603
 AI US 1995-454455 19950530 (8)
 DT Utility
 FS Granted
 LN.CNT 2642
 INCL INCLM: 530/388.200
 INCL: 530/388.700; 530/389.600; 435/070.210; 435/172.200; 424/139.100;
 NCLM: 424/139.100; 424/158.100; 424/172.100
 NCL: 530/388.200
 NCLM: 424/139.100; 424/144.100; 424/158.100; 424/172.100;
 ICS: 530/388.700; 530/389.600
 IC [6]
 ICM: A61K039-395
 ICS: C07K016-28; C12P021-08; C12N015-06
 EXF 424/139.1; 424/143.1; 424/158.1; 424/172.1; 435/69.6;
 435/172.2; 435/172.2; 435/240.27; 530/387.9; 530/388.2; 530/388.22;
 530/388.7; 530/389.2; 530/389.6
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 150 OF 239 USPTAFULL
 AN 97:47438 USPTAFULL
 TI **Methods for inducing differentiation of a cell using**
 IN phenacetic acid and derivatives
 PA Smith, Dvorit, Rockville, MD, United States
 PI The United States of America as represented by the Department of Health
 US 5635533 19970603
 AI US 1995-470229 19950606 (8)
 RLI Division of Ser. No. 1993-135661, filed on 12 Oct 1993 which is a
 continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991
 DT Utility
 FS Granted
 LN.CNT 4108
 INCL INCLM: 514/538.000
 NCL INCLS: 514/563.000; 514/567.000
 NCLM: 514/538.000
 NCLS: 514/563.000; 514/567.000
 IC [6]
 ICM: A01N037-12
 ICS: A01N037-44; A61K031-24
 EXF 514/538; 514/563; 514/567
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 151 OF 239 USPTAFULL
 AN 97:47437 USPTAFULL
 TI **Compositions and methods for therapy and prevention of**
 IN pathologies including cancer, AIDS and anemia
 PA Samdi, Dvorit, Rockville, MD, United States
 PI The United States of America as represented by the Secretary of the
 (U.S. government)
 US 5635532 19970603
 AI US 1993-135661 19931012 (8)
 RLI Continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991
 DT Utility
 FS Granted
 LN.CNT 4105
 INCL INCLM: 514/538.000
 NCLM: 514/563.000; 514/567.000; 560/019.000
 NCLS: 514/563.000; 514/567.000; 560/019.000
 IC [6]
 ICM: A01N037-12
 ICS: A01N037-44; A61K031-19; A61K031-24
 EXF 514/538; 514/563; 514/567; 560/19
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 152 OF 239 USPTAFULL
 AN 97:40821 USPTAFULL
 TI **N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents**
 IN Hagemann, William, Westfield, NJ, United States
 PA Kopya, Inc, Millburn, NJ, United States
 PI Werck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 WO 9407481 19940414
 AI US 1995-392730 19950223 (8)
 WO 1993-US9137 19930927
 DT Utility
 FS Granted
 LN.CNT 1091
 INCL INCLM: 514/513.000
 PCT 371 date
 PCT 102(e) date

NCL INCLS: 514/562.000; 514/616.000; 564/154.000; 558/254.000; 562/426.000
 NCLM: 514/513.000
 NCLS: 514/562.000; 514/616.000; 558/254.000; 562/426.000; 564/154.000
 IC [6]
 ICM: A61K031-21
 EXF 564/154; 558/254; 562/426; 514/513; 514/562; 514/616
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 153 OF 239 USPTAFULL
 AN 97:40640 USPTAFULL
 TI **Diagnostic assay for inhibitor of tissue-type and urokinase-type**
 IN plasminogen activators, and gene coding for the inhibitor
 Loskutoff, David J., Solana Beach, CA, United States
 NY, Tor, Umea, Sweden
 PA Sawdey, Michael, La Jolla, CA, United States
 PI The Scripps Clinic and Research Foundation, La Jolla, CA, United States
 (U.S. corporation)
 US 5629160 19970513
 AI US 1994-248348 19940524 (8)
 RLI Division of Ser. No. US 1992-877271, filed on 29 Apr 1992, now patented,
 Pat. No. US 5314994 which is a continuation of Ser. No. US 1990-573485,
 filed on 27 Aug 1990, now abandoned which is a division of Ser. No. US
 1986-897990, filed on 19 Aug 1986, now patented, Pat. No. US 4952512
 which is a continuation-in-part of Ser. No. US 1984-623357, filed on 22
 Jun 1984, now patented, Pat. No. US 4791068
 DT Utility
 FS Granted
 LN.CNT 2639
 INCL INCLM: 435/007.100
 NCL INCLS: 435/007.920; 435/007.930; 435/013.000; 435/069.200; 436/518.000
 NCLM: 435/007.100
 NCLS: 435/007.920; 435/007.930; 435/013.000; 435/069.200; 436/518.000
 IC [6]
 ICM: G01N033-53
 EXF 435/7.1; 435/7.9; 435/7.92-7.93; 435/13; 435/69.2; 435/240.1; 436/518
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 154 OF 239 USPTAFULL
 AN 97:38606 USPTAFULL
 TI **Integrin-binding peptides**
 IN Ronslahti, Erkki, Rancho Santa Fe, CA, United States
 PA Koivunen, Erkki, San Diego, CA, United States
 PI La Jolla Cancer Research Foundation, La Jolla, CA, United States (U.S.
 corporation)
 US 5627263 19970506
 AI US 1995-425238 19950418 (8)
 RLI Continuation of Ser. No. US 1993-158001, filed on 24 Nov 1993, now
 abandoned
 DT Utility
 FS Granted
 LN.CNT 725
 INCL INCLM: 530/327.000
 NCL INCLS: 530/328.000
 NCLM: 530/327.000
 NCLS: 530/328.000
 IC [6]
 ICM: A61K038-04
 ICS: C07K007-06; C07K007-08
 EXF 530/327; 530/328; 530/329; 514/14; 514/15; 514/16
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 155 OF 239 USPTAFULL
 AN 97:29499 USPTAFULL
 TI **Hydroxamic acid and carboxylic acid derivatives, process for their**

IN preparation and use thereof
Gowravaram, Madhusudan R., West Chester, PA, United States
Johnson, Jeffrey, Phoenixville, PA, United States
Cook, Ewell R., Royersford, PA, United States
Wahl, Robert C., Collegeville, PA, United States
Mathowitz, Alan M., Schwenksville, PA, United States
Tomczuk, Bruce E., Collegeville, PA, United States
Sama, Ashis K., Harleysville, PA, United States
PAPA S.A., Paris Cedex, France (non-U.S. corporation)
PI US 5618844 19970408
US 1995-461079 19950605 (8)
Division of Ser. No. US 1994-201837, filed on 25 Feb 1994, now patented,
Pat. No. US 5514716
RLI Utility
DT Granted
FS
LN CNT 1712
INCL INCLM: 514/575.000
NCL INCLM: 562/621.000
NCLM: 514/575.000
NCLS: 562/621.000
IC [6]
ICM: A61K031-19
ICS: C07C239-00
EXF 562/800; 562/621; 514/575; 514/419; 548/490
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 156 OF 239 USPTAFULL
AN 97:27192 USPTAFULL
TI Peptide derivatives of collagenase inhibitor
IN Gray, Robert D., Louisville, KY, United States
Spatola, Arno F., Louisville, KY, United States
Darlak, Krzysztof, Louisville, KY, United States
Research Corporation Tech., Inc., Tucson, AZ, United States (U.S. corporation)
PI US 5616605 19970401
US 1994-287320 19940808 (8)
Division of Ser. No. US 1992-981149, filed on 24 Nov 1992, now patented,
Pat. No. US 5387610 which is a continuation of Ser. No. US 1991-715948,
filed on 14 Jun 1991, now abandoned
DT Utility
FS Granted
LN CNT 1905
INCL INCLM: 514/415.000
NCL INCLM: 548/415.000; 546/139.000; 546/149.000; 546/175.000; 546/330.000;
546/332.000
NCLM: 514/415.000
NCLS: 546/139.000; 546/149.000; 546/175.000; 546/330.000; 546/332.000;
548/415.000
IC [6]
ICM: C07D209-12
ICS: C07D209-14; A61K031-405
EXF 514/307; 514/311; 514/415; 546/139; 546/149; 546/175; 548/507
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 157 OF 239 USPTAFULL
AN 97:27061 USPTAFULL
TI Effects of growth factors on hair follicle cell proliferation and
release of collagenolytic factors
IN Yuspa, Stuart H., Bethesda, MD, United States
The United States of America as represented by the Department of Health
and Human Services, Washington, DC, United States (U.S. government)
PI US 5616471 19970401
US 1991-650572 19910204 (7)
Continuation-in-part of Ser. No. US 1987-48537, filed on 6 May 1987
RLI

DT Utility
FS Granted
LN CNT 958
INCL INCLM: 435/029.000
NCL INCLM: 435/243.000; 435/244.000; 514/021.000; 514/880.000; 530/356.000;
623/015.000
NCLM: 435/029.000
NCLS: 435/243.000; 435/244.000; 514/021.000; 514/880.000; 530/356.000;
623/015.110
IC [6]
ICM: A01N001-02
ICS: C12N005-00; A61K038-00; C07K001-00
EXF 435/29; 435/240.23; 435/240.21; 435/240.243; 435/260; 435/243; 435/244;
514/880; 514/21; 530/356; 623/15
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 158 OF 239 USPTAFULL
AN 97:16085 USPTAFULL
TI Compositions and methods for treating and preventing
pathologies including cancer
IN Samdi, Dvorit, Rockville, MD, United States
The United States of America as represented by the Department of Health
and Human Services, Washington, DC, United States (U.S. government)
PI US 5605930 19970225
US 1994-207521 19940307 (8)
Continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993,
which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21
Oct 1991
RLI
DT Utility
FS Granted
LN CNT 7722
INCL INCLM: 514/510.000
NCL INCLM: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000
NCLM: 514/510.000
NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000
IC [6]
ICM: A61K031-21
ICS: A01N037-00; A01N047-40; A01N047-46
EXF 514/538; 514/563; 514/567; 514/510; 514/513; 514/515; 514/529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9 ANSWER 159 OF 239 USPTAFULL
AN 96:118515 USPTAFULL
TI DNA encoding a hyaluronan receptor expressed in human umbilical vein
endothelial cells
IN Hawkins, Phillip R., Mountain View, CA, United States
Wilde, Craig G., Sunnyvale, CA, United States
Seilhamer, Jeffrey J., Los Altos Hills, CA, United States
Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5587301 19961224
US 1995-402217 19950310 (8)
RLI
DT Utility
FS Granted
LN CNT 1142
INCL INCLM: 435/069.100
NCL INCLM: 435/252.300; 435/320.100; 536/023.500
NCLM: 435/069.100
NCLS: 435/252.300; 435/320.100; 536/023.500
IC [6]
ICM: C12N005-10
ICS: C12N015-12

EXF 435/69.1: 435/252.3; 435/320.1; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 160 OF 239 USPATFULT

AN 96:116379 USPATFULT
TI Tricyclic cefem sulphones
IN Alpegiani, Marco, Milan, Italy
Bispolino, Pierluigi, San Giorgio di Lomellina, Italy
Perrone, Ettore, Boffalora Ticino, Italy
Rizzo, Vincenzo, Arese, Italy
Pharmacia S.p.A., Milan, Italy (non-U.S. corporation)

PI US 5585312 19941208
WO: 9428003 19941208
US: 1995-367319 19950120
WO: 1994-EP1643 19950120

AI PCT 371 date
PCT 102(e) date

PRAI GB 1993-10428 19930520

DT Utility

FS Granted

LN.CNT 1301

INCL INCLM: 514/200.000

INCL INCLM: 514/202.000; 514/208.000; 540/216.000

NCL INCLM: 514/200.000

NCL INCLM: 514/202.000; 514/208.000; 540/216.000

IC [6]

ICM: C07D501-62

ICS: A61K031-545

EXF 540/221; 540/222; 540/216; 514/202; 514/200; 514/204

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 161 OF 239 USPATFULT

AN 96:113902 USPATFULT

TI Agents affecting thrombosis and hemostasis

IN Wolf, David L., Palo Alto, CA, United States

IN Sinha, Uma, San Francisco, CA, United States

PA COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 5583107 19961210

AI US 1994-268003 19940629 (8)

RI Continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994

RI which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec

1991, now abandoned which is a continuation-in-part of Ser. No. US

1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144

DT Utility

FS Granted

LN.CNT 1935

INCL INCLM: 514/012.000

INCL INCLM: 514/021.000; 424/094.640; 435/069.600; 530/381.000; 530/384.000;

NCL INCLM: 514/012.000

NCL INCLM: 424/094.640; 435/069.600; 514/021.000; 530/381.000; 530/384.000;

IC [6]

ICM: A61K038-36

ICS: A61K035-16; C07K014-435; C07K014-475

EXF 514/12; 514/21; 514/834; 514/8; 530/381; 530/384; 530/350; 530/829;

530/830; 530/380; 530/381; 530/395; 930/100; 435/69.1; 435/69.2;

435/69.6; 435/212; 424/94.64

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 162 OF 239 USPATFULT

AN 96:111551 USPATFULT

TI Single-chain hepatocyte growth factor variants

IN Godowski, Paul J., Pacifica, CA, United States

IN Lokker, Natalie A., San Francisco, CA, United States

IN Mark, Melanie R., San Jose, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 5580963 19961203

AI US 1994-194088 19940209 (8)

RI Division of Ser. No. US 1992-884811, filed on 18 May 1992, now patented,

RI Pat. No. US 5316921

DT Utility

FS Granted

LN.CNT 1985

INCL INCLM: 530/339.000

NCL INCLM: 530/339.000

IC [6]

ICM: C07K014-475

ICS: A61K038-18

EXF 530/339; 530/351; 435/69.4; 435/69.5; 435/106; 435/69.1; 574/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 163 OF 239 USPATFULT

AN 96:97138 USPATFULT

TI Peptides derived from trifluoromethylketones

IN de Nanteuil, Guillaume, Suresnes, France

IN Portevin, Bernard, Elancourt, France

PA Canet, Emmanuel, Paris, France

PA Adir et Compagnie, Courbevoie, France (non-U.S. corporation)

PI US 5567804 19961022

AI US 1995-437433 19950505 (8)

PRAI FR 1994-5494 19940505

DT Utility

FS Granted

LN.CNT 522

INCL INCLM: 530/331.000

INCL INCLM: 530/345.000; 530/350.000; 514/018.000

NCL INCLM: 530/331.000

NCL INCLM: 530/345.000; 530/350.000

IC [6]

ICM: A61K038-06

EXF 514/18; 530/331; 530/350; 530/323; 530/345

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 164 OF 239 USPATFULT

AN 96:94559 USPATFULT

TI Peptides derived from trifluoromethylketones

IN Vincent, Michel, Bagneux, France

IN de Nanteuil, Guillaume, Suresnes, France

IN Remond, Georges, Versailles, France

IN Portevin, Bernard, Elancourt, France

IN Herve, Yolande, Puteaux, France

IN Canet, Emmanuel, Paris, France

PA lonchamp, Michel, Rungis, France

PA Adir et Compagnie, Courbevoie, France (non-U.S. corporation)

PI US 5565429 19961015

AI US 1995-439233 19950511 (8)

RI Continuation of Ser. No. US 1993-99915, filed on 30 Jul 1993, now

RI abandoned

PRAI FR 1992-9254 19920728

DT Utility

FS Granted

LN.CNT 1271

INCL INCLM: 514/018.000

INCL INCLM: 530/331.000

NCL INCLM: 514/018.000

IC NCLTS: 530/331.000
[6]
ICM: A61K038-00
ICS: C07K005-00; C07K007-00; C07K017-00
EXF 514/18; 530/331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 165 OF 239 USPTAFULL
96:592094 USPTAFULL
TI Iliudin analogs useful as antitumor agents
IN Keiner, Michael J., La Jolla, CA, United States
McMorris, Trevor C., La Jolla, CA, United States
Taëlle, Raymond, Tucson, AZ, United States
The Regents of the University of California, Oakland, CA, United States
PA (U.S. corporation)
PI US 5563176 19961008
AI US 1994-276169 19940715 (8)
RLI Continuation-in-part of Ser. No. US 1993-15179, filed on 9 Feb 1993, now patented, Pat. No. US 5439936 which is a continuation-in-part of Ser. No. US 1990-606511, filed on 31 Oct 1990, now patented, Pat. No. US 5439942 which is a continuation-in-part of Ser. No. US 1989-416395, filed on 3 Oct 1989, now abandoned

DT Utility
FS Granted
LN.CNT 1120
INCLM: 514/691.000
NCLM: 560/162.000; 560/255.000; 560/256.000; 568/374.000
NCLTS: 514/691.000
NCLM: 560/162.000; 560/255.000; 560/256.000; 568/374.000
IC [6]
ICM: A61K031-12
ICS: C07C049-403
EXF 514/691; 568/374; 560/162; 560/255; 560/256
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 166 OF 239 USPTAFULL
96:80286 USPTAFULL
AN Arysulfonamido-substituted hydroxamic acids
TI MacPherson, Lawrence J., Hampton, NJ, United States
IN Parker, David T., Livingston, NJ, United States
PA Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)
PI US 5552419 19960903
AI US 1994-333676 19941103 (8)
RLI Continuation-in-part of Ser. No. US 1994-265296, filed on 24 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-1136, filed on 6 Jan 1993, now patented, Pat. No. US 5455258
PRAI NZ 1993-250517 19931220
DT Utility
FS Granted
LN.CNT 3589
INCLM: 514/357.000
NCLM: 544/058.100; 544/168.000; 544/130.000; 544/131.000; 544/133.000; 540/524.000; 540/531.000; 514/604.000; 546/175.000; 546/194.000; 546/247.000; 546/209.000; 546/265.000; 546/283.400; 546/282.100; 546/333.000; 546/337.000; 546/280.400; 546/284.400; 549/281.700; 546/275.100; 548/205.000; 548/335.100; 548/338.100; 549/013.000; 549/065.000; 549/426.000; 564/084.000; 564/090.000; 564/092.000; 564/094.000; 514/237.800; 514/311.000; 514/331.000; 514/332.000; 514/341.000; 514/365.000; 514/396.000; 514/406.000; 514/432.000; 514/445.000; 514/451.000; 514/602.000
NCLM: 514/357.000
NCLTS: 514/237.800; 514/311.000; 514/331.000; 514/332.000; 540/524.000; 540/531.000; 544/058.100; 544/130.000; 544/131.000; 544/133.000; 544/168.000; 546/175.000; 546/194.000; 546/209.000; 546/247.000;

IC 546/265.000; 546/275.100; 546/280.400; 546/281.700; 546/282.100; 546/283.400; 546/284.100; 546/284.400; 546/333.000; 546/337.000; 548/205.000; 548/335.100; 548/338.100; 549/013.000; 549/065.000; 549/426.000; 564/084.000; 564/090.000; 564/092.000; 564/094.000
EXF 546/175; 546/247; 546/265; 546/276; 546/333; 546/337; 544/168; 548/205; 548/335.100; 548/338.100; 549/426; 549/426; 549/426; 564/84; 564/90; 564/92; 564/94; 514/237.800; 514/311; 514/331; 514/332; 514/331; 514/365; 514/396; 514/406; 514/432; 514/445; 514/451; 514/602; 514/604; 514/357
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 167 OF 239 USPTAFULL
96:77966 USPTAFULL
AN Transgenic animal model system for human cutaneous melanoma
TI Mintz, Beatrice, Elkins Park, PA, United States
IN Fox Chase Cancer Center, Philadelphia, PA, United States (U.S. corporation)
PI US 5550316 19960827
AI US 1993-11060 19930129 (8)
RLI Continuation-in-part of Ser. No. US 1991-636798, filed on 2 Jan 1991, now abandoned

DT Utility
FS Granted
LN.CNT 1436
INCLM: 800/002.000
NCLM: 800/DIG.001; 435/172.300; 536/023.100; 536/023.720; 536/024.100; 424/009.200
NCLTS: 800/010.000
NCLM: 424/009.200; 424/093.210; 424/573.000; 536/023.100; 536/023.720; 536/024.100; 800/018.000
IC [6]
ICM: C12N015-00
ICS: A01K067-00
EXF 800/2; 800/DIG.1; 435/172.3; 536/23.1; 536/23.72; 536/24.1; 424/9
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 168 OF 239 USPTAFULL
96:75302 USPTAFULL
AN Hepatocyte growth factor variants
TI Godowski, Paul J., Burlingame, CA, United States
IN Lokker, Natalie A., San Francisco, CA, United States
PA Mark, Melanie R., Burlingame, CA, United States
PI US 5547856 19960820
AI US 1993-87783 19930713 (8)
RLI Continuation-in-part of Ser. No. US 1992-884811, filed on 18 May 1992, now patented, Pat. No. US 5316921 which is a continuation-in-part of Ser. No. US 1992-885971, filed on 18 May 1992, now patented, Pat. No. US 5328837
DT Utility
FS Granted
LN.CNT 2175
INCLM: 435/694.000
NCLM: 435/240.100; 435/320.100; 536/023.510; 530/399.000
NCLTS: 435/069.400
NCLM: 435/320.100; 435/325.000; 530/399.000; 536/023.510
IC [6]
ICM: C12P021-06
ICS: C12N015-18; C07H017-00; C07K014-475
EXF 530/399; 530/351; 536/23.51; 435/69.4; 435/106; 435/240.1; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 169 OF 239 USPATFULL
 LN 96:70435 USPATFULL
 TI Proline phosphonate derivatives
 IN Bowers, James C., Atlanta, GA, United States
 Boduszek, Bogdan, Wroclaw, Poland
 Oleksyszyn, Jozef, Arlington, MA, United States
 Georgia Tech Research Corp., Atlanta, GA, United States (U.S. corporation)
 PI US 5543396
 AI US 1994-234181
 DT Utility
 FS Granted
 INCL INCLM: 514/019.000
 INCLS: 514/087.000; 514/089.000; 514/094.000; 548/412.000; 548/111.000; 546/021.000; 540/542.000; 540/450.000; 544/053.000; 544/057.000; 544/088.000; 544/106.000; 558/170.000
 NCL NCIM: 514/019.000
 NCLS: 514/087.000; 514/089.000; 514/094.000; 540/450.000; 540/542.000; 544/053.000; 544/057.000; 544/088.000; 544/106.000; 546/021.000; 548/111.000; 548/412.000; 558/170.000
 IC [6]
 ICM: A61K038-00
 EXF ICS: A61K031-67; A01N057-00; C07F005-02
 514/87; 514/89; 514/94; 514/101; 548/412; 548/111; 546/21; 546/450;
 540/542; 544/53; 544/57; 544/88; 544/106; 558/170
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 170 OF 239 USPATFULL
 AN 96:65461 USPATFULL
 TI Prostate-specific membrane antigen
 IN Israel, Ron S., Forest Hills, NY, United States
 Heston, Warren D. W., New York, NY, United States
 Fair, William R., New York, NY, United States
 Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
 PI US 5538866
 AI US 1994-325553
 RLI 19941018 (8)
 Continuation of Ser. No. US 1992-973337, filed on 5 Nov 1992, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1966
 INCL INCLM: 435/069.300
 INCLS: 435/252.300; 435/320.500; 435/240.200; 435/254.200; 935/012.000; 935/023.000; 935/022.000; 935/086.000; 536/023.500
 NCL NCIM: 435/069.300
 NCLS: 435/252.300; 435/254.200; 435/320.100; 435/325.000; 435/348.000; 536/023.500
 IC [6]
 ICM: C12N015-12
 EXF ICS: C12N001-21; C12P071-02
 435/69.3; 435/320.1; 435/252.3; 435/254.2; 435/240.2; 935/8; 935/12;
 935/23; 935/24; 935/27; 935/66; 935/70; 935/72; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 171 OF 239 USPATFULL
 AN 96:63201 USPATFULL
 TI Integrin-binding peptides
 IN Ruoslahti, Erkki, Rancho Santa Fe, CA, United States
 Koivunen, Erkki, San Diego, CA, United States
 La Jolla Cancer Research Foundation, United States (U.S. corporation)
 PI US 5536814
 19960716

AI US 1994-212186
 RLI 19940311 (8)
 Continuation-in-part of Ser. No. US 1993-127422, filed on 27 Sep 1993, now abandoned
 DT Utility
 FS Granted
 LN.CNT 847
 INCL INCLM: 530/329.000
 INCLS: 530/317.000; 530/328.000
 NCL NCIM: 530/329.000
 NCLS: 530/317.000; 530/328.000
 IC [6]
 ICM: C07K007-06
 EXF ICS: C07K007-64
 530/300; 530/317; 530/321; 530/326; 530/327; 530/328; 530/329; 530/330
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 172 OF 239 USPATFULL
 AN 96:58109 USPATFULL
 TI Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
 IN Wang, Ning, Wuhan, China
 Barlovatz-Meimon, Georgia, Paris, France
 Fredberg, Jeffrey J., Sharon, MA, United States
 President and Fellows of Harvard University, Cambridge, MA, United States (U.S. corporation)
 PI US 5532132
 AI US 1993-127977
 DT Utility
 FS Granted
 LN.CNT 984
 INCL INCLM: 435/007.210
 INCLS: 435/007.230; 435/007.900; 436/501.000; 436/503.000
 NCL NCIM: 435/007.210
 NCLS: 435/007.230; 435/007.900; 436/501.000; 436/503.000
 IC [6]
 ICM: G01N033-567
 EXF ICS: 435/7.21; 435/7.23; 435/7.9; 435/13; 435/24; 436/503; 436/501
 435/7.21; 435/7.23; 435/7.9; 435/13; 435/24; 436/503; 436/501
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 173 OF 239 USPATFULL
 AN 96:55915 USPATFULL
 TI Hydroxamic acid based collagenase inhibitors
 IN Campion, Colin, Oxon, England
 Davidson, Alan H., Oxon, England
 Dickens, Jonathan P., Buckinghamshire, England
 Crimm, Michael J., Ascot, England
 British Bio-technology Limited, Oxford, England (non-U.S. corporation)
 PI US 5530161
 AI US 1994-195818
 RLI 19940214 (8)
 Division of Ser. No. US 1993-48413, filed on 14 Apr 1993, now patented, Pat. No. US 5310763 which is a continuation of Ser. No. US 1991-689848, filed on 8 Jul 1991, now patented, Pat. No. US 5240958
 DT Utility
 FS Granted
 LN.CNT 1525
 INCL INCLM: 562/623.000
 NCL NCIM: 562/623.000
 IC [6]
 ICM: C07C259-04
 EXF ICS: A61K031-19
 514/575; 562/623; 562/621
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 174 OF 239 USPATFULL
 AN 96:48574 USPATFULL
 TI Illudin analogs
 IN Kellner, Michael J., La Jolla, CA, United States
 PA McMorris, Trevor C., La Jolla, CA, United States
 Tietze, Raymond, Tucson, AZ, United States
 The Regents of the University of California, Oakland, CA, United States
 (U.S. corporation)
 PI US 5523490 19860604
 AI US 1994-332940 19941101 (8)
 RLI Continuation of Ser. No. US 1993-15179, filed on 9 Feb 1993, now patented, Pat. No. US 5439936 which is a continuation-in-part of Ser. No. US 1990-606511, filed on 31 Oct 1990, now patented, Pat. No. US 5439942 which is a continuation-in-part of Ser. No. US 1989-416395, filed on 3 Oct 1989, now abandoned
 DT Utility
 FS Granted
 LN.CNT 919
 INCL INCLM: 568/374.000
 NCL NCLM: 568/374.000
 IC [6]
 ICM: C07C211-00
 EXF 514/546; 514/691; 568/374
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 175 OF 239 USPATFULL
 AN 96:43770 USPATFULL
 TI Urokinase-type Plasminogen activator receptor antibodies
 IN Dano, Keld, Charlottenlund, Denmark
 Ronne, Ebbe, Copenhagen, Denmark
 Behrendt, Niels, Bagsvaerd, Denmark
 Ellis, Vincent, Copenhagen, Denmark
 Hoyer-Hansen, Gunilla, Gentofte, Denmark
 Pyke, Charles, Soborg, Denmark
 Bruener, Nils, Virum, Denmark
 Cancerforskningsfondet af 1989, Copenhagen, Denmark (non-U.S. corporation)
 PI US 5519120 19960521
 AI US 1993-88122 19930617 (8)
 RLI Continuation-in-part of Ser. No. US 1991-824189, filed on 6 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-374854, filed on 3 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-334613, filed on 7 Apr 1989, now abandoned
 DT Utility
 FS Granted
 LN.CNT 5458
 INCL INCLM: 530/388.220
 INCLS: 530/388.100; 530/388.800; 530/388.260; 530/391.100; 530/391.300; 435/240.270
 NCLM: 530/388.220
 NCL NCLS: 530/388.100; 530/388.260; 530/388.800; 530/391.100; 530/391.300
 IC [6]
 ICM: C07K016-40
 ICS: C07K016-18; C07K016-00; C12N005-12
 EXF 530/391.1; 530/391.3; 530/388.22; 530/388.26; 530/388.1; 530/388.8; 435/240.27
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 176 OF 239 USPATFULL
 AN 96:38938 USPATFULL
 TI Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
 IN Gowravaram, Madhusudan R., West Chester, PA, United States

Johnson, Jeffrey, Phoenixville, PA, United States
 Cook, Ewell R., Royersford, PA, United States
 Wahl, Robert C., Collegeville, PA, United States
 Mathewicz, Allen M., Schwenksville, PA, United States
 Tomazuk, Bruce E., Collegeville, PA, United States
 Saha, Ashut K., Harleysville, PA, United States
 Stealing Winthrop, Inc., Malvern, PA, United States (U.S. corporation)
 PI US 5514716 19960507
 AI US 1994-201837 19940225 (8)
 RLI Utility
 DT Utility
 FS Granted
 LN.CNT 1648
 INCL INCLM: 514/563.000
 INCLS: 560/034.000; 560/035.000; 560/037.000; 560/038.000; 560/039.000; 560/040.000; 560/041.000; 560/042.000; 560/168.000; 560/169.000; 562/437.000; 562/439.000; 562/442.000; 562/445.000; 562/448.000; 562/450.000; 564/448.000; 564/450.000; 564/155.000; 564/164.000; 564/168.000; 564/169.000; 564/170.000; 564/171.000; 564/193.000; 564/199.000; 564/201.000
 NCLM: 514/563.000
 NCL NCLS: 560/034.000; 560/035.000; 560/037.000; 560/038.000; 560/039.000; 560/040.000; 560/041.000; 560/042.000; 560/168.000; 560/169.000; 562/437.000; 562/439.000; 562/442.000; 562/445.000; 562/448.000; 562/450.000; 564/154.000; 564/164.000; 564/165.000; 564/168.000; 564/169.000; 564/170.000; 564/193.000; 564/199.000; 564/201.000
 IC [6]
 ICM: A61K031-195
 EXF 514/825; 514/563; 514/534; 514/567; 514/538; 514/540; 514/542; 514/613; 514/616; 514/617; 514/618; 514/619; 514/626; 514/825; 560/34; 560/35; 560/37; 560/38; 560/40; 560/41; 560/42; 560/158; 560/159; 562/437; 562/439; 562/442; 562/445; 562/448; 562/450; 564/164; 564/165; 564/168; 564/169; 564/170; 564/193; 564/199; 564/201
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 177 OF 239 USPATFULL
 AN 96:21100 USPATFULL
 TI Signal transduction inhibitor 1,2,3-triazolo compounds
 IN Kohn, Elise C., Olney, MD, United States
 Liotta, Lance A., Potomac, MD, United States
 Felder, Christian C., Bethesda, MD, United States
 The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
 PI US 5498620 19960312
 AI US 1995-455761 19950531 (8)
 RLI Continuation-in-part of Ser. No. US 1992-894891, filed on 8 Jun 1992, now abandoned and a continuation of Ser. No. US 1994-270181, filed on 1 Jul 1994 which is a division of Ser. No. US 1992-965402, filed on 4 Dec 1992, now patented, Pat. No. US 5359078 which is a continuation-in-part of Ser. No. US 1989-359744, filed on 19 May 1989, now patented, Pat. No. US 5132315 And a continuation-in-part of Ser. No. US 1992-944009, filed on 11 Sep 1992, now abandoned which is a continuation of Ser. No. US 1991-637145, filed on 3 Jan 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1396
 INCL INCLM: 514/359.000
 INCLS: 548/255.000; 548/264.800; 548/326.500
 NCLM: 514/359.000
 NCL NCLS: 548/255.000; 548/264.800; 548/326.500
 IC [6]
 ICM: A61K031-41
 ICS: C07D249-06
 EXF 548/255; 548/264.8; 548/326.5; 514/359
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 178 OF 239 USPATFULL
 AN 96:5730 USPATFULL
 TI Antipodes specific for human stromelysin-3 and a method for
 IN detection of stromelysin-3
 Bassett, Paul, Strasbourg, France
 Bellocq, Jean-Pierre, Strasbourg, France
 Chamion, Pierre, Blesheim, France
 Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S.
 corporation)
 PA Institut National de la Sante et de la Recherche Medicale, Paris Cedex,
 France (non-U.S. government)
 Centre National de la Recherche Scientifique, Paris Cedex, France
 (non-U.S. government)
 Universite Louis Pasteur, Strasbourg Cedex, France (non-U.S.
 corporation)
 PI US 5484726 19960116
 AI US 1993-1711 19930107 (8)
 RLI Continuation-in-part of Ser. No. US 1991-794393, filed on 21 Nov 1991,
 now patented, Pat. No. US 5236844
 PRAI GB 1990-25326 19901121
 DT Utility
 FS Granted
 LN.CNT 2805
 INCL INCLM: 435/007.400
 INCLM: 530/387.100; 530/388.100; 530/387.700; 530/388.260; 530/388.800
 NCLM: 435/007.400
 NCLM: 530/387.100; 530/387.700; 530/388.100; 530/388.260; 530/388.800
 IC [6]
 ICM: C120001-25
 ICS: C07K016-40; C07K016-30
 435/7.23; 435/7.1.1; 435/7.4; 530/387.1; 530/388.1; 530/387.7; 530/388.26;
 530/388.8
 EXF 530/388.8
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 179 OF 239 USPATFULL
 TI Signal transduction inhibitor triazole and diazole compounds
 IN Kohn, Elise C., Olney, MD, United States
 Liotta, Lance A., Potomac, MD, United States
 Felder, Christian C., Bethesda, MD, United States
 PA The United States of America as represented by the Department of Health
 and Human Services, Washington, DC, United States (U.S. government)
 PI US 5482954 19960109
 AI US 1994-270181 19940701 (8)
 RLI Division of Ser. No. US 1992-985402, filed on 4 Dec 1992, now patented,
 Pat. No. US 5359078 which is a continuation-in-part of Ser. No. US
 1989-35744, filed on 19 May 1989, now patented, Pat. No. US 5132315 And
 Ser. No. US 1992-944009, filed on 11 Sep 1992, now abandoned which is a
 continuation of Ser. No. US 1991-637145, filed on 3 Jan 1991, now
 abandoned And a continuation-in-part of Ser. No. US 1992-894891, filed
 on 8 Jun 1992, now abandoned
 DT Utility
 FS Granted
 IN.CNT 1451
 INCL INCLM: 514/359.000
 INCLM: 548/255.000; 548/264.800; 548/265.400; 548/265.600; 548/326.500;
 548/335.100; 548/374.100; 514/383.000; 514/398.000; 514/407.000
 NCLM: 514/359.000
 NCLM: 514/383.000; 514/398.000; 514/407.000; 548/255.000; 548/264.800;
 548/265.400; 548/265.600; 548/326.500; 548/335.100; 548/374.100
 IC [6]
 ICM: A61K031-41
 ICS: A61K031-415; C07D249-06

EXF 514/255; 514/256; 514/258; 514/261; 514/283; 514/359; 514/398; 514/407;
 548/255; 548/264.8; 548/265.4; 548/265.6; 548/326.5; 548/335.1;
 548/374.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 180 OF 239 USPATFULL
 AN 95:105959 USPATFULL
 TI Maspin, a serpin with tumor suppressing activity
 IN Sager, Ruth, Brookline, MA, United States
 Anisowicz, Anthony, West Newton, MA, United States
 Zou, Zhifang, Gaithersburg, MD, United States
 PA Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S.
 corporation)
 PI US 5470970 19951128
 AI US 1993-121714 19930901 (8)
 RLI Continuation-in-part of Ser. No. US 1992-938823, filed on 1 Sep 1992,
 now abandoned which is a continuation-in-part of Ser. No. US
 1992-844296, filed on 28 Feb 1992, now abandoned which is a
 continuation-in-part of Ser. No. US 1991-662216, filed on 28 Feb 1991,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 1403
 INCL INCLM: 536/023.500
 INCLM: 536/023.310; 435/320.100; 435/252.300; 435/240.100; 530/350.000;
 INCLM: 530/828.000; 930/250.000; 930/010.000; 935/009.000
 NCLM: 536/023.500
 NCLM: 435/252.300; 435/320.100; 435/354.000; 530/350.000; 530/828.000;
 536/023.310; 930/010.000; 930/250.000
 IC [6]
 ICM: C12N001-21
 ICS: C12N005-10; C12N015-15; C07K014-47
 435/6; 435/69.1; 435/69.2; 435/320.1; 536/23.1; 536/23.2; 530/350;
 530/828; 930/250
 EXF 530/828; 930/250
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 181 OF 239 USPATFULL
 TI Cell signaling inhibitors
 IN Michnick, John, Seattle, WA, United States
 Underiner, Gail E., Brier, WA, United States
 Klein, J. Peter, Vashon Island, WA, United States
 Rice, Glenn C., Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5470878 19951128
 AI US 1993-164081 19931208 (8)
 RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 2665
 INCL INCLM: 514/558.000
 INCLM: 514/258.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000;
 514/418.000; 514/423.000; 514/529.000; 514/552.000; 514/561.000;
 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/659.000;
 544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000;
 548/486.000; 548/556.000; 554/055.000; 554/061.000; 554/108.000;
 554/213.000; 560/130.000; 560/145.000; 562/553.000; 562/567.000;
 564/183.000; 564/197.000; 564/198.000; 564/201.000; 564/506.000
 NCLM: 514/558.000
 NCLM: 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000;
 514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000;
 514/626.000; 514/629.000; 514/659.000; 544/254.000; 544/285.000;
 544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000

IC [6]
 ICM: A61K031-20
 ICS: C07C233-00
 554/4/1; 554/6/1; 554/5/5; 554/10/8; 554/21/3; 564/22/4; 564/50/6; 564/19/8;
 564/4/15; 564/20/1; 564/19/7; 514/6/25; 514/6/29; 514/6/13; 514/5/58; 514/5/52;
 514/5/29; 514/5/61; 514/5/26; 514/6/9; 560/13/0; 560/14/5; 562/5/53; 562/5/67
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 182 OF 239 USPTAFULL
 AN 95:105824 USPTAFULL
 TI Sulfonamide and sulfoximide matrix metalloproteinase inhibitors
 IN Schwartz, Martin A., Tallahassee, FL, United States
 PA Van Wart, Harold, Los Altos, CA, United States
 PI Florida State University, Tallahassee, FL, United States (U.S. corporation)
 PI US 5470834 19951128
 AI US 1993-132411 19931006 (8)
 DT Utility
 FS Granted
 LN.CNT 4014
 INCL INCLM: 514/019.000
 INCLS: 260/998.000; 514/397.000; 514/400.000; 514/414.000; 514/415.000;
 514/562.000; 514/607.000; 514/824.000; 514/825.000; 514/843.000;
 514/912.000; 530/331.000; 548/312.100; 548/313.100; 548/313.700;
 548/336.100; 548/455.000; 548/503.000
 NCL NCLM: 514/019.000
 NCLS: 260/998.000; 514/397.000; 514/400.000; 514/414.000; 514/415.000;
 514/562.000; 514/607.000; 514/824.000; 514/825.000; 514/843.000;
 514/912.000; 530/331.000; 548/312.100; 548/313.100; 548/313.700;
 548/336.100; 548/455.000; 548/503.000

IC [6]
 ICM: A61K038-05
 ICS: A61K038-06; C07K005-062; C07K005-065
 514/1/9; 514/6/07; 514/8/24; 514/8/25; 514/8/43; 514/9/12; 514/39/7; 514/40/0;
 514/4/4; 514/4/5; 514/5/62; 530/331; 564/101; 260/998-2; 548/312.1;
 548/313.1; 548/313.7; 548/336.1; 548/455; 548/503; 562/426; 562/427;
 562/556
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 183 OF 239 USPTAFULL
 AN 95:88477 USPTAFULL
 TI Mercaptosulfide metalloproteinase inhibitors
 IN Schwartz, Martin A., Tallahassee, FL, United States
 PA Van Wart, Harold, Los Altos, CA, United States
 PI Florida State University, Tallahassee, FL, United States (U.S. corporation)
 PI US 5435262 19951003
 AI US 1993-132414 19931006 (8)
 DT Utility
 FS Granted
 LN.CNT 4063
 INCL INCLM: 514/418.000
 INCLS: 514/399.000; 514/419.000; 514/601.000; 514/602.000; 514/604.000;
 514/616.000; 514/618.000; 548/340.100; 548/485.000; 548/494.000;
 548/495.000; 564/080.000; 564/081.000; 564/085.000; 564/153.000;
 564/154.000
 NCL NCLM: 514/418.000
 NCLS: 514/399.000; 514/419.000; 514/601.000; 514/602.000; 514/604.000;
 514/616.000; 514/618.000; 548/340.100; 548/485.000; 548/494.000;
 548/495.000; 564/080.000; 564/081.000; 564/085.000; 564/153.000;
 564/154.000

IC [6]
 ICM: A61K031-40
 ICS: A61K031-165; C07D209-32; C07C233-05

EXF 564/154; 564/153; 564/80; 564/81; 564/85; 564/154; 514/618; 514/19;
 514/20; 514/601; 514/602; 514/604; 514/616; 514/418; 514/419; 514/399;
 548/485; 548/494; 548/495; 548/340.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 184 OF 239 USPTAFULL
 AN 95:86442 USPTAFULL
 TI Hydroxamic acid based collagenase inhibitors
 IN Davidson, Colin, Oxon, England
 PA Dickens, Jonathan P., Buckinghamshire, England
 PI Cirmann, Michael J., Ascot, England
 PI British Biotech Pharmaceuticals Limited, Oxford, England (non-U.S. corporation)
 PI US 5453438 19950926
 AI WO 9102716 19910307
 WO 1992-820664 19920116 (7)
 WO 1990-GB1117 19900720
 PCT 371 date
 19920116
 19920116 PCT 102(e) date
 19890824

PRAI GB 1989-19251 19890824
 DT Utility
 FS Granted
 LN.CNT 1170
 INCL INCLM: 514/424.000
 INCLS: 514/343.000; 514/422.000; 514/269.000; 548/543.000; 548/527.000;
 546/281.000; 544/333.000
 NCL NCLM: 514/424.000
 NCLS: 514/269.000; 514/343.000; 514/422.000; 544/333.000; 546/278.400;
 548/527.000; 548/543.000

IC [6]
 ICM: C07D207-27
 ICS: C07D401-12; C07D409-12; C07D405-12; A61K031-505
 548/543; 514/424; 514/343; 514/423; 514/269; 546/281; 544/333
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 185 OF 239 USPTAFULL
 AN 95:71366 USPTAFULL
 TI Method of treating certain tumors using illudin analogs
 IN Keiner, Michael J., La Jolla, CA, United States
 IN McMorris, Trevor C., La Jolla, CA, United States
 PA Taetle, Raymond, Tucson, AZ, United States
 PI The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
 PI US 5439936 19950808
 AI US 1993-15179 19930209 (8)
 RLI Continuation-in-part of Ser. No. US 1990-606511, filed on 31 Oct 1990
 which is a continuation-in-part of Ser. No. US 1989-416395, filed on 3 Oct 1989, now abandoned
 DT Utility
 FS Granted
 LN.CNT 984
 INCL INCLM: 514/546.000
 INCLS: 514/678.000; 514/681.000; 514/691.000
 NCL NCLM: 514/546.000
 NCLS: 514/678.000; 514/681.000; 514/691.000

IC [6]
 ICM: A61K031-22
 ICS: A61K031-12
 514/681; 514/546; 514/678; 514/691
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 186 OF 239 USPTAFULL
 AN 95:38854 USPTAFULL

TI P2'-modified hydroxamic acid collagenase inhibitors
 IN Crimmin, M. J., Marlow Bottom, England
 Davidson, A. H., Witney, England
 Beckett, R. P., Aston, England
 British Bio-Technology Limited, Oxford, England (non-U.S. corporation)
 PI US 5412145
 US 1993-172440
 Division of Ser. No. US 1991-760741, filed on 16 Sep 1991, now patented,
 Pat. No. US 5300674, issued on 5 Apr 1994
 PRAI GB 1991-2635 19910207
 Utility
 FS Granted
 LN.CNT 1227
 INCL INCLM: 558/414.000
 INCLM: 560/039.000; 562/444.000
 NCLM: 558/414.000
 NCLM: 560/039.000; 562/444.000
 IC [6]
 ICM: C07C255-50
 ICS: C07C259-06
 EXF 558/414; 560/39; 562/444
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 187 OF 239 USPTAFULL
 AN 95:38689 USPTAFULL
 TI Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors
 IN Ladislav, Robert, Santeny, France
 Mocar, Elmer, Gif Sur Yvette, France
 Hornebeck, William Georges, Versailles, France
 Kerneux, Christiane M., Vitry Sur Seine, France
 Cheebrough-Pond's USA Co., Division of Conopco, Inc., Greenwich, CT,
 PA United States (U.S. corporation)
 PI US 5411978 19950502
 US 1994-230048 19940419 (8)
 Division of Ser. No. US 1991-666093, filed on 7 Mar 1991, now patented,
 Pat. No. US 538747 19900308
 PRAI FR 1990-2951
 Utility
 FS Granted
 LN.CNT 833
 INCL INCLM: 514/373.000
 NCLM: 514/373.000
 IC [6]
 ICM: C07D275-06
 ICS: A61K031-41
 EXF 514/373
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 188 OF 239 USPTAFULL
 AN 95:29749 USPTAFULL
 TI Substituted cyclic derivatives as novel antidiabetic agents
 IN Hagmann, William, Westfield, NJ, United States
 Caldwell, Charles G., Scotch Plains, NJ, United States
 Gooley, Paul R., Westfield, NJ, United States
 Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PI US 5403952 19950404
 US 1993-133493 19931008 (8)
 Utility
 FS Granted
 LN.CNT 1679
 INCL INCLM: 510/085.000
 INCLM: 560/010.000; 560/015.000; 560/018.000; 560/024.000; 560/025.000;
 560/026.000; 560/034.000; 560/051.000; 560/053.000; 560/054.000;
 560/055.000; 560/056.000; 560/060.000; 560/076.000; 560/080.000;

NCL INCLM: 560/085.000
 NCLM: 560/010.000; 560/015.000; 560/018.000; 560/024.000; 560/025.000;
 560/026.000; 560/034.000; 560/051.000; 560/053.000; 560/054.000;
 560/055.000; 560/056.000; 560/060.000; 560/076.000; 560/080.000;
 560/100.000; 562/433.000; 562/439.000; 562/488.000; 562/490.000
 IC [6]
 ICM: C07K007-100
 EXF 560/85; 560/10; 560/15; 560/18; 560/24; 560/25; 560/26; 560/34; 560/51;
 560/53; 560/54; 560/55; 560/56; 560/60; 560/76; 560/80; 560/100;
 560/122; 562/433; 562/439; 562/459; 562/461; 562/470; 562/473; 562/488;
 562/490; 514/530; 514/561; 514/562; 514/564; 514/565
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 189 OF 239 USPTAFULL
 AN 95:16247 USPTAFULL
 TI Method for inhibition of cell motility by sphingosine-1-phosphate, its derivatives and mimetics and method of synthesizing sphingosine-1-phosphate and its derivatives
 IN Igarashi, Yasuyuki, Seattle, WA, United States
 Ruan, Fuguang, Seattle, WA, United States
 Sadahira, Yoshito, Seattle, WA, United States
 Kawa, Shigeyuki, Seattle, WA, United States
 Hakomori, Sen-Itiro, Seattle, WA, United States
 The Biomedical Institute, Seattle, WA, United States (U.S. corporation)
 PI US 5391800 19950221
 US 1993-104504 19930809 (8)
 Division of Ser. No. US 1992-863179, filed on 3 Apr 1992, now patented,
 Pat. No. US 5260288
 PRAI
 Utility
 FS Granted
 LN.CNT 970
 INCL INCLM: 558/145.000
 INCLM: 558/169.000; 558/170.000
 NCLM: 558/145.000
 NCLM: 558/169.000; 558/170.000
 IC [6]
 ICM: C07F009-113
 EXF 558/101; 558/145; 558/169
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 190 OF 239 USPTAFULL
 AN 95:11626 USPTAFULL
 TI Peptide derivatives of collagenase inhibitor
 IN Gray, Robert D., Louisville, KY, United States
 Spatola, Arno F., Louisville, KY, United States
 Darlak, Krzysztof, Louisville, KY, United States
 Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S. corporation)
 PI US 5387610 19950207
 US 1992-981149 19921124 (7)
 Continuation of Ser. No. US 1991-715948, filed on 14 Jun 1991, now
 abandoned
 PRAI
 Utility
 FS Granted
 LN.CNT 1949
 INCL INCLM: 514/575.000
 INCLM: 514/018.000; 514/507.000; 530/323.000; 530/330.000; 530/331.000;
 562/623.000
 NCLM: 514/575.000
 NCLM: 514/018.000; 514/507.000; 530/323.000; 530/330.000; 530/331.000;
 562/623.000

IC (6)
 ICM: A61K037-02
 EXF 530/323; 530/330; 530/331; 562/623; 514/575; 514/507; 514/18
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 194 OF 239 USPTAFULL
 AN 94:102319 USPTAFULL
 TI Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules
 involved in leukocyte adhesion (MLAs)
 IN Hesslon, Catherine A., South Weymouth, MA, United States
 Lobd, Roy R., Westwood, MA, United States
 Goelz, Susan E., Winchester, MA, United States
 Osborn, Laurence, Brighton, MA, United States
 Benjamin, Christopher D., Beverly, MA, United States
 Rosen, Margaret D., Winchester, MA, United States
 PA Bogen, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 5367056 19941122
 AI US 1993-35674 19930323 (8)

INCL INCLM: 514/008.000; 514/969.000; 424/550.000; 530/843.000
 NCLM: 514/008.000
 NCL: 424/550.000; 514/007.000; 514/969.000; 530/843.000
 IC (6)
 ICM: A61K037-16
 ICS: A61K033-37
 EXF 514/2; 514/338; 514/969; 514/7; 514/8; 424/85.8; 424/550; 530/843
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 192 OF 239 USPTAFULL
 AN 94:102323 USPTAFULL
 TI Structure, production and use of heregulin
 IN Vandlen, Richard L., Hillsborough, CA, United States
 Holmes, William E., Pacifica, CA, United States
 PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)
 PI US 5367060 19941122
 AI US 1992-847743 19920306 (7)
 RLI Continuation-in-part of Ser. No. US 1991-790801, filed on 8 Nov 1991,
 now abandoned which is a continuation-in-part of Ser. No. US
 1991-765212, filed on 25 Sep 1991, now abandoned which is a
 continuation-in-part of Ser. No. US 1991-705256, filed on 24 May 1991,
 now abandoned

DT Utility
 FS Granted
 LN.CNT 3698
 INCL INCLM: 530/339.000
 INCLM: 530/350.000
 NCLM: 530/339.000
 NCL: 530/350.000
 IC (5)
 ICM: C07K013-00
 ICS: A61K037-36
 EXF 435/69.1; 530/350; 530/399; 530/389.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 193 OF 239 USPTAFULL
 AN 94:102319 USPTAFULL
 TI Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules
 involved in leukocyte adhesion (MLAs)
 IN Hesslon, Catherine A., South Weymouth, MA, United States
 Lobd, Roy R., Westwood, MA, United States
 Goelz, Susan E., Winchester, MA, United States
 Osborn, Laurence, Brighton, MA, United States
 Benjamin, Christopher D., Beverly, MA, United States
 Rosen, Margaret D., Winchester, MA, United States
 PA Bogen, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 5367056 19941122
 AI US 1993-35674 19930323 (8)

RLI Division of Ser. No. US 1989-452675, filed on 18 Dec 1989, now patented,
 Pat. No. US 5272263 which is a continuation-in-part of Ser. No. US
 1989-359516, filed on 1 Jun 1989, now abandoned which is a
 continuation-in-part of Ser. No. US 1989-345151, filed on 28 Apr 1989,
 now patented, Pat. No. US 5217870

DT Utility
 FS Granted
 LN.CNT 2368
 INCL INCLM: 530/380.000
 INCLM: 530/350.000
 NCLM: 530/380.000
 NCL: 530/350.000
 IC (5)
 ICM: C07K013-00
 ICS: 530/380; 530/350
 EXF 530/380; 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 194 OF 239 USPTAFULL
 AN 94:93457 USPTAFULL
 TI Signal transduction inhibitor compounds
 IN Kohn, Elise C., Olney, MD, United States
 Liotta, Lance A., Potomac, MD, United States
 Felder, Christian C., Bethesda, MD, United States
 PA The United States of America as represented by the Department of Health
 and Human Services, Washington, DC, United States (U.S. government)
 PI US 5359078 19941025
 AI US 1992-985402 19921204 (7)
 RLI Continuation-in-part of Ser. No. US 1989-355744, filed on 19 May 1989,
 now patented, Pat. No. US 5132315 And a continuation-in-part of Ser. No.
 US 1992-944009, filed on 11 Sep 1992, now abandoned which is a
 continuation of Ser. No. US 1991-637145, filed on 3 Jan 1991, now
 abandoned which is a continuation-in-part of Ser. No. US 1992-894891,
 filed on 8 Jun 1992, now abandoned

DT Utility
 FS Granted
 LN.CNT 1287
 INCL INCLM: 544/255.000
 INCLM: 544/238.000; 544/242.000; 544/254.000; 544/264.000; 544/335.000;
 548/262.200; 548/262.800; 548/264.800; 548/265.400; 548/265.600;
 548/265.800; 548/266.800; 548/267.600
 NCLM: 548/255.000
 NCL: 544/238.000; 544/242.000; 544/254.000; 544/264.000; 544/335.000;
 548/262.200; 548/262.800; 548/264.800; 548/265.400; 548/265.600;
 548/265.800; 548/266.800; 548/267.600
 IC (5)
 ICM: C07D249-06
 EXF 544/254; 544/264; 544/335; 544/336; 544/238; 544/242; 548/255;
 548/263.2; 548/265.4; 548/265.8; 548/267.5; 548/267.8; 548/265.4;
 548/337; 548/346; 548/262.8; 548/264.8; 548/266.8; 548/262.2; 548/265.6;
 548/267.6
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 195 OF 239 USPTAFULL
 AN 94:71030 USPTAFULL
 TI Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors
 IN Robert, Ladislav, Senteay, France
 Moczar, Elemer, Gif sur Yvette, France
 Hornebeck, William G., Versailles, France
 PA Kerner, Christiane M. P., Vitz sur Seine, France
 Chesebrough-Pond's USA Co., Division of Conopco, Inc., Greenwich, CT,
 United States (U.S. corporation)
 PI US 5338747 19940816
 AI US 1991-666093 19910307 (7)
 PRAI FR 1990-2951 19900308

DT Utility
FS Granted
LN CNT 797
INCL INCLM: 514/373.000
INCLS: 548/210.000
NCLM: 514/373.000
NCLS: 548/210.000
IC {5}
ICM: C07D275-06
EXF 548/210: 514/373
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 196 OF 239 USPTAFULL
AN 94:60089 USPTAFULL
TI Hepatocyte growth factor protease domain variants
IN Godowski, Paul J., Pacifica, CA, United States
Locker, Natalie A., San Francisco, CA, United States
Mark, Melanie R., San Jose, CA, United States
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 5328837 19940712
AI US 1992-885971 19920518 (7)
DT Utility
FS Granted
LN CNT 1881
INCL INCLM: 435/069.400
INCLS: 530/399.000; 536/023.510
NCLM: 435/069.400
NCLS: 530/399.000; 536/023.510
IC {5}
ICM: C12P021-06
ICS: A61K037-36
EXF 530/399: 536/27; 435/23.51; 435/69.1; 435/69.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 197 OF 239 USPTAFULL
AN 94:47042 USPTAFULL
TI Cysteine proteinase inhibitors and inhibitor precursors
IN Bartlett, Paul A., Kensington, CA, United States
Mader, Mary M., El Cerrito, CA, United States
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

PI US 5317086 19940531
AI US 1992-848377 19920309 (7)
DT Utility
FS Granted
LN CNT 555
INCL INCLM: 530/327.000
INCLS: 530/331.000; 530/330.000; 530/329.000; 530/328.000
NCLM: 530/327.000
NCLS: 530/328.000; 530/329.000; 530/330.000; 530/331.000
IC {5}
ICM: C07K005-00
ICS: C07K007-00; A61K037-00
EXF 514/19; 514/18; 514/17; 514/16; 514/15; 514/14; 530/331; 530/330; 530/329; 530/328; 530/327
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 198 OF 239 USPTAFULL
AN 94:46878 USPTAFULL
TI Single-chain hepatocyte growth factor variants
IN Godowski, Paul J., Pacifica, CA, United States
Locker, Natalie A., San Francisco, CA, United States
Mark, Melanie R., San Jose, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US-5316921 19940531
AI US-1992-884811 19920518 (7)
DT Utility
FS Granted
LN CNT 1870
INCL INCLM: 435/069.400
INCLS: 530/399.000; 536/023.510
NCLM: 435/069.400
NCLS: 530/399.000; 536/023.510
IC {5}
ICM: C12P021-06
ICS: A61K037-36
EXF 530/399: 536/27; 536/23.51; 435/69.1; 435/69.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 199 OF 239 USPTAFULL
AN 94:44735 USPTAFULL
TI Inhibitor of tissue-type and urokinase-type plasminogen activators
IN Loskutoff, David J., Solana Beach, CA, United States
Ny, Tor, Umea, Sweden
Sawdey, Michael, La Jolla, CA, United States
Scripps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)

PI US 531994 19940524
AI US 1992-877271 19920429 (7)
RLI Abandoned which is a division of Ser. No. US 1986-897990, filed on 19 Aug 1986, now patented, Pat. No. US 4952512 which is a continuation-in-part of Ser. No. US 1984-623357, filed on 22 Jun 1984, now patented, Pat. No. US 4791068
DT Utility
FS Granted
LN CNT 2544
INCL INCLM: 530/350.000
INCLS: 530/395.000
NCLM: 530/350.000
NCLS: 530/395.000
IC {5}
ICM: C07K013-00
EXF 435/69.2; 530/350; 530/395; 930/250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 200 OF 239 USPTAFULL
AN 94:40082 USPTAFULL
TI Hydroxamino acid based collagenase inhibitors
IN Campion, Colin, Oxon, England
Davidson, Alan H., Oxon, England
Dickens, Jonathan P., Buckinghamshire, England
Crimmin, Michael J., Ascot, England
British Bio-technology Limited, Oxford, England (non-U.S. corporation)

PI US 5310763 19940510
AI US 1993-48413 19930414 (8)
RLI Continuation of Ser. No. US 1991-689848, filed on 8 Jul 1991, now patented, Pat. No. US 5240958
PRAI GR 1988-27305 19881123
DT Utility
FS Granted
LN CNT 1437
INCL INCLM: 514/575.000
INCLS: 514/616.000; 558/230.000; 562/621.000; 562/623.000
NCLM: 514/575.000
NCLS: 514/616.000; 558/230.000; 562/621.000; 562/623.000

IC [5]
 ICM: A61K031-19
 ICS: A61K031-16; C07C327-04
 EXF 514/575; 514/615; 558/230; 562/621; 562/623
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 201 OF 239 USPTFULL
 AN 93:107133 USPTFULL
 TI DNA sequences encoding vascular cell adhesion molecules (VCAMs)
 IN Hession, Catherine A., South Weymouth, MA, United States
 Lobb, Roy R., Westwood, MA, United States
 Goelz, Susan E., Winchester, MA, United States
 Osborn, Laurelee, Brighton, MA, United States
 Benjamin, Christopher D., Beverly, MA, United States
 Rosa, Margaret D., Winchester, MA, United States
 Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 5272263 19931221
 AI US 1989-452675 19891218 (7)
 RLI Continuation-in-part of Ser. No. US 1989-359516, filed on 1 Jun 1989,
 now abandoned which is a continuation-in-part of Ser. No. US
 1989-345151, filed on 28 Apr 1989

DT Utility
 FS Granted
 LN.CNT 2440
 INCL INCLM: 536/023.500
 INCLS: 530/380.000; 435/066.600; 435/320.100
 NCLM: 536/023.500
 NCLS: 435/066.600; 435/320.100; 530/380.000
 IC [5]
 ICM: C07K013-00
 ICS: C12N015-00; C12P021-06
 EXF 435/69.1; 435/69.9; 435/320.1; 530/380; 536/27
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 202 OF 239 USPTFULL
 AN 93:96120 USPTFULL
 TI Glycosaminoglycan derivatives and their use as inhibitors of tumor
 IN invasiveness of metastatic profusion-II
 Nicolson, Garth L., Kingwood, TX, United States
 Iimura, Tatsuro, Tokyo, Japan
 Nakajima, Motoo, Kamagaya, Japan
 Board of Regents, The University of Texas System, Austin, TX, United
 States (U.S. corporation)
 PI US 5262403 19931116
 AI US 1990-550827 19900710 (7)
 RLI Continuation-in-part of Ser. No. US 1989-342627, filed on 8 Apr 1989,
 now abandoned which is a continuation of Ser. No. US 1986-899511, filed
 on 21 Aug 1986, now abandoned And a continuation-in-part of Ser. No. US
 1986-839890, filed on 7 Mar 1986, now abandoned

DT Utility
 FS Granted
 LN.CNT 1188
 INCL INCLM: 514/056.000
 INCLS: 514/054.000; 536/021.000
 NCLM: 514/056.000
 NCLS: 514/054.000; 536/021.000
 IC [5]
 ICM: A61K031-725
 ICS: C08B037-10
 EXF 514/45; 514/56; 536/21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 203 OF 239 USPTFULL
 AN 93:93778 USPTFULL

TI Method for inhibition of cell motility by sphingosine-1-
 IN phosphate and derivatives
 Igarashi, Yasuyuki, Seattle, WA, United States
 Ruan, Eugenia, Seattle, WA, United States
 Sadahira, Yoshito, Seattle, WA, United States
 Kawa, Shigeyuki, Seattle, WA, United States
 Hakomori, Sen-Itiro, Seattle, WA, United States
 The Biomembrane Institute, Seattle, WA, United States (U.S. corporation)
 PI US 5260288 19931109
 AI US 1992-863179 19920403 (7)
 DT Utility
 FS Granted
 LN.CNT 880
 INCL INCLM: 514/114.000
 INCLS: 514/119.000
 NCLM: 514/114.000
 NCLS: 514/119.000
 IC [5]
 ICM: A61K031-66
 EXF 514/114; 514/119
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 204 OF 239 USPTFULL
 AN 93:67545 USPTFULL
 TI Analytical markers for malignant breast cancer
 IN Bassett, Paul, Strasbourg, France
 Bellocq, Jean-Pierre, Strasbourg, France
 Chambon, Pierre, Blaesheim, France
 Institut National de la Sante et de la Recherche Medicale, France
 (non-U.S. government)
 Centre National de Recherche Scientifique, France (non-U.S. government)
 Universite Louis Pasteur Strasbourg, France (non-U.S. corporation)
 PI US 5236844 19930817
 AI US 1991-794393 19911121 (7)
 PRAI GB 1990-25326 19901121
 DT Utility
 FS Granted
 LN.CNT 1495
 INCL INCLM: 435/320.100
 INCLS: 536/023.500
 NCLM: 435/320.100
 NCLS: 536/023.500
 IC [5]
 ICM: C12N015-70
 ICS: C07H021-04
 EXF 435/6; 435/320.1; 536/27; 536/23.5; 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 205 OF 239 USPTFULL
 AN 93:18572 USPTFULL
 TI Method of ophthalmic testing
 IN Salonen, Eeva-Marjatta, Espoo, Finland
 Labystems Oy, Helsinki, Finland (non-U.S. corporation)
 PI US 5192665 19930309
 AI US 1989-336249 19890411 (7)
 RLI Division of Ser. No. US 1986-838339, filed on 11 Mar 1986, now patented,
 Pat. No. US 4849406

DT Utility
 FS Granted
 LN.CNT 663
 INCL INCLM: 435/018.000
 INCLS: 424/009.000; 435/023.000
 NCLM: 435/018.000
 NCLS: 435/023.000

IC [5]
 ICM: C120001-34
 EXF 435/18; 435/23; 424/9
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 206 OF 239 USPATFULT
 AN 93:5469 USPATFULT
 TI Adhesion receptor for laminin and its use
 IN Engvall, Erkki I., Rancho Santa Fe, CA, United States
 †Engvall, Eva, Rancho Santa Fe, CA, United States
 †Genslen, Kurt R., San Diego, CA, United States
 PA La Jolla Cancer Research Foundation, La Jolla, CA, United States (U.S. corporation)
 PI US 5180809
 AI US 1989-357354
 RLI Continuation-in-part of Ser. No. US 1988-196986, filed on 20 May 1988, now abandoned
 DT Utility
 FS Granted
 LN.CNT 849
 INCL INCLM: 530/350.000
 INCLS: 530/395.000; 530/413.000; 530/810.000; 530/388.220; 530/389.100; 424/450.000
 NCL NCIM: 530/350.000
 NCIS: 424/450.000; 530/388.220; 530/389.100; 530/395.000; 530/413.000; 530/810.000

IC [5]
 ICM: C07K015-06
 EXF ICS: C07K015-14; C07K003-20; C07K017-02
 436/501; 436/503; 436/518; 436/534; 436/547; 436/548; 436/829; 435/7.21; 435/7.23; 424/420; 424/450; 530/350; 530/387; 530/395; 530/413; 530/810; 514/2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 207 OF 239 USPATFULT
 AN 92:76614 USPATFULT
 TI Inhibition of tumor growth by blockade of the protein C system
 IN Esmon, Charles T., Oklahoma City, OK, United States
 PA Comp, Philip C., Oklahoma City, OK, United States
 PI Oklahoma Medical Research Foundation, Oklahoma City, OK, United States (U.S. corporation)
 PI US 5147638
 AI US 1989-389617
 RLI Continuation-in-part of Ser. No. US 1988-292447, filed on 30 Dec 1988, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1023
 INCL INCLM: 424/085.800
 INCLS: 424/085.100; 424/085.200; 424/085.400; 424/085.500; 435/212.000; 514/002.000; 514/008.000; 514/012.000; 530/351.000; 530/381.000; 530/388.250; 530/389.300
 NCL NCIM: 424/085.100
 NCIS: 424/085.200; 424/085.400; 424/085.500; 424/152.100; 424/172.100; 424/282.100; 435/212.000; 514/002.000; 514/008.000; 514/012.000; 530/351.000; 530/381.000; 530/388.250; 530/389.300

IC [5]
 ICM: A61K037-00
 ICS: A61K037-66; A61K039-00
 EXF 424/85.1; 424/85.2; 424/85.5; 424/85.8; 514/2; 514/12; 530/387
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 208 OF 239 USPATFULT
 AN 92:66111 USPATFULT

TI Cyclopeptide derivatives usable as selective inhibitors with respect to
 IN proteases with active serine
 Marsekman, Michel, Paris, France
 Mazaleyrat, Jean-Paul, Choisy-Le-Roi, France
 Reboud-Ravaux, Michele, Paris, France
 PA Centre National de la Recherche Scientifique, Paris, France (non-U.S. corporation)
 PI US 5138035
 AI US 1990-47820r
 PRAI FR 1988-11528
 DT Utility
 FS Granted
 LN.CNT 1074
 INCL INCLM: 530/317.000
 INCL NCIM: 530/317.000
 NCL INCLM: 530/317.000
 IC [5]
 ICM: C07K005-12
 ICS: A61K037-00
 EXF 530/317; 514/9
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 209 OF 239 USPATFULT
 AN 92:59884 USPATFULT
 TI Therapeutic application of an anti-invasive compound
 IN Kohn, Elise C., Olney, MD, United States
 PA Liotta, Lance A., Potomac, MD, United States
 PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
 PI US 5132315
 AI US 1989-355744
 DT Utility
 FS Granted
 LN.CNT 460
 INCL INCLM: 514/359.000
 INCLS: 514/650.000; 514/648.000; 548/257.000
 NCL NCIM: 514/359.000
 NCIS: 514/648.000; 514/650.000; 548/257.000

IC [5]
 ICM: A61K031-41
 EXF 514/263; 514/663; 514/648; 514/359; 514/650; 548/257
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 210 OF 239 USPATFULT
 AN 92:59483 USPATFULT
 TI Method of treating a synthetic naturally occurring surface
 IN with a collagen laminate to support microvascular endothelial cell growth, and the surface itself
 IN Williams, Stuart K., Wilmington, DE, United States
 PA Jarrell, Bruce E., Philadelphia, PA, United States
 PA Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)
 PI US 5131907
 AI US 1991-666475
 RLI Continuation of Ser. No. US 1986-848453, filed on 4 Apr 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-742086, filed on 6 Jun 1985, now patented, Pat. No. US 4820626
 DT Utility
 FS Granted
 LN.CNT 1848
 INCL INCLM: 600/036.000
 INCLS: 623/001.000; 427/040.000; 427/041.000; 424/093.000; 435/001.000; 435/240.700; 435/240.241
 NCL NCIM: 600/036.000
 NCIS: 424/093.700; 427/534.000; 427/538.000; 435/001.100; 435/375.000;

IC 435/399.000; 623/921.000

[5]
 ICM: A61F002-04
 ICS: A61F002-02; B05D003-06; C12N005-06
 EXF 435/240.241; 623/1; 424/93; 427/40; 427/41; 600/36
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 211 OF 239 USPATFOLL
 AN 92:38510 USPATFOLL
 TI Method of stabilizing plasminogen activator inhibitor by
 treatment with vitronectin
 IN Wun, Tze-Chen, St. Louis, MO, United States
 PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)
 PI US 5112955 19920512
 AI US 1991-681304 19910408 (7)
 RLI Division of Ser. No. US 1990-532410, filed on 4 Jun 1990, now patented,
 1988-268916, filed on 9 Nov 1988, now abandoned

DT Utility
 FS Granted

LN.CNT 714
 INCL INCLM: 530/409.000
 INCLM: 530/350.000; 530/402.000; 530/395.000
 NCL NCLM: 530/409.000
 NCLM: 530/350.000; 530/395.000; 530/402.000
 IC [5]
 ICM: A61K037-64
 ICS: C07K003-04
 EXF 530/402; 530/409; 530/350; 530/395; 514/2; 514/13; 514/21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 212 OF 239 USPATFOLL
 AN 92:38361 USPATFOLL
 TI Pharmaceutical preparation for promoting epithelial healing and
 prevention of epithelial destruction
 IN Salonen, Eeva-Marjatta, Espoo, Finland
 PA LabSystems, Oy, Helsinki, Finland (non-U.S. corporation)
 PI US 5112805 19920512
 AI US 1989-336231 19890411 (7)
 RLI Continuation of Ser. No. US 1986-838339, filed on 11 Mar 1986, now
 patented, Pat. No. US 4849406

DT Utility
 FS Granted

LN.CNT 655
 INCL INCLM: 514/008.000
 INCLM: 514/012.000; 514/802.000
 NCL NCLM: 514/008.000
 NCLM: 514/012.000; 514/802.000
 IC [5]
 ICM: A61K037-02
 ICS: A61K037-64
 EXF 424/101; 424/530; 514/802; 514/12; 514/8; 514/912
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 213 OF 239 USPATFOLL
 AN 91:102292 USPATFOLL
 TI Affinity purification of plasminogen activator inhibitor I using a
 modified urokinase
 IN Wun, Tze-Chen, St. Louis, MO, United States
 PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)
 PI US 5073626 19911217
 AI US 1990-532410 19900604 (7)
 RLI Continuation-in-part of Ser. No. US 1988-268916, filed on 9 Nov 1988,
 now abandoned

DT Utility
 FS Granted

LN.CNT 748
 INCL INCLM: 530/350.000
 INCLM: 530/413.000; 435/069.200; 435/212.000; 435/215.000
 NCL NCLM: 530/350.000
 NCLM: 435/069.200; 435/212.000; 435/215.000; 530/413.000
 IC [5]
 ICM: C07K003-18
 ICS: C07K005-06
 EXF 530/413; 530/350; 435/69.2; 435/212; 435/215
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 214 OF 239 USPATFOLL
 AN 91:102238 USPATFOLL
 TI Bioactive metabolites from cribrochalina vasculum
 IN Gunasekera, Sarah P., Vero Beach, FL, United States
 PA Faircloth, Glynn T., Ft. Pierce, FL, United States
 PI Wright, Amy E., Ft. Pierce, FL, United States
 AI Thompson, Winnie C., Vero Beach, FL, United States
 RLI Burres, Neal, Highland Park, IL, United States
 Harbor Branch Oceanographic Institution, Inc., Fort Pierce, FL, United
 States (U.S. corporation)
 PI US 5073572 19911217
 AI US 1990-481475 19900216 (7)

DT Utility
 FS Granted

LN.CNT 501
 INCL INCLM: 514/739.000
 INCLM: 514/544.000; 514/546.000; 514/552.000; 560/113.000; 560/261.000;
 568/873.000
 NCL NCLM: 514/739.000
 NCLM: 514/544.000; 514/546.000; 514/552.000; 560/113.000; 560/261.000;
 568/873.000
 IC [5]
 ICM: C07C033-02
 ICS: C07C033-03; A61K031-045; A61K031-22
 EXF 568/873; 560/113; 560/261; 514/739; 514/544; 514/546; 514/552
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 215 OF 239 USPATFOLL
 AN 91:102160 USPATFOLL
 TI Synergistic composition for endothelial cell growth
 IN Chen, Chung-Ho, Phoenix, MD, United States
 PA The Johns Hopkins University, Baltimore, MD, United States (U.S.
 corporation)
 PI US 5073492 19911217
 AI US 1987-1844 19870109 (7)

DT Utility
 FS Granted

LN.CNT 624
 INCL INCLM: 435/240.200
 INCLM: 435/240.300; 435/240.310; 435/240.230
 NCL NCLM: 435/384.000
 NCLM: 435/392.000; 435/405.000
 IC [5]
 ICM: C12N005-00
 EXF 435/240.1; 435/240.2; 435/240.3; 435/240.21; 435/240.23; 435/240.31;
 530/449; 424/95; 424/531; 424/571; 514/2; 514/21; 514/42; 514/43
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 216 OF 239 USPATFOLL
 AN 91:73352 USPATFOLL

TI Tripeptide compounds having a nitrogenous polycyclic structure
IN Vincent, Michel, Bagnaux, France
Remond, Georges, Versailles, France
Portevin, Bernard, Elancourt, France
Cuemec, Claude, La Celle St-Cloud, France
PA Adir et Cie, Neuilly-sur-Seine, France (non-U.S. corporation)
PI US 50479400 19910910
AI US 1988-207710 19880616 (7)
PRAI FR 1987-8350 19870616
DT Utility
FS Granted
LN.CNT 773
INCL INCLM: 514/018.000
INCLS: 546/112.000; 546/146.000; 546/147.000; 546/164.000; 546/165.000;
546/169.000; 546/175.000; 548/472.000; 548/515.000
NCLM: 514/018.000
NCLS: 546/112.000; 546/146.000; 546/147.000; 546/164.000; 546/165.000;
546/169.000; 546/175.000; 548/472.000; 548/515.000
IC [5]
ICM: A61K031-40
EXF ICS: C07D221-02; C07D217-00; C07D209-46
546/146; 546/147; 546/112; 546/164; 546/165; 546/169; 546/175; 548/472;
548/515; 514/18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 217 OF 239 USPTFULL
AN 91:13045 USPTFULL
TI cDNA encoding 92-KDA type IV collagenase
IN Eisen, Arthur Z., St. Louis, MO, United States
PA Washington University, St. Louis, MO, United States (U.S. corporation)
PI US 4992537 19910212
AI US 1989-352078 19890515 (7)
DT Utility
FS Granted
LN.CNT 562
INCL INCLM: 536/027.000
INCLS: 435/069.100; 435/172.300; 530/219.000; 530/226.000
NCLM: 536/023.200
NCLS: 435/069.100; 530/219.000; 530/226.000
IC [5]
ICM: C12N015-00
EXF 536/27; 435/69.1; 435/172.3; 530/219; 530/226
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 218 OF 239 USPTFULL
AN 90:81777 USPTFULL
TI Peptide compounds having a nitrogenous polycyclic structure
IN Vincent, Michel, Bagnaux, France
Remond, Georges, Versailles, France
Cuemec, Claude, La Celle St-Cloud, France
PA Adir et Cie, Neuilly-sur-Seine, France (non-U.S. corporation)
PI US 4965250 19901023
AI US 1988-148027 19880125 (7)
PRAI FR 1987-1810 19870213
DT Utility
FS Granted
LN.CNT 692
INCL INCLM: 514/018.000
INCLS: 514/885.000; 530/330.000
NCLM: 514/018.000
NCLS: 514/885.000; 530/330.000
IC [5]
ICM: A61K037-02

ICS: C07K005-10
EXF 530/330; 514/18; 514/885
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 219 OF 239 USPTFULL
AN 90:79963 USPTFULL
TI Boron analogs of amino acid/peptide protease inhibitors
IN Kinder, David H., Rochester, MN, United States
PA Ames, Matthew M., Rochester, MN, United States
Mayo Foundation for Medical Education and Research, Rochester, MN, United States (U.S. corporation)
PI US 4963655 19901016
AI US 1988-199891 19880527 (7)
DT Utility
FS Granted
LN.CNT 376
INCL INCLM: 530/331.000
INCLS: 548/110.000; 549/213.000; 560/029.000; 564/008.000
NCLM: 530/331.000
NCLS: 548/110.000; 549/213.000; 560/029.000; 564/008.000
IC [5]
ICM: C07K005-08
EXF 514/64; 514/18; 514/19; 530/331; 548/110; 549/213; 560/29; 564/8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 220 OF 239 USPTFULL
AN 90:67565 USPTFULL
TI Gene encoding an inhibitor of tissue-type and urokinase-type plasminogen
IN Loskutoff, David J., 426 Glencrest Dr., Solana Beach, CA, United States
92075
NY, Tor, Lodjursvagen 11, Umea, Sweden
Sawdey, Michael, 9232 (C) Regents Rd., La Jolla, CA, United States
PI US 4952512 19900828
AI US 1986-897990 19860819 (6)
RLI Continuation-in-part of Ser. No. US 1984-623357, filed on 22 Jun 1984,
now patented, Pat. No. US 4791068
DT Utility
FS Granted
LN.CNT 2547
INCL INCLM: 435/320.000
INCLS: 435/091.100; 435/172.300; 435/069.200; 435/212.000; 435/219.000;
536/027.000; 935/009.000; 935/060.000
NCLM: 435/320.100
NCLS: 435/069.200; 435/212.000; 435/219.000; 536/023.200; 536/023.500;
536/024.310
IC [5]
ICM: C12N015-12
EXF ICS: C12N015-58
435/91; 435/172.3; 435/68; 435/253; 435/240.2; 435/320; 435/219;
435/212; 435/11; 935/29; 935/73; 935/9; 935/60; 536/27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 221 OF 239 USPTFULL
AN 90:54619 USPTFULL
TI Use of bis-(5-amidino-2-benzimidazolyl) methane (BABIM) to treat
IN arthritis
Tidwell, Richard R., Chapel Hill, NC, United States
Geratz, Joachim D., Chapel Hill, NC, United States
Schwab, John H., Chapel Hill, NC, United States
Pryzwansky, Katherine B., Chapel Hill, NC, United States
Anderle, Sonia K., Chapel Hill, NC, United States
PA University of North Carolina, Chapel Hill, Chapel Hill, NC, United

States (U.S. corporation)
 PI US 4940723 19900710
 AI US 1988-260056 19881020 (7)
 DT Utility
 FS Granted
 LN.CNT 489
 INCL INCLM: 514/396.000
 NCL INCLM: 514/401.000
 NCIM: 514/396.000
 NCIS: 514/401.000
 IC [5]
 ICM: A61K031-415
 EXE 514/401; 514/396
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 222 OF 239 USPATFULL
 AN 90:48878 USPATFULL
 TI Protease inhibitors
 IN Bachovchin, William W., Melrose, MA, United States
 Plat, Andrew G., Lexington, MA, United States
 Kettner, Charles A., Wilmington, DE, United States
 E. I. Du Pont de Nemours and Company, Wilmington, DE, United States
 PA (U.S. corporation)
 New England Medical Center Hospitals, Inc., Boston, MA, United States
 (U.S. corporation)
 Tuts University, Medford, MA, United States (U.S. corporation)
 PI US 4935493 19900619
 AI US 1987-105768 19871006 (7)
 DT Utility
 FS Granted
 LN.CNT 524
 INCL INCLM: 530/331.000
 NCL INCLM: 530/330.000
 NCIM: 530/331.000
 NCIS: 530/330.000
 IC [5]
 ICM: A61K037-02
 ICS: C07K005-08; C07K005-10
 EXF 514/2; 514/18; 514/19; 530/330; 530/331
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 223 OF 239 USPATFULL
 AN 90:48835 USPATFULL
 TI Cancer therapy system for effecting oncolysis of malignant neoplasms
 IN Cone, Jr., Clarence D., Yorktown, VA, United States
 PA Therapeutic Systems Corporation, Yorktown, VA, United States (U.S. corporation)
 PI US 4935450 19900619
 AI US 1988-234036 19880822 (7)
 RLI Continuation-in-part of Ser. No. US 1987-130563, filed on 8 Dec 1987, now abandoned And Ser. No. US 1987-130290, filed on 8 Dec 1987, now abandoned which is a continuation of Ser. No. US 1985-792257, filed on 28 Oct 1985, now patented, Pat. No. US 4728234, issued on 9 Feb 1988 which is a continuation of Ser. No. US 1982-419324, filed on 17 Sep 1982, now abandoned, said Ser. No. 130563 which is a continuation of Ser. No. US 1984-634267, filed on 25 Jul 1984, now patented, Pat. No. US 4724230, issued on 9 Feb 1988 which is a continuation-in-part of Ser. No. 419324
 DT Utility
 FS Granted
 LN.CNT 4266
 INCL INCLM: 514/728.000
 NCIM: 514/558.000; 514/561.000
 NCL INCLM: 514/728.000

NCIS: 514/558.000; 514/561.000
 IC [5]
 ICM: A61K031-045
 ICS: A61K031-20; A61K031-195
 EXF 514/728; 514/558; 514/561
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 224 OF 239 USPATFULL
 AN 90:7722 USPATFULL
 TI Immobilized fluorogenic substrates for enzymes; and processes for their preparation
 IN Brynes, Paul J., Libertyville, IL, United States
 Andrade-Gordon, Patricia, Port Jefferson, NY, United States
 PA The Research Foundation of the State University of New York, Albany, NY, United States (U.S. corporation)
 PI US 4897444 19900130
 AI US 1985-740706 19850603 (6)
 RLI Continuation-in-part of Ser. No. US 1985-739746, filed on 31 May 1985, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1569
 INCL INCLM: 525/054.100
 NCL INCLM: 435/023.000; 435/024.000; 530/330.000; 530/331.000; 530/300.000
 NCIM: 525/054.100
 NCIS: 435/023.000; 435/024.000; 530/300.000; 530/330.000; 530/331.000
 IC [4]
 ICM: C08L089-00
 EXF 530/380; 530/330; 530/331; 525/54.1; 435/23; 435/24
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 225 OF 239 USPATFULL
 AN 89:92234 USPATFULL
 TI Device and method for separating leucocytes from platelet concentrate
 IN Pail, David B., Roslyn Estates, NY, United States
 Gsell, Thomas C., Glen Cove, NY, United States
 PA Pail Corporation, Glen Cove, NY, United States (U.S. corporation)
 PI US 4880548 19891114
 AI US 1988-185993 19880425 (7)
 RLI Continuation-in-part of Ser. No. US 1988-156894, filed on 17 Feb 1988, now abandoned
 DT Utility
 FS Granted
 LN.CNT 2857
 INCL INCLM: 210/767.000
 NCL INCLM: 210/435.000; 210/504.000; 210/508.000
 NCIM: 210/767.000
 NCIS: 210/435.000; 210/504.000; 210/508.000
 IC [4]
 ICM: B01D039-04
 EXF 210/51; 210/767; 210/435; 210/446; 210/506; 210/507; 210/508; 210/503; 210/504; 210/505; 210/648

L9 ANSWER 226 OF 239 USPATFULL
 AN 89:90794 USPATFULL
 TI Method of isolating tumor-secreted products using a novel protein-free medium
 IN Alderman, Edward M., Dedham, MA, United States
 Fect, James W., Waltham, MA, United States
 PA Vallee, Bert L., Brookline, MA, United States
 President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
 PI US 4879222 19891107

AI US 1986-901101 19860828 (6)
 DT Utility
 FS Granted
 LN CNT 619
 INCL INCLM: 435/068.000
 INCLM: 435/240.230; 435/240.310
 NCL NCIM: 435/068.100
 IC [4]
 ICM: C12P021-00
 ICS: C12N005-00
 EXF 435/240.83; 435/68; 435/240.31
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 227 OF 239 USPAPFUL
 AN 89:69709 USPAPFUL
 TI Affinity column and process for detection of low molecular weight toxic substances
 IN Groopman, John D., Lynnfield, MA, United States
 Wogan, Gerald N., Belmont, MA, United States
 Bargoet, Frederick G., Wellesley, MA, United States
 Ferarri, Christopher, Marlborough, MA, United States
 PA Massachusetts Institute of Technology, Cambridge, MA, United States
 (U.S. corporation)
 PI Boston University, Boston, MA, United States (U.S. corporation)
 AI US 4859611 19890822
 RI US 1986-820388 19860121 (6)
 Continuation-in-part of Ser. No. US 1985-706984, filed on 28 Feb 1985
 And a continuation-in-part of Ser. No. US 1985-706983, filed on 28 Feb 1985
 DT Utility
 FS Granted
 LN CNT 795
 INCL INCLM: 436/518.000
 INCLM: 436/518.000; 436/548.000; 436/815.000; 436/824.000; 436/825.000
 NCL NCIM: 436/518.000
 NCLM: 436/518.000
 NCL: 436/513.000; 436/548.000; 436/815.000; 436/824.000; 436/825.000
 IC [4]
 ICM: G01N033-543
 ICS: G01N033-577
 EXF 422/69; 422/70; 436/513; 436/518; 436/529; 436/807; 436/815; 436/824;
 436/825; 436/112; 436/548; 530/413
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 228 OF 239 USPAPFUL
 AN 89:58716 USPAPFUL
 TI Method for promoting epithelial healing and prevention of epithelial destruction
 IN Salonen, Eeva-Marjatta, Espoo, Finland
 PA Labystems Oy, Helsinki, Finland (non-U.S. corporation)
 PI US 4849406 19890718
 AI US 1986-838339 19860311 (6)
 PRI FI 1985-4634 19851122
 DT Utility
 FS Granted
 LN CNT 661
 INCL INCLM: 514/008.000
 INCLM: 514/012.000; 514/802.000; 424/101.000
 NCL NCIM: 514/008.000
 NCL: 514/012.000; 514/802.000
 IC [4]
 ICM: A61K037-02
 EXF 424/101; 514/802; 514/12; 514/8
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 229 OF 239 USPAPFUL
 AN 89:25776 USPAPFUL
 TI Affinity column and process for detection of low molecular weight toxic substances
 IN Groopman, John D., Essex County, MA, United States
 Wogan, Gerald N., Middlesex County, MA, United States
 PA Massachusetts Institute of Technology, Cambridge, MA, United States
 (U.S. corporation)
 PI Boston University, Boston, MA, United States (U.S. corporation)
 AI US 4818687 19890404
 RI US 1985-667069 19850228 (2)
 DT Utility
 FS Granted
 LN CNT 633
 INCL INCLM: 436/518.000
 INCLM: 436/529.000; 436/548.000; 436/815.000; 436/822.000; 436/824.000;
 436/825.000
 NCL NCIM: 436/518.000
 NCLM: 436/518.000
 NCL: 436/529.000; 436/548.000; 436/815.000; 436/822.000; 436/824.000;
 436/825.000
 IC [4]
 ICM: G01N033-543
 ICS: G01N033-577
 EXF 436/518; 436/529; 436/815; 436/824; 436/825; 436/548; 436/822; 530/413

L9 ANSWER 230 OF 239 USPAPFUL
 AN 88:47337 USPAPFUL
 TI Serine protease inhibitors and methods for isolation of same
 IN Thompson, Robert C., Boulder, CO, United States
 PA Synergen Biologicals, Inc., Boulder, CO, United States (U.S. corporation)
 PI US 4760130 19880726
 RI US 1985-803423 19851202 (6)
 Continuation-in-part of Ser. No. US 1984-678823, filed on 6 Dec 1984,
 now abandoned
 DT Utility
 FS Granted
 LN CNT 805
 INCL INCLM: 530/350.000
 INCLM: 530/350.000
 NCL NCIM: 530/350.000
 NCL: 930/010.000; 930/250.000; 930/DIG.821
 IC [4]
 ICM: C07K013-00
 EXF 530/324; 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 231 OF 239 USPAPFUL
 AN 88:29409 USPAPFUL
 TI Hydroxamic acid based collagenase inhibitors
 IN Dickens, Jonathan P., High Wycombe, England
 PA Kneen, Geoffrey, West Wycombe, England
 PI Mckay, William R., High Wycombe, England
 G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
 PI US 4743587 19880510
 AI US 1986-880130 19860707 (6)
 RLI Continuation-in-part of Ser. No. US 1985-774491, filed on 10 Sep 1985,
 now patented, Pat. No. US 4599361
 DT Utility
 FS Granted
 LN CNT 1007
 INCL INCLM: 514/575.000
 INCLM: 260/500.500H

NCL NCLM: 514/575.000
NCLS: 562/623.000

IC [4]
ICM: C07C083-10
ICS: A61K031-085; A61K031-165; A61K031-185
260/500.5H; 514/575

EXF 260/500.5H; 514/575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 232 OF 239 USPTAFULL
88:4279 USPTAFULL
TI Method of inhibiting vertebrate collagenase activity using
peptide hydroxamic acid derivatives
IN Spillburg, Curtis A., Chesterfield, MO, United States
Moore, William M., St. Charles, MO, United States
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)
PI US 4720486 19870119
AI US 1987-1265 19870107 (7)
RLI Division of Ser. No. US 1985-789271, filed on 18 Oct 1985, now patented,
Pat. No. US 4687841
DT Utility
FS Granted
LN.CNT 565
INCL INCLM: 514/018.000
INCLS: 525/054.100
NCL NCLM: 514/018.000
NCLS: 525/054.100

IC [4]
ICM: A61K037-02
ICS: C08E283-00
514/18; 525/54.1

EXF 514/18; 525/54.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 233 OF 239 USPTAFULL
87:38655 USPTAFULL
TI Peptide hydroxamic acid derivatives
IN Spillburg, Curtis A., Chesterfield, MO, United States
Moore, William M., St. Charles, MO, United States
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)
PI US 4687841 19870818
AI US 1985-789271 19851018 (6)
DT Utility
FS Granted
LN.CNT 542
INCL INCLM: 530/331.000
INCLS: 530/810.000; 530/813.000
NCL NCLM: 530/331.000
NCLS: 530/810.000; 530/813.000

IC [4]
ICM: C07C103-52
ICS: 530/331; 530/810; 530/813

EXF 530/331; 530/810; 530/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 234 OF 239 USPTAFULL
87:34104 USPTAFULL
TI Peptide derivatives, the preparation and their use as elastase
inhibitors
IN Robert, Ladislav, Santeny, France
Hornebeck, William, Saint Cyr l'Ecole, France
Moczar, Elemer, Gif-sur-Yvette, France
PA Centre National de la Recherche Scientifique, Paris, France (non-U.S.
government)
PI US 4665053 19870512
AI US 1984-610111 19840514 (6)
PRAI FR 1983-8052 19830516

DT Utility
FS Granted
LN.CNT 631
INCL INCLM: 514/018.000
INCLS: 514/844.000; 540/330.000; 530/331.000
NCL NCLM: 514/018.000
NCLS: 514/844.000; 530/330.000; 530/331.000; 930/250.000; 930/DIG.785

IC [4]
ICM: A61K037-02
ICS: C07K005-08; C07K005-10
424/177; 260/112.5R; 514/18; 514/844; 530/330; 530/331

EXF 424/177; 260/112.5R; 514/18; 514/844; 530/330; 530/331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 235 OF 239 USPTAFULL
86:76655 USPTAFULL
TI Hydroxamic acid based collagenase inhibitors
IN Dickens, Jonathan P., High Wycombe, England
Donald, David K., High Wycombe, England
Kneen, Geoffrey, West Wycombe, England
McKay, William R., High Wycombe, England
PA G. D. Searle & Co., Skokie, IL, United States (U.S. corporation)
PI US 4599361 19860708
AI US 1985-774491 19850910 (6)
DT Utility
FS Granted
LN.CNT 714
INCL INCLM: 514/575.000
INCLS: 260/500.500H
NCL NCLM: 514/575.000
NCLS: 562/623.000

IC [4]
ICM: C07C083-10
ICS: A61K031-085; A61K031-165; A61K031-185
260/500.5H; 514/575

EXF 260/500.5H; 514/575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 236 OF 239 USPTAFULL
86:6621 USPTAFULL
TI Carboxylalkyl peptide derivatives
IN McCullagh, Keith G., Princes Risborough, United Kingdom
Wadsworth, Harry J., High Wycombe, United Kingdom
Hann, Michael M., Watlington, United Kingdom
PA G. D. Searle & Co., Skokie, IL, United States (U.S. corporation)
PI US 4568666 19860204
AI US 1984-662129 19841018 (6)
DT Utility
FS Granted
LN.CNT 3163
INCL INCLM: 514/020.000
INCLS: 260/112.500R
NCL NCLM: 514/020.000
NCLS: 260/001.000; 562/443.000; 930/250.000

IC [4]
ICM: A61K037-00
ICS: C07C103-52
514/20; 260/112.5R

EXF 514/20; 260/112.5R
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 237 OF 239 USPTAFULL
84:64289 USPTAFULL
TI Therapeutic hypothermia instrument
IN Witeles, Eleonora M., Rancho Palos Verdes, CA, United States
Atlantic Richfield Company, Los Angeles, CA, United States (U.S.
corporation)

PI US 4483341 19841120
 AI US 1982-448114 19821209 (6)
 DT Utility
 FS Granted
 LN.CNT 805
 INCL INCLM: 128/402.000
 NCL INCLS: 128/303.100; 128/784.000; 062/003.000
 NCLM: 606/021.000
 NCLS: 062/003.100; 062/003.200
 IC 131
 ICM: A61F007-00
 EXF 128/303.1; 128/399-403; 128/DIG.27; 128/784; 062/3; 062/335
 L9 ANSWER 238 OF 239 USPATFULL
 AN 77:51189 USPATFULL
 TI Steroidal erythropoietic agents and therapeutic compositions and methods
 IN Strade, Henry A., Montville, NJ, United States
 PA Akzona Incorporated, Asheville, NC, United States (U.S. corporation)
 PI US 4049805 19770920
 AI US 1976-693249 19760604 (5)
 RLI Continuation-in-part of Ser. No. US 1975-618176, filed on 30 Sep 1975, now patented, Pat. No. US 4004005
 DT Utility
 FS Granted
 LN.CNT 235
 INCL INCLM: 424/243.000
 NCL NCLM: 514/178.000
 IC 121
 ICM: A61K031-565
 EXF 424/243
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 239 OF 239 USPATFULL
 AN 77:3777 USPATFULL
 TI Steroidal erythropoietic agents and therapeutic compositions and methods
 IN Strade, Henry A., Montville, NJ, United States
 PA Akzona Incorporated, Asheville, NC, United States (U.S. corporation)
 PI US 4004005 19770118
 AI US 1975-618176 19750930 (5)
 DT Utility
 FS Granted
 LN.CNT 188
 INCL INCLM: 424/243.000
 NCL NCLM: 514/178.000
 IC 121
 ICM: A61K031-56
 ICS: A61K031-575
 EXF 424/243
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.